Image features for the future in stage IV non-small cell lung cancer by de Jong, Evelyn (Elizabeth Catharina)
  
 
Image features for the future in stage IV non-small cell
lung cancer
Citation for published version (APA):
de Jong, E. E. C. (2019). Image features for the future in stage IV non-small cell lung cancer. Maastricht:
Ipskamp Printing BV. https://doi.org/10.26481/dis.20190206ej
Document status and date:
Published: 01/01/2019
DOI:
10.26481/dis.20190206ej
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 1
Image features for the future
in stage IV non-small cell lung cancer
Evelyn de Jong
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 2
Cover
The cover shows a voxel representation of a tumor imaged using CT and using PET/CT. The
original CT and PET/CT image of the tumor is shown at the back. In the lung, names of image
features are shown.
Production Typesetting: This thesis was created using LATEX
Printing: Ipskamp Printing BV, Enschede
ISBN: 978-94-028-1347-0
Copyrights
© Copyright E.E.C. de Jong, Maastricht 2019
No parts of this thesis publication may be reproduced in any form without prior written permission
of the holder of the copyrights.
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 3
Image features for the future
in stage IV non-small cell lung cancer
Proefschrift
ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector Magniﬁcus Prof. dr. Rianne M. Letschert,
volgens het besluit van het College van Decanen,
in openbaar te verdedigen
op woensdag 6 februari 2019 om 14:00 uur
door
Evelyn Elizabeth Catharina de Jong
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 4
Promotors
Prof. dr. P. Lambin
Prof. dr. A.-M.C. Dingemans
Co-promotor
Dr. ir. W. van Elmpt
Beoordelingscommissie
Prof. dr. F.M. Mottaghy (voorzitter)
Prof. dr. J.G.J.V. Aerts (Erasmus Medisch Centrum)
Prof. dr. W.H. Backes
Prof. dr. M. van den Heuvel (Radboud Universitair Medisch Centrum)
Dr. A. Hoeben
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 5
Contents
General introduction
Chapter 1 Introduction and outline of the thesis 11
Chapter 2 Radiomics applied to lung cancer: a review 27
Methodological challenges in image feature studies
Chapter 3 Quality assessment of positron emission tomography scans:
recommendations for future multicenter trials 49
Chapter 4 What you see is (not) what you get: tools for a non-radiologist to
evaluate image quality in lung cancer 65
Chapter 5 Inﬂuence of gray level discretization on radiomic feature stability for
diﬀerent CT scanners, tube currents and slice thicknesses: a
comprehensive phantom study 77
Image features for prognosis and cachexia
Chapter 6 18F-FDG PET/CT-based response assessment of stage IV non-small
cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with
or without nitroglycerin patches 111
Chapter 7 Applicability of a prognostic CT-based radiomic signature model
trained on stage I-III non-small cell lung cancer in stage IV
non-small cell lung cancer 127
Chapter 8 Can radiomic features describe lung semantic features in non-small
cell lung cancer patients? 145
Chapter 9 Radiomics approach to predict skeletal muscle response to
chemotherapy in stage IV non-small cell lung cancer 211
Discussion
Chapter 10 General discussion and future perspectives 229
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 6
Appendices
Summary 255
Samenvatting 261
Valorisation addendum 267
Dankwoord 271
Curriculum vitae 277
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 7
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 8
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 9
General introduction
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 10
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 11
1
Chapter 1
Introduction and outline of the thesis
11
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 12
1 Chapter 1
Lung Cancer
Incidence and mortality
In the Netherlands, each year more than 100,000 people are diagnosed with cancer, and
while many of them are cured, still about 40,000 patients yearly die. In the Netherlands
in 2016, 6291 men and 4383 women died due to lung cancer, which is about 24 % of
all cancer deaths in the Netherlands. Lung cancer is the type of cancer with the highest
mortality in the Netherlands [1]. Lung cancer can be divided into non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC). Of all lung cancers about 80 % is speciﬁed
as NSCLC. NSCLC can be subdivided into squamous cell carcinoma, adenocarcinoma and
large cell carcinoma. The biggest risk factor in lung cancer is smoking, about 71 % of the
1.59 million deaths yearly is due to lung cancer caused by smoking. In Asian countries,
an increase in lung cancer diagnosis in non-smokers is observed, which is associated with
speciﬁc molecular and genetic tumor characteristics.
Molecular subtypes
Examples of molecular tumor subtypes of NSCLC are epidermal growth factor (EGFR)
mutated tumors, tumors with mutations in v-Ki-ras2 Kirsten rat sarcoma (KRAS) and
tumors with a rearrangement in the anaplastic lymphoma kinase (ALK) [2]. About 10-12 %
of the Caucasians with adenocarcinoma have an EGFR mutation. EGFR mutations are
more frequent in females, never smokers and East Asian patients. Almost 15-25 % of the
NSCLC patients have a KRAS mutation, which occur more frequently in adenocarcinomas,
Caucasian patients and smokers [2]. ALK rearrangements, which are present in about 5 %
of the adenocarcinomas, are more frequent seen in never smokers and younger patients.
Testing for EGFR mutations and ALK rearrangements is recommended in all patients with
advanced non-squamous cell carcinoma [3].
Staging of non-small cell lung cancer
The overall survival rate in lung cancer is low, on average the 5-years survival rate is
16 % [4] and is dependent on the stage of the disease. NSCLC is staged according to the
Tumor-Node-Metastasis classiﬁcation of the American Joint Committee on Cancer (AJCC)
and grouped into eight stages (Stage 0, IA, IB, IIA, IIB, IIIA, IIIB and IV). Patients with
distant metastases are classiﬁed as stage IV patients independent of the T- and N-stage
of the tumor [5]. The 5-years survival rate in stage I NSCLC is 61 %, stage II 43 %, stage
III 18 % and it decreased to only 3 % in stage IV [6]. The extent of the primary tumor
is determined using computed tomography (CT) imaging, and the assessment of lymph
node involvement and metastases is performed using positron emission tomography (PET)
imaging. In advanced stage patients, it is recommended to image the brain, preferably by
magnetic resonance imaging (MRI) with gadolinium enhancement or by CT with iodine
contrast.
Treatment of non-small cell lung cancer
Treatment of lung cancer is diﬀerent for the various stages of lung cancer. But next to
the tumor stage, other clinical variables like smoking history, performance status, age,
molecular pathology, age, co-morbidities and patient preferences are taken into account
12
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to determine the optimal treatment for the patient. In all stages of NSCLC, patients
should be motivated to quit smoking, because smoking may interact with systemic therapy
[3]. About 40 % of the NSCLC patients are diagnosed with stage IV disease. Systemic
therapy is advised in all stage IV patients with a good performance status. Chemotherapy
for stage IV patients, at the time of the studies described in this thesis, consisted of
platinum doublets [3]. The drugs most often used in NSCLC are cisplatin, carboplatin,
paclitaxel, docetaxel, gemcitabine, pemetrexed. Many clinical trials are performed to
improve outcome and quality of life of patients and individualize treatment in the future.
An example, described in this thesis, is the Dutch randomized phase II trial, the NVALT12,
in which the eﬀect of the addition of nitroglycerin, to paclitaxel-carboplatin-bevacizumab
therapy, on progression free survival, was investigated [7]. Carboplatin is in the platinum-
based antineoplastic family and works by interfering with duplication of DNA [8]. Paclitaxel
is in the taxane family and works by interference with the normal function of microtubules
during cell division [9].Tumor hypoxia is a poor prognostic factor in lung cancer. Hypoxia
Inducible Factor (HIF-1α) is the major factor regulating the response to hypoxia. HIF
directly activates the vascular endothelial growth factor which helps the tumor to grow.
Hypoxia is related to treatment resistance. Hypoxic cells are more radio-resistant, more
chemo-resistant and more prone to develop distant metastases than normoxic cells [10]. A
phase III study showed that the addition of bevacizumab to paclitaxel-carboplatin therapy
improved overall survival, due to the blocking of the vascular endothelial growth factor by
bevacizumab [11]. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody
family and works by slowing the growth of new blood vessels [12]. Bevacizumab helps
reducing hypoxia which might lead to a more eﬃcient treatment. By adding nitroglycerin,
which is a vasodilator [13], the blood ﬂow the tumor was expected to increase, which
could therefore also decrease hypoxia related drug resistance. However, the conclusion of
the NVALT12 study was that by adding NTG the progression free survival as well as the
overall survival did not improve [7].
In September 2018 the clinical practice guidelines for diagnosis, treatment and follow-
up in metastatic NSCLC are updated [14]. Recent development of immune checkpoint
inhibitors have shown that immunotherapy can play an important role in the treatment of
stage IV NSCLC.
The preferred treatment of EGFR mutated and ALK rearranged NSCLC is with speciﬁc
targeted tyrosine kinase inhibitors. By individualization of the treatment according to the
molecular tumor characteristics a better progression free survival and overall survival is
typically obtained.
Prognostic and predictive models
Although many diﬀerent treatments are available for lung cancer patients, it is quite
diﬃcult to select patients for a speciﬁc treatment. Prognostic models exists of a
combination of variables that estimate the probability of an outcome, for example
survival, as good as possible, while predictive models can distinguish patients who can
beneﬁt from a speciﬁc treatment [15]. Prognostic and predictive models can be used to
tailor treatment decisions and therefore, individualization of the balance of reduction of
side eﬀects and prognosis and quality of life of patients is optimized [16]. Clinical
variables used in prognostic models in lung cancer are for example age, gender, smoking
history, comorbidity, performance status, forced expiratory volume in 1 second, T-stage,
N-stage, M-stage, histological grading and mutation status. Another phenomenon
13
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related to a worse prognosis in lung cancer is cachexia. Cachexia describes involuntary
weight loss in patients with cancer that cannot be reversed by normal nutritional support.
A deﬁning feature of cancer cachexia is loss of muscle, but fat may be lost as well. In
addition to muscle wasting and loss of appetite, patients who suﬀer from cancer cachexia
have a poor quality of life and experience pain and fatigue. About 61 % of newly
diagnosed NSCLC patients have weight loss. Patients with cachexia have a higher
prevalence of toxic adverse eﬀects to systemic treatment, while the dose of systemic
treatment is speciﬁed for a certain body mass which decreases in cachectic patients.
Cancer cachexia is a multidimensional syndrome and therefore a multimodal treatment is
needed. The main driver of the cachexia is the tumor. All factors that have a negative
impact on food intake and well-being need to be minimized. Inﬂammatory mediators
possibly play a role in the development of cachexia [17].
In predictive models diﬀerent treatment groups are the input variables. Prognostic
models can also contain biological markers that can for example be measured in the blood,
so called biomarkers. Image characteristics, like SUV metrics, but also CT intensity values
can potentially improve prognostic and predictive models.
Imaging in stage IV NSCLC
CT, PET and MRI
Medical imaging is an important part of routine care in diagnosing, treatment and follow-
up in oncology. For most lung cancer patients a contrast-enhanced CT of the chest and
upper abdomen including complete assessment of liver, kidneys and adrenal glands is used
for diagnosis and staging. CT is a diagnostic imaging procedure that uses X-rays to build
cross sectional images (“slices”) of the body. Slices are reconstructed from attenuation
measurements of the X-rays through the patient’s body. The attenuation is measured
from diﬀerent angles to make transmission or projection images. These projection images
are reconstructed into a (electron) density volumetric image expressed in Hounsﬁeld units
(HU).
PET is a molecular imaging technique that is used in staging, because it oﬀers the
highest sensitivity for tumor inﬁltration of mediastinal lymph nodes and distant
metastases assessment [18]. Depending on tracer characteristics speciﬁc biological
processes can be monitored. The most frequently used tracer in oncology is
2-deoxy-2-ﬂuorine-18-ﬂuoro-D-glucose (18F-FDG), which is an analogue of glucose.
Unlike glucose, when 18F-FDG is taken up into the cell, it is converted to
18F-FDG-6-phosphate, which cannot undergo further metabolism and is therefore
trapped in the cell. An increased cellular uptake of 18F-FDG and a higher rate of
intracellular phosphorylation lead to higher uptakes and trapping of FDG in cancer cells
[19]. The FDG is labeled with 18F, which is a radioactive isotope of ﬂuorine that emits a
positron during radioactive decay, which annihilates with a nearby electron to emit two
511 keV photons in almost opposite directions. These two annihilations photons are
registered by the PET scanner using a coincidence detection principle, providing 3D
information on the tracer distribution. Nowadays, the PET and CT are often combined
in one imaging device, the PET/CT scanner. This has the advantage that the patient is
in exactly the same position for the CT as for the PET scan, which makes the fusion of
the PET scan with the CT scan easier. Using the attenuation properties of the patient
derived from the CT, a higher quantitative accuracy is achieved by taking into account
14
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the patient self-attenuation. However, accurate quantiﬁcation of tracer uptake remains
diﬃcult as many processes inﬂuence the PET image. The measured concentration of
radioactivity in tissue depends on the tracer concentration in blood over time, which in
turn depends on the injected dose and distribution volume. The standardized uptake
value (SUV) is corrected for those variabilities. Next to that, the PET signal does not
necessarily reﬂect speciﬁc uptake, e.g. trapping of the tracer by the process of interest.
Pharmacokinetic modelling can be applied to distinguish between the various kinetic
processes and separates the total signal into the uptake in blood, uptake free in tissue,
speciﬁc uptake (tumor) and non-speciﬁc uptake [20]. Figure 1.1 shows an example of a
PET/CT scan. In advanced NSCLC PET/CT is the used in the detection of bone
metastasis, the evaluation of solitary pulmonary nodules, intra-thoracic pathological
lymph nodes and distant metastasis [14].
MRI may complement or improve diagnostic accuracy, mainly in assessing local chest
wall, vascular or vertebra invasion. MRI is also eﬀective for identiﬁcation of nodal and
distant metastases. MRI is more sensitive than CT in detecting brain metastasis [14]. In
MRI a strong magnetic ﬁeld is produced by a powerful magnet that forces the protons in
the body to align with the ﬁeld. A radiofrequency pulse let the magnetic vector of the
protons deﬂect. When the radiofrequency pulse is switched oﬀ the protons start to align
again with the magnetic ﬁeld. The energy released by the protons during alignment as
well as the time it takes is measured and is diﬀerent for diﬀerent tissues [21].
Figure 1.1: Left image shows an 18F-FDG-PET scan of a patient with stage IV non-small cell lung
cancer, with a tumor in the left lung, positive lymph nodes in the top of the lung and a metastasis
in the spine; the middle image shows the CT scan of the same patient and the right image shows
the fusion of the PET and the CT scan.
Image quality and standardization
Due to technology innovations and the combination of PET and CT in one imaging
device, the image quality of CT and PET scans has improved over the years. Although
due to the many available image settings a large variability in image parameters exists
between diﬀerent hospitals. When comparing scans from diﬀerent hospitals, it is
therefore important to be aware of possible diﬀerences. To minimize diﬀerences the
European Association of Nuclear Medicine (EANM) and some other initiatives provided
guidelines for imaging [22, 23, 24]. The ﬁrst initiative for standardization of PET imaging
was the Netherlands protocol for standardization of FDG whole body PET studies in
15
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multi-center trials (NEDPAS) in 2008 [24]. The protocol is based on standardization of
1) patient preparation; 2) matching of scan statistics by prescribing dosage as function of
patient weight, scan time per bed position, percentage of bed overlap and image
acquisition mode; 3) matching of image resolution by prescribing reconstruction settings
for each type of scanner; 4) matching of data analysis procedure by deﬁning volume of
interest methods and SUV calculations and 5) a multicenter quality control procedure for
veriﬁcation of scanner calibration and of activity concentration recoveries using the
National Electrical Manufacturers Association (NEMA) image quality phantom. The
protocol reduced variability of SUV across centers participating in multicenter trials.
Quality control phantom experiments demonstrated that use of the protocol reduced
calibration errors from up to 15 % to within 6 % [24]. In 2010 the NEDPAS guidelines
were further extended in the EANM procedure guidelines for tumour imaging version 1.0
[22], which were updated in 2014 to the EANM procedure guidelines for tumour imaging
version 2.0 [23]. The purpose of these guidelines is to assist physicians in recommending,
performing, interpreting, and reporting the results of FDG PET/CT for oncological
imaging of adult patients. PET is a quantitative imaging technique and therefore
requires a common quality control assurance procedure to maintain the accuracy and
precision of quantiﬁcation. Repeatability and reproducibility are two essential
requirements for any quantitative measurement. Repeatability relates to the uncertainty
in obtaining the same result in the same patient when he or she is examined more than
once on the same system. Reproducibility, is the ability to yield the same result in the
same patient when that patient is examined on diﬀerent systems and at diﬀerent imaging
sites. Adequate repeatability and reproducibility are essential for the clinical management
of patients and the use of FDG PET/CT within multicenter trials. A common
standardized imaging procedure will help promote the appropriate use of FDG PET/CT
imaging and increase the value of publications and therefore, their contribution to
evidence based medicine. Moreover, consistency in numerical values between platforms
and institutes that acquire the data will potentially enhance the role of semi-quantitative
and quantitative image interpretation. Precision and accuracy are additionally important
as FDG PET/CT is used to evaluate tumor response as well as for diagnosis, prognosis
and staging. Therefore, guidelines speciﬁcally aim to achieve standardized uptake value
harmonization in multicenter settings [23].
For CT the guidelines are less pronounced. In some countries, for example in the
United States, low dose CT scans are performed for lung cancer screening. CT guidelines
are developed for those screenings, while for CT scans not performed during screening,
protocols are not always standardized. The Alliance for Quality Computed Tomography
(AQCT) working group provided information, to ensure that the minimum amount of
radiation, to obtain the diagnostic information needed to answer the clinical question, is
used. Reference protocols are developed for speciﬁc diagnostic tasks by the AQCT working
group. The lung cancer screening protocol from the American Association of Physicists in
Medicine (AAPM) speciﬁes that the CT scan should be performed in breath hold, because
tumor motion is problematic. Next to that, thin image slices should be used, slice thickness
preferably less than 2.5 mm. It is encouraged to reconstruct in the axial, but also in the
sagittal and coronal direction. The dose should be adjusted to the patient size but should
be around 3 mGy [25]. The AAPM protocol for a routine adult chest-abdomen-pelvis CT
states that contrast can be applied orally or intravenously, depending on the indication
and the preference of the radiologist. The patient should be in supine position with the
arms above the head, centered within the gantry for a proper functioning of the automatic
16
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exposure control system. The scan range is typically from the top of the lungs to either
the iliac crest or the pubic symphysis. The slice thickness should be as small as possible,
but is dependent on manufacturer [26].
Image biomarkers
Image characteristics used in prognostic and predictive models are called image
biomarkers. An application for image biomarkers is the TNM-stage [27]. Image
biomarkers can be qualitative, so called semantic features, or quantitative, for example
radiomic features. Image biomarkers can reveal the tumor’s phenotype, which represents
the underlying biology of the tumor. To determine the tumor’s phenotype, typically a
biopsy was taken. However, a biopsy might be diﬃcult to obtain, is invasive for the
patient and is just a sample from a generally heterogeneous larger lesion. It has been
shown that semantic features like, air bronchogram and pleural retraction are related to
EGFR mutated tumors, while pleural eﬀusion is related to ALK mutated tumors [28].
This shows that using imaging, mutation statuses, as EGFR, KRAS and ALK, can be
distinguished and the invasive biopsy is in the future possibly superﬂuous. Semantic
features are mostly visually scored by radiologists and describe a tumor’s shape and
internal structure [29]. Examples of semantic features in lung cancer are location of the
lesion in the lung; shape (round, complex, oval); presence of ground-glass opacity and
presence of cavitation. Figure 1.2 shows some examples of semantic features in NSCLC.
Figure 1.2: Examples of the semantic features: ground glass opacity, pleural eﬀusion, emphysema
and necrosis.
While semantic features are scored manually, radiomic features can be extracted
automatically. These features describe the intensity distribution, spatial relationships
between the various intensity levels, texture heterogeneity patterns, shape and the
relation of the tumor with its surroundings The region of interest need to be segmented
and then radiomic software can extract hundreds of features For radiomics, it is
important that the images are of high quality and performed according to a standardized
protocol. To select useful features for the speciﬁc research question a feature selection
procedure need to be performed [30].
In 2014 a radiomic signature model is built in a cohort of stage I-III lung cancer patients
and validated in an independent cohort of stage I-III lung cancer patients. This radiomic
signature was surprisingly as well prognostic in head and neck cancer [31]. Figure 1.3
shows an example of radiomic features.
17
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Objective and outline of the thesis
The aim of this thesis is to investigate the use of image features in stage IV NSCLC and
presents the challenges for using image features in prognostic and predictive models. The
hypothesis is that simple and advanced qualitative and quantitative image features from
standardized medical imaging help to improve patient care.
After an introduction, the thesis is divided in three parts. Part I, the introduction
of radiomics in lung cancer, contains chapter 2, which is a comprehensive review on the
multiple radiomics studies performed in lung cancer. This review summarizes the results of
3 PET radiomics papers and 8 CT radiomics papers. The main applications of radiomics
were the classiﬁcation of lung nodules (diagnostic) and prognostication of lung cancer
(theragnostic). Only 5 of the 22 studies were externally validated. It was clear that
radiomics had great potential although some methodological issues need to be solved ﬁrst
which some are investigated in this thesis (see Chapter 5).
Part II describes the methodological challenges in image feature studies that have
Figure 1.3: Examples of radiomic features. The left images show the delineated tumor on CT; on
the right the intensity histogram of the tumor with an example of the radiomic features: median
and skewness.
18
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Figure 1.4: Schematic outline of the thesis.
to be overcome in the future. In chapter 3 the challenges of PET response assessment
in multicenter studies are described. Although standardization protocols and guidelines
are available, an image sub-study of the NVALT12 trial, in which repeated PET images
were performed, showed that there is still a large variability in image acquisition and
reconstruction parameters. In this chapter the image parameters of the PET scans of the
NVALT12 were compared to the image parameters recommended by the EANM.
Based on the results recommendations are proposed for future multicenter studies
using PET for response assessment. Chapter 4 describes the problems with imaging in two
clinical trials. Clinicians are not always aware of the technical details inﬂuencing image
interpretation, and imaging experts are not always aware of the clinical aim of a particular
scan. This chapter describes simple guidelines for clinicians to judge if a scan can be used
to answer the clinical question. In chapter 5 the inﬂuence of diﬀerent image parameters
19
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on radiomic features is reported. In this chapter a phantom study is done to investigate
the inﬂuence of slice thickness, exposure, bin width and resampling methods on radiomic
texture features.
Part III describes the use of simple and advanced qualitative and quantitative image
features for the prediction of cachexia and treatment outcome (survival). In chapter 6 the
use of simple quantitative PET features for prognosis prediction based on the NVALT12
trial was investigated. The chapter describes the investigation of the feasibility of 18F-
FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab treatment with
and without NTG patches. A 30 % decrease in CT and PET parameters was used to
investigate response, which was correlated to overall survival. Chapter 7 describes the
applicability of the radiomic signature trained on stage I-III NSCLC patients in stage IV
non-small cell lung cancer patients. Many studies showed prognostic factors in stage IV
non-small cell lung cancer, but no consensus on which factors are prognostic is reached and
next to that, none of the prognostic factors are based on standard imaging. In this study, a
previously developed radiomic signature, which was prognostic in stage I-III NSCLC and as
well in head-and-neck cancer, was tested in two independent cohorts of stage IV NSCLC.
In chapter 8 the association between qualitative CT features and quantitative CT features
in stage IV NSCLC was studied. While qualitative features are inter-observer dependent,
quantitative features can be scored automatically. The study investigated if a combination
of radiomic features could describe semantic features, which makes it less time consuming
and less inter-observer dependent. A decrease in skeletal muscle volume after 3 weeks was
previously described to be prognostic for overall survival. A decrease in skeletal muscle
volume probably also causes a change in the muscle texture. In chapter 9 is investigated
if radiomic texture features of skeletal muscle are changed during treatment.
To conclude, chapter 10 provides a general discussion and thoughts on future
perspectives on the use of image features for personalized medicine. The outline of the
thesis is schematically illustrated in Figure 1.4.
20
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Abstract
Lung cancers exhibit strong phenotypic diﬀerences that can be visualized
noninvasively by medical imaging. Radiomics, a concept introduced in 2012,
refers to the comprehensive quantiﬁcation of tumor phenotypes by applying a
large number of quantitative image features (watch the animation:
https://youtu.be/Tq980GEVP0Y and the website www.radiomics.org). Here,
we review the literature related to radiomics for lung cancer. We found 11
papers related to computed tomography (CT) radiomics, 3 to radiomics or
texture analysis with positron emission tomography (PET) and 8 relating to
PET/CT radiomics. There are two main applications of radiomics, the
classiﬁcation of lung nodules (diagnostic) or prognostication of established
lung cancer (theragnostic). There are quite a few methodological issues in
most of the reviewed papers. Only 5 studies, out of the 22, were externally
validated. Overall, it is clear that radiomics oﬀers great potential in
improving diagnosis and patient stratiﬁcation in lung cancer. It may also
have a real clinical impact, as imaging is routinely used in clinical practice,
providing an unprecedented opportunity to improve decision support in lung
cancer treatment at low cost.
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Introduction
Globally, lung cancer is the most frequent cause of death in men and the second most
frequent cause amongst women in the USA [1]. Past smoking patterns strongly inﬂuence
actual cancer rates amongst both men and women and vary considerably due to
geographical location, age, race, and socioeconomic status. There is a broad consensus
that it is necessary to develop better biomarkers predicting treatment response or
survival, in order to identify subgroups that would beneﬁt from individualized treatment
to improve the patient’s outcome.
Most tumours do not represent a homogenous entity; they are composed of multiple
clonal sub-populations of cancer cells. This heterogeneous complex needs to be analysed
in order to tailor the cancer care to the patient and their tumour. One way of
characterizing the tumour is by extracting tumour tissue in a tumour biopsy, the tissue is
then characterised using genomics based approaches. Although these approaches have
successfully been used in clinical oncology, there are intrinsic limitations; repeated
tumour biopsies increase the risk of complications for the patients, in particular in lung
cancer and the results may vary depending on which part of the tumour is biopsied.
These challenges can be addressed by medical imaging. Medical imaging is an
important part of cancer care, it is essential to cancer staging and diagnosis. Unlike
biopsies, it is noninvasive, three dimensional and provides information regarding the
entire tumour.
Radiomics, ﬁrst introduced by Lambin et al. [2] in 2012 and summarized in a two
minute animation (http://youtu.be/Tq980GEVP0Y), is a process that converts standard
of care images into minable high-dimensional data. The radiomics process can extract
quantitative features from digital medical images, which can then be used to build
descriptive and predictive models, linking the image features to the tumour’s
gene-protein signatures or the tumour’s phenotype. As shown in recent studies,
quantitative imaging features have a prognostic value and potential in predicting clinical
outcomes or treatment monitoring in diﬀerent cancer types [3, 4, 5, 6, 7]. The aim of
radiomics is to use these models, which can include biological or medical data, to help
provide valuable diagnostic, prognostic or predictive information. Radiomics aims to
utilise the full potential of medical imaging by extracting and analysing large amounts of
advanced quantitative imaging features, with high throughput from digital medical
images, obtained with computed tomography (CT), positron emission tomography
(PET) or magnetic resonance imaging (MRI). This in turn provides a more detailed
quantiﬁcation of tumour phenotypic characteristics describing its intensity, shape,
texture, intra-tumour heterogeneity and in doing so it eﬀectively converts medical images
into a high dimensional minable feature space.
Precision oncology is the customization of cancer care where therapies and/or
practices are being tailored to individual patients, with all of the information about the
tumour characteristics that radiomics provides; it presents numerous new opportunities
for precision medicine.
In this paper we will review the literature and discuss the potential advantages and
pitfalls of radiomics in lung cancer.
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Workﬂow of radiomics
The radiomics process consists of three steps: (I) image acquisition and volume
segmentation; (II) feature extraction and storage; (III) signature development and
validation on one or several datasets (see Figure 2.1) [2, 8, 9]. Each of these three steps
poses unique challenges, which will be introduced below. Once a signature has been
developed and is applied on a speciﬁc patient, the process is the same except that in step
3 the validated signature is used to determine the prognosis of the patient.
Figure 2.1: Overview of methodological processes in radiomics: data discovery, collection and
preparation, model(s) development/validation and implementation, assessment of clinical utility.
Image acquisition
Modern CT, PET and MRI scanners allow acquisition and reconstruction settings in a large
range. Although this facilitates the subjective needs of the human expert, when the images
are intended to be objectively characterized by a machine, these variations may create a
bias that masks the true underlying biological characteristics. This phenomenon is well
recognized in the ﬁeld of radiomics and consequently, eﬀorts are being made to standardize
acquisition and reconstruction protocols. This advance in quantitative imaging is being
led by several organizations or consortia such as the European Association of Nuclear
Medicine (EANM), the QuIC-ConCePT project from the Innovative Medicine Initiative
Joint Undertaking (IMIJU).
Volumes of interest
One of the central processes of radiomics is to identify one or several volumes of interest
(the primary tumour, nodules, etc.) on the diagnostic imaging. However, predictive
value may lie in the detailed analysis of subvolumes within the tumour, also known as
habitats. The heterogeneity within the tumour is due to particular combinations of blood
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ﬂow, oedema, necrosis, and cell density, which creates a unique pathophysiology. Using
radiomics, important additional information from these habitats as well as information
from a normal healthy lung, can be extracted.
Segmentation
Segmentation or delineation plays a crucial role within radiomics, because the features
that are generated depend on the segmented volumes. However, many tumours, as well
as subvolumes, have ambiguous borders. This can lead to a signiﬁcant inter-reader bias
and low reproducibility when these volumes are manually delineated. Unfortunately, there
is no universal automatic segmentation algorithm that can work for all medical images
[10, 11]. Consequently, the consensus that emerges out of this debate is that the
optimum reproducible segmentation can be obtained via semi-automatic segmentation,
which consists of automatic segmentation followed by, if necessary, manual curation [12].
The diﬀerent image modalities have also their own segmentation methods. For CT, the
region of interest (ROI) represents for example the gross tumor volume (GTV), while for
PET the metabolic target volume (MTV) is segmented as ROI. The segmentation
method also depends on the endpoint of the study. Cheebsumon et al. [13] showed that
CT-based delineation was overestimated compared to pathology while PET-based
tumour delineation methods provided maximum diameters in closer agreement with
pathology. They also showed that for example the contrast-oriented methods seem to
best suited for assessing tumour size, while an adaptive 70 % threshold-based method is
better for response monitoring [13].
Feature extraction
The essential part of radiomics is the high throughput extraction of quantitative image
features that characterize the volumes of interest. The number of features is enormous,
more then 1000, and complex, and this leads to the risk of overﬁtting. Overﬁtting exists
when a model is speciﬁcally and exclusively optimized for the training dataset and
consequently performs poorly on new data. To avoid overﬁtting, the ratio of the number
of evaluated features to the number of outcome events must be kept as low as possible.
To oﬀset this risk, there is a key process of feature reduction and ranking. In order to do
so, one approach consists in looking at robustness and reproducibility of features in
test-retest datasets. The information extracted from two datasets of images acquired
within a small period of time (few minutes to few days) from a single patient cohort is
called test-retest data and is highly advantageous for ranking features thanks to their
reproducibility and stability. Therefore, when coupled with robust segmentation,
test-retest data should be exploited whenever possible. Another complementary approach
consists of identifying features that may be redundant, if they are for example, highly
correlated with one another. Groups of highly correlated features can in turn be reduced
to one archetypal feature.
Model development and validation
Developing a model based on the calculated radiomics features can be data-driven or
hypothesis driven. The data-driven approach makes no assumption about the meaning
of individual features, therefore all features are treated with equal weight during model
development, whereas the hypothesis-driven approach treats cluster features according
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to predeﬁned information content and a clinical context. The best models start with
a well-deﬁned end-point, such as overall survival (OS), and ideally can accommodate
non-radiomics features. Covariates that need to be taken into account include clinical,
treatment and genomic data (age, histology, tumour-node-metastasis (TNM) stage, serum
markers, chemotherapy, radiotherapy, dose, fractionation, treatment time, gene expression,
mutation status, gene polymorphisms. . . ). This information is occasionally missing for
some patients; therefore models should accommodate sparse data. It is necessary that
the models be adequately validated with an external dataset, preferably from an external
institute. If data from an external institute is not available, the available data must be
split into a model training dataset and a validation dataset.
Model performance is often measured in terms of calibration and discrimination.
Accurate models correctly discriminate between patients. This can be measured using
the c-index or the area under the curve (AUC) of receiver operating characteristic (ROC)
for censored data [14]. On the other hand, the calibration is the association between
observed outcomes and model prediction.
Analysis of the literature
Reviewing all the literature about radiomics in lung cancer has shown that radiomics can
be useful in many ﬁelds, such as in the classiﬁcation of nodules, in the description of the
tumour, and it has already been shown to be a tool that can assess patient prognosis [3,
15]. All of the articles published to date, to the best of our knowledge, about radiomics
in lung cancer have been placed in Table 2.1.
First of all, 16 articles in the table assess the prognostic value of texture analysis from
standard of care CT and FDG-PET images, which can predict treatment outcome in some
ways.
Certain methodological aspects of radiomics have been studied, for example, in order
to ﬁnd a way of reducing redundancy and comparing the prognostic characteristics of
radiomics features across cancer types. Parmar et al. [16], investigated cancer-speciﬁc
radiomics feature clusters in his study published in 2015. This study concluded that
consensus clustering could provide robust radiomics feature clusters and therefore could
reduce feature redundancy. Another study, published by Leijenaar et al. [17] analysed
the test-retest and inter-observer variability of radiomics features in FDG-PET images.
The study concluded that the majority of assessed features had both a high test-retest
(71 %) and inter-observer (91 %) stability, and that overall, features that were more
stable in repeated PET imaging were also found to be more robust against inter-observer
variability.
One of the ﬁrst studies showing the potential of CT texture analysis as independent
marker of survival for patients with non-small cell lung cancer (NSCLC) is the study of
Ganeshan et al. [18] from 2012. They showed that patients with heterogeneous tumours
with low uniformity values demonstrated poorer survival and that CT texture and PET
stage were signiﬁcant independent predictors of survival. Another study of Balagurunathan
et al. [8] showed that a large value of run length calculated on CT images (one of the
reproducible features) indicated a more homogeneous tumour, and that this was related
to a longer survival. The largest, the most comprehensive and rigorous study is from
Aerts et al. [15] who worked on radiomics to decode the tumour phenotype, found that
a large number of radiomics features have prognostic power in independent datasets of
lung and head and neck cancer patients, many of which were previously not identiﬁed as
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signiﬁcant. After a very strict features reduction process, using test-retest datasets and
multiple delineations datasets, they created a signature consisting of “only” four features
quantifying tumour heterogeneity, consistently with their initial hypothesis. Combining
this radiomics signature with TNM staging showed a signiﬁcant improvement in all data
sets, compared with TNM staging alone, considered as gold standard. Remarkably, the
same signature was working on lung and head neck cancer suggesting that radiomics
identiﬁes a general prognostic phenotype existing in both lung and head and neck cancer.
They also showed in a series of operated patients, having had standardized CT imaging
and gene expression array, the so-called “radiogenomic approach”, that the four feature
prognostic radiomics signature, capturing intratumour heterogeneity, is associated with
underlying gene-expression patterns linked to tumour proliferation [19]. Overall, this study
convincingly validate the signature on three external datasets and recently in a fourth one
[20].
Next to the studies describing radiomics alone to stratify patients, there are also
some studies describing the value of adding radiomics features to conventional prognostic
factors alone. A study of Desseroit et al. [21] described the development of a nomogram
combining clinical staging with PET/CT image features stage I-III NSCLC patients. The
nomogram had a higher stratiﬁcation power than the clinical staging alone. Patients with
stage III disease, with a large tumour volume, low CT heterogeneity although a high PET
heterogeneity had the poorest prognosis. A study of Fried et al. [4] also showed that
models using textural features and conventional prognostic factors improved stratiﬁcation
power compared to models using conventional prognostic factors alone.
In addition, it was found that radiomics features can reﬂect diﬀerent biologic
mechanisms, such as gene-expression patterns or cell cycling pathways. A study of Yoon
et al. [22] also made the link with gene-expression and showed that quantitative imaging
using radiomics can capture distinct phenotypic diﬀerences between tumours. They
showed that ALK/ROS1/RET fusion positive lung adenocarcinomas possesses certain
imaging features next to clinical features that enable good discrimination between fusion
positive and fusion negative tumours.
Three articles studied the imaging texture analysis of lung cancer in patients treated
by stereotactic radiotherapy [23, 24, 25]. Two studies by Mattonen et al. [24, 25]
investigated the use of imaging texture analysis in a decision support system in order to
support earlier salvage for patients with recurrence and fewer investigations of benign
radiation-induced lung injury. They found that radiomic features, extracted from CT
images using an automated method, are able to predict recurrence with better
performance than physicians. The study of Lovinfosse et al. [23] used radiomics along
with clinical features, using univariate and multivariate analysis for OS, disease-speciﬁc
survival (DSS) and disease-free survival (DFS) in order to assess the predictive value of
the radiomics features. They concluded that the textural feature “dissimilarity” measured
on the baseline 18F-FDG PET/CT appears to be a strong independent predictor of the
outcome in patients with NSCLC treated by stereotactic body radiation therapy.
Prognostic value of metabolic metrics extracted from baseline PET images in NSCLC
is studied in three separate articles using OS to assess the prognostic value [5, 7, 26].
The study from 2013 by Carvalho et al. [5] examined the prognostic value of metabolic
PET descriptors on OS for NSCLC patients and they showed that only one metric, relative
volume above 80 % SUV, was signiﬁcantly related to OS (p = 0.05).
The study from Cook et al. [7] investigated the relation of radiomics features to
response and survival after chemoradiotherapy for 53 NSCLC patients. This study
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concluded that three textural features were able to diﬀerentiate between responders and
non-responders to chemoradiotherapy (determined using RECIST) and were independent
predictors of OS.
A study by Cook et al. [6] showed that the response to erlotinib is associated with
reduced heterogeneity at 18F-FDG PET and that changes in ﬁrst-order entropy are
independently associated with OS and treatment response.
And the 2016 study by Fried et al. [26] showed that pretreatment PET features were
associated with OS in 195 patients with stage III NSCLC. In this study, predictors of
OS generated with both quantitative imaging features and conventional prognostic factors
demonstrated improved risk stratiﬁcation compared with those generated with conventional
prognostic factors.
Another study investigating the prognostic value of PET features by van Gómez
López et al. [34] showed that textural analyses of 18F-FDG PET images to assess tumour
heterogeneity were related to global metabolic parameters (e.g., SUVmax, SUVmean, MTV
and TLG) and pathologic staging.
In addition, the study by Coroller et al. [27] identiﬁed predictive radiomic features
for pathological response in 127 patients with locally advanced NSCLC after neoadjuvant
chemoradiation. This study demonstrated that radiomics can provide valuable clinical
information, and perform better than conventional imaging.
Furthermore, one study published in 2015 used radiomics to predict tumour distant
metastasis, and concluded that radiomics features capture detailed information of the
tumour phenotype and therefore can be used as a prognostic biomarker for clinically-
relevant factors such as distant metastasis [3]. However, distant metastasis is not the only
clinically-relevant factor with which radiomics features can be correlated. A diﬀerent study
assessed the relationship between radiation dose and change of texture-based features of
lung tissue in order to determine the ability of texture analysis to identify patients who
develop radiation pneumonitis (RP). A relationship between dose and change in a set
of image-based features was observed. For 12 features, feature values were signiﬁcantly
related to RP development. This study demonstrated the ability of radiomics to provide
a quantitative, individualized measurement of patient lung tissue reaction to radiation
therapy and assess RP development.
In the ﬁeld of diagnostics, radiomics can be used for the classiﬁcation of nodules. A
study by Dhara et al. [30] showed that using support vector machine nodules can be
classiﬁed as benign or malignant. In addition the study by Dilger et al. [31] showed that
this classiﬁcation can be improved by including features quantiﬁed from the surrounding
lung tissue.
Radiomics is usually performed using textural information derived from the primary
tumor. However, textural information derived from the lymph nodes may contain
complementary information. An ongoing study on 18F-FDG PET images of 262 NSCLC
patients is performing radiomics on both primary tumour and lymph nodes and is
investigating the predictive performance to OS [35].
The above-mentioned studies performed radiomics on pre-treatment scans to advance
the stratiﬁcation of patients for therapy leading to improvements in health outcomes. Some
other studies focused more on radiomics for response assessment by comparing radiomics
features of a baseline scan with radiomics features of a second scan performed during
treatment. Information about early changes in radiomics features can potentially increase
the prognostic value of a model. Currently, percentage variations of radiomics features
derived from PET images at baseline and the second week of treatment are calculated
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and related to OS for NSCLC patients [28]. The next challenge will be to use radiomics
approaches for PET biomarkers diﬀerent then ﬂuorodeoxyglucose in an attempt to extract
more information [36, 37, 38, 39].
Challenges and future prospects
Tumour motion
Standardization of image acquisition and reconstruction is one of the major challenges of
radiomics [40, 41, 42]. Reproducibility and stability of radiomics features is important for
potential clinical utility [12, 17, 43]. In lung cancer, breathing-induced tumour motion
is one of the factors causing variability in image features, and diﬀerent methods exist to
reduce the inﬂuence of breathing motion on image characteristics [44]. Due to the scan
duration of a 3D (free-breathing) PET scan, images are averaged over multiple breathing
cycles and introduce some noise. During a respiratory correlated 4D PET acquisition,
counts are binned into typically 5 to 10 phases. This gating based on respiratory motion
reduces blurring, but due to the reduced acquisition time per phase an increased noise is
observed. However, there are also motion correction techniques available [45, 46, 47]. For
CT images of lung cancer patients, the mid-ventilation phase of a respiratory-gated (4D)
acquisition is commonly used, in the motion management option, for target delineation.
This phase is typically used for treatment planning purposes and the GTV or MTV can
also be used as the ROI for tumour quantiﬁcation with radiomics. Variations in radiomics
feature values may occur when a diﬀerent phase or a static (3D) CT is used instead. In
Figure 2.2, variations in SUVmax are shown using diﬀerent acquisition methods.
Figure 2.2: Fused PET/CT images obtained with optimal gating (left), 3D reconstruction
(middle) and 3D reconstruction (4D), showing variations in SUVmax [45]. PET, positron emission
tomography; CT, computed tomography.
For generalizability and robust extraction of radiomics for lung cancer, it is important
that the impact of tumour motion on the radiomics feature values is minimized, using
gated acquisitions or breath-hold methods.
Two recent studies investigated the inﬂuence of motion on radiomics feature values
derived from PET and CT. Relative diﬀerences in features values were calculated between
3D and 4D acquisitions. A study by Yip et al. [33] investigated ﬁve texture features
derived from 3D PET and 4D PET for 26 lung cancer patients. In this study, 4D PET
counts were binned into ﬁve phases and the diﬀerences in features values between all ﬁve
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phase bins were assessed. They reported signiﬁcant diﬀerences between 3D and all bins
of 4D PET for three features and signiﬁcant diﬀerences between 3D and 4D for four out
of ﬁve bins for one feature. The textural feature ‘Contrast’ was not signiﬁcantly diﬀerent
between 3D and 4D PET. Between diﬀerent breathing phases, none of the ﬁve features
was signiﬁcantly diﬀerent. A second study evaluated the inﬂuence of 56 radiomics features
between 3D PET/CT and 4D PET/CT acquisitions for lung cancer patients (n=23) [32].
The acquired data from the PET scan were binned into ten phases. Features were extracted
from the ﬁrst phase (inhale) and the ﬁfth phase (exhale) of the respiratory-gated scan.
They found that the diﬀerences in features between a 3D and 4D acquisitions varied
between 0 % and 193 % for PET and 0 % and 176 % for CT, with the feature kurtosis
being an outlier for both modalities. Substantial diﬀerences between radiomics features
derived from 3D and 4D acquisitions were observed for both CT and PET. Respiratory-
gated imaging reduces eﬀects of motion, including blurring, rotation and deformation at
the expense of a somewhat higher noise level. It is important to choose the respiratory
phase-bin with robust features for quantitative tumour characterization using 4D imaging.
To improve standardization in radiomics, acquisition and reconstruction protocols used to
acquire quantitative image features should always be described in detail for both PET and
CT.
Methodological issues
There is one major risk in radiomics studies: the selection of signiﬁcant features by chance
and overﬁtting. This issue is very similar to that in the ﬁeld of genomics. Authors
should clearly state in their publication, in what way the study has advanced the ﬁeld
of radiomics and how it has speciﬁcally identiﬁed and met an unmet need. It is also
important that authors avoid making overly optimistic claims concerning robustness and
generalizability as they diminish scientiﬁc and clinical impact. Furthermore, only 5 of the
22 articles were externally validated, this highlights another methodological issue. Study
design, protocols, detailed quality assurance processes and standard operating procedures
should be exhaustively reported in the publications. Rigorous reporting guidelines and
requirements are necessary for the maturation of radiomics. While the minute technical
details of radiomics and ﬁnding external validation datasets can be tedious, they potentially
have a great inﬂuence on the robustness, generalizability and confound meta-analyses. The
following points are crucial in radiomics studies:
1. I. Standardized imaging protocols allow for appropriate meta-analysis;
2. II. The eﬀects of inter-scanner diﬀerences should considered and minimized;
3. III. Robust segmentation, preferably automated, is advantageous for ranking features
on the basis of their spatial reproducibility/stability;
4. IV. Test-retest is useful for ranking features on the basis of their temporal
reproducibility/stability [17];
5. V. Independent validation datasets, preferably from another centre and multiple
datasets can provide crucial information with regard to overﬁtting, clinical
performance and generalizability.
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Conclusions
There are two main applications of radiomics in lung cancer, classiﬁcation of lung nodules
(diagnostic) or prognostication of established lung cancer (theragnostic). Overall, it is clear
that radiomics has great potential to improve diagnosis and patients stratiﬁcation in lung
cancer. It may also have a clinical impact as imaging is routinely used in clinical practice,
providing an unprecedented opportunity to improve decision support in lung cancer for
diagnosis or treatment at low cost [48, 49, 50, 51].
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Abstract
Background
Standardization protocols and guidelines for positron emission tomography
(PET) in multicenter trials are available, despite a large variability in image
acquisition and reconstruction parameters exist. In this study, we investigated
the compliance of PET scans to the guidelines of the European Association of
Nuclear Medicine (EANM). From these results, we provide recommendations
for future multicenter studies using PET.
Material and methods
Patients included in a multicenter randomized phase II study had repeated
PET scans for early response assessment. Relevant acquisition and
reconstruction parameters were extracted from the digital imaging and
communications in medicine (DICOM) header of the images. The PET
image parameters were compared to the guidelines of the EANM for tumor
imaging version 1.0 recommended parameters.
Results
From the 223 included patients, 167 baseline scans and 118 response scans
were available from 15 hospitals. Scans of 19 % of the patients had an uptake
time that fulﬁlled the Uniform Protocols for Imaging in Clinical Trials response
assessment criteria. The average quality score over all hospitals was 69 %.
Scans with a non-compliant uptake time had a larger standard deviation of
the mean standardized uptake value (SUVmean) of the liver than scans with
compliant uptake times.
Conclusion
Although a standardization protocol was agreed on, there was a large
variability in imaging parameters. For future multicenter studies including
PET imaging, a prospective central quality review during patient inclusion is
needed to improve compliance with image standardization protocols as
deﬁned by EANM.
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Background
Many studies have shown that 18F-ﬂuorodeoxy glucose positron emission tomography (18F-
FDG-PET) can be used for early response assessment [1, 2, 3, 4, 5]. Treatment response
is measured by the relative change in standardized uptake value (SUV) during treatment.
Many factors aﬀect SUV, such as patient preparation procedures, acquisition parameters
and reconstruction parameters. Therefore, if response assessment using 18F-FDG-PET
data is performed in multicenter studies it is of utmost importance that acquisition and
reconstruction are standardized. Also in preclinical research the development of PET as
a predictive tool is desirable. However, reaching a high degree of reproducibility and
sensitivity in small animal studies using FDG-PET is also challenging. Therefore it is
important to minimize methodological issues in preclinical as well as clinical studies as
much as possible by standardize acquisition and reconstruction [6].
In 2010, the European Association of Nuclear Medicine (EANM) published the tumor
PET imaging guidelines version 1.0, which give a minimum standard for acquisition and
reconstruction of FDG-PET scans [7]. This protocol standardizes patient preparation, FDG
dosage, reconstruction settings, data analysis and include a multi-center quality control
phantom measurement procedure [7, 8, 9, 10].
In 2011, the multicenter randomized phase II NVALT12 (NCT01171170) study in
stage IV non-small cell lung cancer started. Part of this study was an imaging sub-study
where repeated 18F-FDG-PET imaging for early response assessment was performed [11].
In the NVALT12 protocol it was assumed that the EANM 1.0 imaging guidelines had
been implemented in the hospitals and that 18F-FDG-PET scans were performed
according to these guidelines. EANM 1.0 reconstruction of the 18F-FDG-PET images
was recommended, although reconstruction might be performed according to
institutional standards and therefore variability in image parameters could be expected.
In this study, we investigated the quality of the 18F-FDG-PET scans in the NVALT12
study and the impact of deviations on the mean SUV of the liver. By identifying the sources
of variability we derived recommendations for future reduction of these uncertainties for
early response assessment.
Material and methods
Between January 2011 and January 2013, a total of 223 patients were included in the
NVALT12 study [12]. The baseline 18F-FDG-PET scan was standard of care, and only for
patients who had an 18F-FDG-PET at baseline as part of the standard work-up for lung
cancer a second 18F-FDG-PET scan was performed. Scans were anonymized locally and per
CD sent to the central hospital were the analysis was done. One hundred and sixty-seven
baseline 18F-FDG-PET scans and 118 response 18F-FDG-PET scans were retrieved. Scans
that could not be converted to SUV (i.e. SUV conversion information missing) were also
excluded (baseline n=9; response n=9), which meant that only for 158 baseline scans and
109 response scans the SUVmean of the liver could be analyzed. The 18F-FDG-PET scans
were obtained in a multicentric setting from 15 diﬀerent hospitals using PET scanners
from three diﬀerent vendors: vendor A (Philips Healthcare, Best, the Netherlands), vendor
B (GE Healthcare, Chicago, IL, USA) and vendor C (Siemens Healthineers, Erlangen,
Germany).
For the quality analysis, we performed a Digital Imaging and Communications in
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Medicine (DICOM) header extraction to extract the radiopharmaceutical start time,
series time, attenuation correction method, randoms correction method, scatter
correction method, reconstruction method, convolution kernel width and matrix size.
To check the quality of the 18F-FDG-PET scans, the image acquisition and
reconstruction parameters extracted from the DICOM header were compared to the
acquisition and reconstruction parameters as recommended by the EANM 1.0. In the
paragraphs below the EANM parameters that were used for the quality check are
described.
Uptake time
The EANM 1.0 guidelines recommend that emission scanning should start 55-65 minutes
after FDG administration. To test if the scans of a patient could be used for response
assessment the Uniform Protocol for Imaging in Clinical Trials (UPICT) criteria were used.
The UPICT protocol speciﬁes that when a scan is repeated on the same patient, it is
important that the uptake time is consistent with an acceptable variance of ±15 minutes,
provided that both scans do not start before 55 minutes after FDG administration [10].
The uptake time in our study was the diﬀerence in time between the radiopharmaceutical
start time and the start of the PET acquisition (i.e. DICOM series time).
Corrections
In order to obtain the quantitative information from a 18F-FDG-PET scan, an attenuation
correction and corrections for random and scatter coincidences are required [13]. Diﬀerent
methods to correct for randoms and scatter exist, depending on the speciﬁc implementation
at the scanner and the vendor. For this analysis, it was only checked if the correction was
applied.
Image reconstruction
Based on a phantom study in 2008, most PET/CT scanners provide images with a spatial
resolution close to 7 mm full width at half maximum (FWHM) when using the default by
the manufacturer-recommended image reconstruction settings [9]. Other settings, such as
smoothing ﬁlters and image matrix size can be changed with preservation of a ﬁnal image
resolution of approximately 7 mm FWHM and harmonized interpretation and analysis of
multicenter data is possible.
The scans in this study were performed on eight diﬀerent PET scanners from three
diﬀerent vendors: 41 % (69/167) of the scans were performed on a scanner of vendor A,
2 % (4/167) on a scanner of vendor B and 56 % (94/167) on a scanner of vendor C. For
scans performed on a scanner of vendor B or C, the indicative reconstruction settings are
a matrix size of 128x128 or 256x256, a post-reconstruction smoothing using a 5-6 mm
FWHM Gaussian ﬁlter and a 2D/3D ordered subset expectation maximization (OSEM)
reconstruction with the number of iterations times the number of subsets above 30. For
scans performed on a scanner of vendor A, the indicative reconstruction settings are a
matrix size of 144x144 and a line-of-response (LOR-RAMLA)/3D RAMLA/3D ordered-
subset iterative time-of-ﬂight (BLOB-OS-TF) reconstruction method. For reconstructions
with point spread function (PSF) corrections, the post-reconstruction smoothing need to
be increased to 7-8 mm.
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Quality score
To check possible diﬀerences in PET quality between the diﬀerent hospitals we scored
every scan individually and calculated the average score of the scans per hospital. For
every correct parameter, the scan received a point and the number of points per scan were
divided by the number of known parameters for that scan, so missing data were excluded
from the quality score.
Inﬂuence on SUV
To investigate the inﬂuence of image parameters on SUV, a spherical volume of interest
with a diameter of 3 cm was delineated in the right lobe of the liver [14]. A mean SUV of
the liver between 1.3 and 2.5 was deﬁned as a correct quality scan [8].
Results
There were only a few scans with diﬀerences in reconstruction parameters between the
baseline scan and the response scan; some patients had the baseline scan on a scanner of
vendor C and the response scan on a scanner of vendor A (n=2) and some other patients
had the baseline scan without PSF and the response scan with PSF (n=2) (see also Figure
3.1).
About one-third of the scans (35 %; 97/280) of all scans had an uptake time between
55 and 65 min. Twelve percent (14/118) of the scans had an uptake time between 55 and
65 min for the baseline scan and for the response scan (Figure 3.2). Due to the range in
uptake time we calculated the median instead of the mean. The median uptake time was
64 min for the baseline scan as well as for the response scan (see also Table 3.1 in the
Supplementary Material). In 11 patients both scans had an uptake time less than 55 min.
In only 19 % (53/285) of the patients, both scans had an uptake time of more than 55
min and a diﬀerence of less than 15 min between the two scans and could therefore be
used for response assessment according to UPICT.
The corrections for attenuation, random and scatter coincidences could be retrieved for
86 % (144/167) of the baseline scans and for 78 % (92/118) of the response scans (Table
3.1 in the Supplementary Material). For the other scans the information was missing.
Scans that had missing information were from the same hospital (see also Figure 3.1).
About 50 % of the baseline scans and 50 % of the response scans performed on a
scanner of vendor A were reconstructed according to the EANM 1.0 guidelines. For 24 %
of the baseline scans and 25 % of the response scans performed on a scanner of vendor A
the reconstruction method was missing. For the scans performed on a scanner of vendor
B or C a large variability in reconstruction method existed. Thirty-three percent of the
baseline scans and 37 % of the response scans performed on a scanner of vendor B or C
were reconstructed according to the EANM 1.0 guidelines. No reconstruction parameters
were missing for the scans performed on a scanner of vendor B or C.
The average quality score over all hospitals was 0.69 (range 0.46–0.88), which means
that on average more than two-third of the image parameters were EANM 1.0 guideline
compliant. Hospitals with a scanner of vendor A scored on average slightly higher than
hospitals with a scanner of vendor B or C (vendor A: 0.80 (range: 0.56–0.88); vendor B
or C: 0.64 (0.46–0.88)).
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Although there was a large variability in image parameters, most scans had a SUVmean
of the liver which was EANM 1.0 guideline compliant (64 %; 171/267), only 5 % (8/158)
of the baseline scans and 2 % (2/109) of the response scans had a SUVmean below 1.3.
Twenty percent (53/267) of the scans had a SUVmean of the liver as well as an uptake
time that was EANM 1.0 guideline compliant (Figure 3.4 in the Supplementary Material).
There was no diﬀerence in mean SUVmean of the liver for baseline or response scans with
an EANM 1.0 or UPICT compliant uptake time. When looking at the scans with a non-
guideline compliant uptake time, the mean SUVmean of the liver is comparable 2.33 for the
baseline scan and 2.23 for the response scan although the standard deviation is slightly
increased 0.62 for the baseline scan and 0.49 for the response scan.
In Figure 3.3, the hospitals were ranked in descending order according to their quality
score and there seems no trend between the quality score of the hospital and the variability
in SUVmean of the liver. No diﬀerence in SUVmean of the liver was found for the diﬀerent
vendors.
Figure 3.1: (A) Heatmap
of the image parameters of
the baseline scan ranked in
descending order according
to the quality score of the
hospital. (B) Heatmap
of the diﬀerence in image
parameters between the
baseline scan and the response
scan ranked in descending
order according to the quality
score of the hospital. Green:
EANM guideline compliant,
white: missing information,
orange: improved for response
scan, red: EANM guideline
non-compliant/worsened
for response scan, striped:
response scan on diﬀerent
scanner than baseline scan.
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Figure 3.2: Time interval between injection and start time of scan per patient ranked in ascending
order for the baseline scan. The horizontal lines show the NEDPAS speciﬁed maximum (65) and
minimal (55) uptake times. One outlier (106; 251) is removed for visualization purposes.
Discussion
Despite the availability of imaging guidelines for 18F-FDG-PET [7, 8, 9, 10, 15], our
analysis shows that a large variability in image acquisition and reconstruction parameters
existed in the 18F-FDG-PET scans of the multicenter NVALT12 trial. In this study, we
investigated the number of 18F-FDG-PET scans of the NVALT12 study that were EANM
1.0 guideline compliant and the impact of deviations on SUV. Next to that, we speculate
about possible reasons for deviations from this guideline.
The EANM 1.0 guideline recommend that PET imaging takes place 60 ± 5 min after
administration of FDG [9]. This uptake time window is essentially empiric and determined
taken ﬁnancial considerations into account, and probably not optimal [15]. It is well known
that lesion SUV for FDG continues to rise for at least 45 min after FDG injection, reaching
a plateau between 60 and 90 minutes [16, 17]. In our study, only 34 % of all scans had
an uptake time as recommended by the EANM 1.0. With that we show that in clinical
practice it is hard to have an uptake time within the recommended window of 10 min. In
the EANM guidelines version 2.0, this is changed to an acceptable uptake time window
of 55-75 min, 59 % of the scans in this study had an uptake time within this window.
Another possible reason for deviations is that the radiopharmaceutical start time extracted
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Figure 3.3: Boxplot of SUVmean of the liver of the baseline scan ranked in descending order
according to the quality score and per vendor, the scans of hospital A were, due to a missing SUV
conversion tag, not converted to SUV and are therefore empty in the graph.
from the DICOM header was not the time of FDG administration as we assumed. Because
it is currently not possible to separately store information on injection time and calibration
time in the DICOM header, some ambiguity which time is in the DICOM header under
the name radiopharmaceutical start time exists [18].
Reconstruction algorithms and voxel size are diﬀerent for the various available PET
systems and vendor dependent. Therefore, it is a challenge to ensure that images of PET
scanners from diﬀerent vendors are quantitatively comparable [15]. Multiple studies have
shown that liver metabolism can be used as reference organ due to its stable uptake over
time and therefore suitable for assessment of scan parameters [18]. We therefore used
the SUVmean of liver as quality control measure. However, our results did not show a
relation between the quality score and SUVmean of the liver. Kuhnert et al. [19] showed
that for parameters other than reconstruction method and settings (injected activity and
uptake time for example), the SUVmean of the liver could be used for quality assessment
in compliance with the EANM guideline, meaning that the large variability in SUVmean
of the liver is most probably caused by the diﬀerences in uptake time and net injected
activity. We showed that like Hristova et al. [18] the variability in SUVmean of the liver
is slightly smaller for the scans with a guideline compliant uptake time than for the scans
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with non-compliant uptake times (SUVmean 2.29 ± 0.46 vs. 2.33 ± 0.62).
The hospital analysis showed that the average score over all hospitals is 0.69 and
that scans from the same hospital mostly have the same non-compliant image parameters.
Scans with missing parameters are typically from the same hospitals which is most probably
caused by the anonymization procedure.
Our study shows that in a multicenter trial still a large variability in image parameters
exist. Especially when using the PET information for treatment decisions, like in dose
painting the high uptake region [20], it is important that acquisition and reconstruction
are standardized, otherwise diﬀerent sub-volumes will be boosted. When more complex
analysis methods (e.g., Radiomics) are used to predict therapy response using PET in the
future, it is important that image acquisition and reconstruction are standardized [21]. A
study of Carvalho et al. [22] investigated next to common PET descriptors like SUVmax
and SUVpeak if more complex descriptors like intensity volume histograms of the PET
signal are prognostic in NSCLC. They only found a trend that patients with tumors with
a more homogeneous distribution of SUV had a better prognosis [22]. Although they
only had data from one hospital, the image protocol changed during inclusion criteria and
therefore variability in SUV could be present what could have a caused the non-signiﬁcance
of SUVmax for prognosis.
A few recommendations for future multicenter studies with repeated PET imaging are
drawn. For drafting the study protocol, it is recommended to collaborate with radiologists
and nuclear medicine experts to assure access to the current imaging guidelines to keep
the variability in image acquisition and reconstruction parameters as low as possible. Next,
it is recommended to use an anonymization process that keeps all DICOM ﬁelds necessary
for SUV quantiﬁcation and investigation of the acquisition and reconstruction parameters.
For calculating the uptake time, take the acquisition time near the midplane slice of the
tumor. A ﬁnal recommendation in a multicenter trial setting using 18F-FDG-PET involves
a prospective rapid quality review, which is a good procedure to improve compliance
with imaging guidelines and tackle diﬃculties in image sharing and processing as early as
possible [18]. More details of these recommendations can be found in Table 3.2 in the
Supplementary Material.
In conclusion, although guidelines for tumor imaging exist, there is still a large
variability in acquisition and reconstruction parameters of 18F-FDG-PET imaging in
multicenter studies. In the future, these variations should be minimized by performing a
rapid quality review that tackle diﬃculties in image sharing and processing as early as
possible.
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Baseline scan Response scan Overlap baseline
and response
Analyzed 18F-FDG-PET/CT scans 167 118 118
Time interval injection-scan Median(range) Median(range)
< 55 min 50 (1-54) 51 (1-54)
55-65 min 60 (55-64) 59 (55-64)
> 65 min 76 (65-164) 74 (65-251)
Time interval injection-scan % of total (#) % of total (#) % of total (#)
55-65 min 32 % (53) 37 % (44) 12 % (14)
missing 2 % (3) 2 % (2) 2 % (2)
Attenuation correction yes 86 % (144) 83 % (98) 86 % (101)
missing 14 % (23) 17 % (20) 14 % (17)
Randoms correction yes 86 % (144) 83 % (98) 85 % (100)
missing 14 % (23) 17 % (20) 15 % (18)
Scatter correction yes 86 % (144) 83 % (98) 86 % (101)
missing 14 % (23) 17 % (20) 14 % (17)
Reconstruction method correct 44 % (74) 44 % (52) 42 % (50)
missing 14 % (24) 18 % (21) 16 % (19)
Convolution kernel correct 14 % (24) 14 % (16) 12 % (14)
missing 57 % (96) 64 % (75) 62 % (73)
Matrix size correct 44 % (74) 59 % (70) 58 % (68)
missing 0 % (0) 2 % (2) 0 % (0)
Table 3.1: Results of the quality analysis per scan. Correct means EANM guideline compliant;
missing means not in DIOCM header; yes means correction is applied.
Minimal information needed for SUV quantiﬁcation and quality assessment
DICOM header should contain:
 Modality
 Patient’s body weight
 Patient’s height
 Convolution kernel
 Attenuation correction method
 Randoms correction method
 Scatter correction method
 Reconstruction method
 Matrix size
 Study time
 Series time
 Radiopharmaceutical start time
 Radionuclide total dose
 Radionuclide half life
 Radionuclide positron fraction
 SUV conversion ﬁeld
The CRF should contain:
 Calibration dose
 Calibration time
 Injection time
Table 3.2: Minimal information in DICOM header and Case Report Form that is needed for SUV
quantiﬁcation and quality assesment.
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Figure 3.4: Uptake time versus the SUVmean of the liver. The horizontal lines show the by EANM
speciﬁed liver SUVmean (1.3-2.5), the vertical lines show the by the EANM speciﬁed uptake time
interval (55-65 min). (x-and y-axis shortened, two outliers missing (251, 2.09; 164, 2.20)).
63
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 64
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 65
4
Chapter 4
What you see is (not) what you get: tools for a non-
radiologist to evaluate image quality in lung cancer
Authors
Evelyn E.C. de Jong∗, Lizza E.L. Hendriks∗, Wouter van Elmpt, Hester A. Gietema,
Paul A.M. Hofman, Dirk K.M. De Ruysscher, Anne-Marie C. Dingemans
Adapted from
Lung Cancer, 2018 September; 123: 112–115
DOI: 10.1016/j.lungcan.2018.07.014
∗equal contribution
65
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 66
4
Chapter 4
Abstract
Medical images are an integral part of oncological patient records and they are
reviewed by many diﬀerent specialists. Therefore, it is important that besides
imaging experts, other clinicians are also aware that the diagnostic value of a
scan is inﬂuenced by the applied imaging protocol.
Based on two clinical lung cancer trials, we experienced that, even within
a study protocol, there is a large variability in imaging parameters, which has
direct impact on the interpretation of the image. These two trials were: 1)
the NTR3628 in which the added value of gadolinium magnetic resonance
imaging (Gd-MRI) to dedicated contrast enhanced computed tomography
(CE-CT) for detecting asymptomatic brain metastases in stage III non-small
cell lung cancer (NSCLC) was investigated and 2) a sub-study of the NVALT
12 trial (NCT01171170) in which repeated 18F-ﬂudeoxyglucose positron
emission tomography (18F-FDG-PET) imaging for early response assessment
was investigated.
Based on the problems encountered in the two trials, we provide
recommendations for non-radiology clinicians, which can be used in daily
interpretation of imaging. Variations in image parameters cannot only
inﬂuence trial results, but sub-optimal imaging can also inﬂuence treatment
decisions in daily lung cancer care, when a physician is not aware of the
scanning details.
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Introduction
Medical imaging is an essential component of the diagnostic procedures performed in
lung cancer. Next to that, it is also used for response assessment. The imaging
modalities used in oncology have evolved from simple X-rays to computed tomography
(CT)- and magnetic resonance imaging (MRI) scans. Nuclear imaging has innovated by
the introduction of positron-emission tomography (PET) with several tracers being
18F-ﬂudeoxyglucose (18F-FDG) most frequently used. An 18F-FDG-PET-scan using an
integrated PET-CT scanner combined with a contrast enhanced CT is nowadays a
standard staging technique in thoracic oncology. Due to ongoing technological
innovations, the sensitivity and speciﬁcity of these modalities have signiﬁcantly improved.
However, many factors, as patient preparation, image acquisition and reconstruction
parameters aﬀect the quality and accuracy of all these exams [1].
Images are nowadays an integral part of electronic patient records and can be reviewed
directly by many diﬀerent health care specialists. Consequently, it is important that besides
the imaging experts (i.e. radiologists and nuclear medicine physicians), other reviewing
clinicians are aware that the diagnostic value of a scan is inﬂuenced by the applied imaging
protocol and can recognize common artifacts (e.g. breathing artifacts). More knowledge
on this topic will provide clinicians tools to communicate with their imaging colleagues to
prevent image misinterpretation and to select the appropriate image acquisition protocol.
In two recently performed clinical trials (NTR3628 and NCT01171170) studying
patients with non-small cell lung cancer (NSCLC) we experienced that, even though
speciﬁc imaging guidelines were mandated by the trial protocol, there was a large
variability in imaging parameters. This inﬂuenced not only the outcome of the trial but
could also have impact on treatment by their clinical physician (medical oncologist /
pulmonologist). In this manuscript, we describe the imaging problems encountered in
these two trials. Furthermore, we will provide recommendations to guide clinicians in the
interpretation of medical imaging based on our experience. Our goal is that this will
result in improved clinical care as well as imaging standardization, not only in future
multicenter studies, but also in daily clinical care.
Methods
NVALT12 18F-FDG-PET/CT imaging sub-study
In all lung cancer patients eligible for therapy with curative intent, not only a chest CE-
CT, but also a whole body 18F-FDG-PET is recommended [2, 3]. The 18F-FDG-PET,
performed with a non-diagnostic low dose CT (LD-CT) for attenuation correction can
be extended by an additional diagnostic CE-CT of the chest (with or without the upper
abdomen and brain).
In the multicenter randomized phase II NVALT12 trial (NCT01171170) chemo-naïve
patients with stage IV non-squamous NSCLC were treated with paclitaxel-carboplatin-
bevacizumab with or without nitroglycerin patches. For patients in whom an 18F-FDG-PET
at baseline was performed as part of standard work-up, a second study 18F-FDG-PET was
performed within three weeks after start of treatment. The two 18F-FDG-PETs were used
for response assessment, and results have been reported [4]. It was assumed that image
acquisition was per the European Association of Nuclear Medicine (EANM) guidelines for
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tumor imaging version 1 as introduced in 2009, therefore no PET guidelines were added
to the protocol [1].
Study NTR3628: brain imaging
Although patients with brain metastases often have neurological complaints, 3-21 % of
neurologically asymptomatic patients with otherwise stage I-III lung cancer are diagnosed
with brain metastases on MRI [5]. This diagnosis is especially important in patients that
are potentially eligible for therapy with curative intent. A post-gadolinium-MRI (post-Gd-
MRI) is the imaging modality of choice, but when MRI is contra-indicated or too diﬃcult to
arrange within a reasonable time scale, a diagnostic CE-CT is an acceptable alternative [2,
3]. Except for the recommendation to include Gd-contrast series, no recommendations are
given in the ESMO and NCCN lung cancer guidelines regarding the minimal requirements
for this brain MRI (e.g. applied MRI sequences (e.g. T1, T2 FLAIR, diﬀusion weighted
imaging) and minimum contrast amount) [2, 3]. For brain CTs, intravenous administration
of iodine-containing contrast is advised but otherwise no recommendations are made (e.g.
minimum number of mAs and minimum contrast dose) [2, 3].
In the multicenter NTR3628 study, the additional value of a post-contrast brain MRI
was evaluated in stage III (based on 18F-FDG-PET/CE-CT) NSCLC patients. All patients
underwent a dedicated brain CE-CT as part of the staging whole body 18F-FDG-PET
as standard of care [6]. Imaging requirements were: a standard 18F-FDG-PET/CE-CT
protocol that included a diagnostic CE-CT brain, and a 1.5T Gd-MRI brain (1 mm slices,
0.1 mmol/kg gadolinium), with a magnetization transfer contrast (MTC) pre-pulse to
increase sensitivity and an additional post-contrast FLAIR sequence. MRI parameters
were as recommended by an experienced neuro-radiologist (PH) and followed the American
College of Radiology Appropriateness Criteria (ACR AC) [7]. After inclusion of all patients,
CE-CTs and MRIs were per protocol centrally reviewed by PH for protocol adherence and
presence of brain metastases.
Results
NVALT12 18F-FDG-PET/CT imaging sub-study
In the imaging analysis sub-study of the NVALT12, 167 baseline scans and 118 follow-up
PET scans for response evaluation were present. Only 97 (34 %) of the 285 18F-FDG-
PETs performed in this study had an 18F-FDG uptake time as recommended by the EANM.
Fifty-four (19 %) scans had both uptake times in agreement with the uniform protocols
for imaging in clinical trials (UPICT) guidelines. Supplementary Material Figure 4.2 shows
the uptake times of the baseline- and the response scans ranked in ascending order for
the baseline scan, only the uptake times between the red lines can be used for response
assessment. The other investigated parameters in this imaging sub-study, correction factors
(attenuation, randoms, scatter) and reconstruction settings (method, convolution kernel,
matrix size) were assessed in a quality score.
In this study, 60 % (171/285) of the 18F-FDG-PETs had a SUVmean of the liver within
reference values. Figure 4.1 shows an example of how a diﬀerence in SUVmean of the liver
between the baseline and the response scan can lead to a visual underestimation of tumor
response. Although we expected a non-compliant SUVmean of the liver for scans with a
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Figure 4.1: a) Baseline 18F-FDG-PET/CT scan of the NCT01171170 trial; b) Response 18F-FDG-
PET/CT scan of the same patient, showing that a diﬀerent SUVmean of the liver can lead to a
visually underestimation of response in the tumor; c) Axial CT image of the brain of the NTR3628
after contrast administration, reconstructed with a ﬁeld of view of 500 x 500 mm with raised arms
(note the high level of noise and the streak artifacts due to beam hardening); d) Axial CT image
of the brain of the same patient at approximate the same level, also after contrast administration,
reconstructed with a FOV of 200 x 200 mm with the arms lowered. The window and level setting
are identical as well as other acquisition parameters for all imaging, note the diﬀerence in image
quality.
low quality score, our results did not show such a relation between the quality score and
SUVmean of the liver [8].
Study NTR3628: brain imaging
With respect to dedicated brain imaging, imaging related problems were encountered both
during set-up and after central imaging review. Trial set-up was in 2012 and it was planned
to have four hospitals involved, but one did not have a MRI scanner that could meet the
required technical standards and was excluded from participation. Two other hospitals used
MRI protocols that did not meet the required standards (5 mm instead of 1 mm slices, no
MTC technique), but they agreed to update their protocols to be able to participate in
the study.
Two-hundred-ﬁfteen neurologically asymptomatic, extracranial stage III (based on the
18F-FDG-PET-CE-CT) NSCLC patients were included between December 2012 and July
2016. After central review, it turned out that in 56 patients (26 %) the CE-CT of the
brain did not meet the criteria for a dedicated brain imaging protocol. Remarkably, for
these patients CE-CT brain results were reported in the radiology report without noting
the limitations of the study. Problems with these brain CE-CTs were the ﬁeld of view
((FOV), adjusted to the thorax, but not to the brain) and the arm position (above the
head instead of at thorax level, see Figure 4.1).
Discussion
Imaging techniques have signiﬁcantly evolved over the last years and have become more
sensitive for the detection of subtle abnormalities. In (lung) cancer guidelines,
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Image Modality Recommendations Consequences when not performed
MRI brain T2 Combination of sequences gives a complete overview,
missing a sequence can lead to a wrong diagnosis (e.g.)
benign vs. malignant)
T2-FLAIR
DWI
T1 before contrast
T1 post contrast
Axial slice thickness between 3 mm and 5 mm With thicker slices small lesions can be missed
Minimal 1.5 T Too low signal-noise ratio and lower resolution can lead
to missing small lesions
CE-CT brain Field-of-view should be set to head Artefacts
Arms of the patients at thorax level Artefacts
Delayed imaging Less contrast in the head
Higher contrast dose Lesion less visible
18F-FDG-PET/CT Identical scanner Diﬀerent acquisition parameters
Patient position similar to baseline scan Diﬃcult measuring same region of interest
Identical PET acquisition repeated scans Diﬀerent spatial resolution, diﬀerent SUV values
Identical PET reconstruction repeated scans Diﬀerent spatial resolution, diﬀerent SUV values
Uptake times > 55 min; < 75 min Lower, higher SUV values
Δ uptake times between repeated scans > 15 min SUV value deviations
DICOM header/CRF contains: injection time, scan
time, patient weight, radionuclide dose, SUV
conversion tag
SUV value cannot be calculated
Mean SUV liver between 1.3 and 2.5 Misleading visual interpretation
If any of the recommendations is not met, please consult your nuclear medicine or radiology expert.
Table 4.1: Recommendations and consequences for a quality check of repeated 18F-FDG-PET/CT
scans, brain CE-CT scans and brain MRI scans based on current guidelines, expert opinion and
results of two clinical trials
recommendations regarding imaging techniques are made and even separate detailed
18F-FDG-PET-(CT) recommendations exist [1, 2, 3]. However, no recommendations are
made on the minimal technical requirements, resulting in a large variation in accuracy.
Therefore, there is a large variability in imaging parameters and scanners, which can
inﬂuence not only the clinical trial outcome but also the clinical interpretation by the
treating physician. In this manuscript, we report on two trials in which problems were
encountered due to variation in applied imaging protocols, which people did not realize
beforehand.
In NTR3628, after central imaging review, it turned out that the CE-CTs brain of
several included patients suﬀered from unreported serious ﬂaws. In this speciﬁc trial, the
non-diagnostic CE-CT had no clinical consequences, as all patients underwent a post-
Gd-MRI. However, when limitations of an examination are not recognized nor reported,
this can have serious consequences (see Table 4.1). Depending on geographical location
and institution, in 48-62 % of patients a CE-CT is performed instead of a Gd-MRI to
screen for brain metastases [9]. Although not reported in CE-CT imaging guidelines, is
the importance of the patient position: it should be reproducible and standardized, and it
matters what the FOV and patient position is. The FOV should be adjusted to the size
of the head and arms should be at thorax level to reduce artifacts and acquire diagnostic
images (see Figure 4.1). Furthermore, just the application of iodine contrast administration
does not make the CT-brain diagnostic: timing of the scan relative to contrast injection
and the amount of contrast material injected are important.
For tumor response assessment using 18F-FDG-PET, it is important that scans are
performed with the same acquisition and reconstruction settings as baseline. Because
varying uptake times lead to variations in measured SUV, a larger uptake time will result
in a higher SUV because tumor SUV increases over time. In response assessment studies,
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changes in SUV over time are the parameter of interest and therefore diﬀerences in uptake
times between repeated scans can lead to scan misinterpretation. Variability in uptake
times of the baseline as well as the response scan made that only 46 scans could be used
for early response assessment in the NVALT12 sub-study. A study of Kuhnert et al. [10]
showed that for settings like the injected activity and the uptake time the SUVmean of the
liver could be used for quality assessment in compliance with the EANM guideline. This
means that in the NVALT12 sub-study the large variability in SUVmean of the liver is most
probably caused by the diﬀerences in uptake time (although a treatment eﬀect cannot be
excluded). In the NVALT12 sub-study no relation between deviation in image parameters,
reﬂected in the quality score, and the SUVmean of the liver was reported. The SUVmean of
the liver can therefore not exclude all quality issues, although, it could be used as a quick
quality control with reference values between 1.3 and 2.5.
Our recommendations for clinicians regarding repeated 18F-FDG-PET imaging for
response assessment are to try to use the same scanning parameters as for the ﬁrst scan,
or check if the same scan parameters are used as in the previous scan. Scans with an
uptake time less than 55 minutes or more than 75 minutes cannot reliable be used and
checking the SUVmean of liver can be used as quality assurance. For data analysis it is
important that all scan parameters are noted in the DICOM header, but at least injection
time, scan time, patient’s body weight, radionuclide dose and the SUV conversion tag
should be present. An example of a DICOM header with the minimum required tags is
shown in Supplementary Material Figure 4.3.
For brain CE-CT combined with the 18F-FDG-PET scan, we recommend that the
clinician checks the head FOV, the patient arm position and the contrast dose and timing.
For MRI, at least a T2-weighted sequence, a T2-FLAIR and a T1-weighted sequence
pre- and post-contrast should be performed. See for an overview of these recommendations
Table 4.1. If any of the recommendations cannot be met it is advised to consult an imaging
expert.
In addition, radiologists need to be informed about the indication for the requested
scan and therefore clinicians must provide all clinical information that is important to
determine the optimal imaging protocol to apply. Next to that, for non-imaging clinicians
it is important to evaluate whether the applied imaging protocol is indeed adequate for
the requested purpose. Our quality recommendations will potentially lead to a more
uniform clinical interpretation and could be helpful during multidisciplinary meetings.
These recommendations should preferably be tested prospectively.
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Figure 4.2: Time interval between FDG injection and start of PET scan ranked in ascending order
for the baseline scan. The grey area shows uptake times lower than 55 minutes, the red lines
show the 15 minutes diﬀerence between the repeated scans (i.e. only the scans between the red
lines can be used for response assessment). Figure adjusted from [1]
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Figure 4.3: Example of a section of a DICOM header from an 18F-FDG-PET scan. The red boxes
show the minimum required tags.
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Abstract
Background
Radiomic analyses of CT images provide prognostic information that can
potentially be used for personalized treatment. However, heterogeneity of
acquisition- and reconstruction protocols inﬂuences robustness of radiomic
analyses. The aim of this study was to investigate the inﬂuence of diﬀerent
CT-scanners, slice thicknesses, exposures and gray-level discretization on
radiomic feature values and their stability.
Material and methods
A texture phantom with ten diﬀerent inserts was scanned on nine diﬀerent
CT-scanners with varying tube currents. Scans were reconstructed with 1.5
mm or 3 mm slice thickness. Image pre-processing comprised gray-level
discretization in ten diﬀerent bin widths ranging from 5 to 50 HU and
diﬀerent resampling methods (i.e., linear, cubic and nearest neighbor
interpolation to 1x1x3 mm3 voxels) were investigated. Subsequently, 114
textural radiomic features were extracted from a 2.1 cm3 sphere in the center
of each insert. The inﬂuence of slice thickness, exposure and bin width on
feature values was investigated. Feature stability was assessed by calculating
the concordance correlation coeﬃcient (CCC) in a test-retest setting and for
diﬀerent combinations of scanners, tube currents and slice thicknesses.
Results
Bin width inﬂuenced feature values, but this only had a marginal eﬀect on
the total number of stable features (CCC > 0.85) when comparing diﬀerent
scanners, slice thicknesses or exposures. Most radiomic features were aﬀected
by slice thickness, but this eﬀect could be reduced by resampling the CT-
images before feature extraction. Statistics feature ‘energy’ was the most
dependent on slice thickness. No clear correlation between feature values and
exposures was observed.
Conclusions
CT-scanner, slice thickness and bin width aﬀected radiomic feature values,
whereas no eﬀect of exposure was observed. Optimization of gray-level
discretization to potentially improve prognostic value can be performed
without compromising feature stability. Resampling images prior to feature
extraction decreases the variability of radiomic features.
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Introduction
Extraction of quantitative imaging features, also called radiomics [1], has become an
additional source of information for the development of prognostic and predictive models
[2, 3, 4, 5, 6, 7]. The total number of features that can be calculated is almost
unlimited, especially if ﬁlter-based features (e.g., Laplacian of Gaussian or wavelet) are
also taken into consideration. To incorporate such large numbers of features in
prognostic and predictive models, multiple independent and multi-centric datasets are
needed for training and validation. However, recent literature shows that there are some
challenges to overcome [8].
Several studies already showed that radiomic feature values are inﬂuenced by image
acquisition and reconstruction settings, like slice thickness and exposure [2, 9, 10, 11,
12, 13]. For instance, Mackin et al. [13] scanned a phantom with ten unique inserts
using diﬀerent acquisition parameters on computed tomography (CT) scanners of four
manufacturers. They demonstrated that the variability in textural features calculated
on the phantom scans can be in the same order of magnitude as the variability seen in
non-small cell lung cancer patients (NSCLC). Using the same phantom, Shaﬁq-ul-Hassan
et al. [12] investigated voxel-size dependency of radiomic features and found that this
dependency can be minimized by resampling to a nominal voxel size or by normalizing
the voxel size. Next to that, they found that gray-level dependency also can be reduced
by normalization. Since multi-centric data usually are acquired with diﬀerent CT-scanners
using institutional scan protocols, the lack of statistical power in validation datasets might,
therefore, be attributed to the diﬀerent acquisition settings.
In the current study, we investigated the variability in radiomic feature values for scans
with diﬀerent slice thicknesses, diﬀerent exposures and from diﬀerent CT-scanners and
performed a test-retest analysis using the same texture phantom as Mackin et al. and
Shaﬁq-ul-Hassan et al. [13, 12]. In addition to these former studies, we used a more
extensive radiomic features dataset, diﬀerent scanner types and focussed more on the
inﬂuence of gray-level discretization and resampling of voxel size on interchangeability of
radiomic features. Furthermore, we compared the variability of radiomic features values
derived from the phantom with those derived from two independent non-small cell lung
cancer (NSCLC) patient datasets, to investigate the comparability of the phantom inserts
to clinical CT-scans.
Material and Methods
Image acquisition
The Credence Cartridge Radiomics phantom (CCR), previously described by Mackin et
al. [13], consists of an acrylic case with ten diﬀerent inserts with diﬀerent textures and
was scanned on nine diﬀerent CT-scanners. We focussed on the shredded rubber insert,
because the CT-properties of this insert are most similar to tumors [13].
An overview of all scanners and settings is provided in Table 5.1. The scans were
reconstructed using two diﬀerent slice thicknesses per scanner. For the ’H‘ scanner, the
’B‘ scanner and the ’O‘ scanner the increment as well as the slice thickness was 1.5 mm
or 3 mm. For the other scanners the increment was 1 mm for scans with a slice thickness
of 1.5 mm (scanner ’S‘ had a slice thickness of 2 mm instead of 1.5) and 2 mm for the
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scans with a slice thickness of 3 mm. The reconstructed ﬁeld of view was 500 mm for all
scans.
Hospital Vendor Model Coding Exposure
time
(ms)
Convo-
lution
kernel
Tube current (mA) Focal
spot
size
(mm)
Collimation
(# × mm)
1 Siemens SOMATOM Fl 500 B31f 128, 160, 296, 592 1.2 64 × 0.6
Deﬁnition Flash
Philips Brilliance 64 P 561 B 61, 91, 119, 148, 274 1.0 64 × 0.6
2 Siemens Biograph 40 B 500 B31f 40, 60, 80 1.2 24 × 1.2
Siemens SOMATOM C 1000 B31s 26, 39, 52, 66, 121 1.2 32 × 0.6
Conﬁdence RT Pro
Siemens SOMATOM O 500 B31f 60, 80, 100 1.2 24 × 1.2
Sensation Open
3 Siemens SOMATOM L 500 B31f 64, 96, 128, 162, 296, 594 1.2 64 × 0.6
Deﬁnition Flash
4 Siemens SOMATOM V 500 B31f 64, 96, 128, 162, 298, 594 1.2 64 × 0.6
Deﬁnition AS+
5 Siemens Biograph 16 H 500 B31f 40, 60, 84, 112, 140, 216, 274 0.7 16 × 0.75
6 Philips Gemini TF 16 S 534 B 58, 88, 114, 143, 266, 497 1.0 16 × 1.5
Table 5.1: Overview scanners and per scanner exposure time, convolution kernel, tube current,
focal spot size and collimation.
All scans were performed with a tube voltage of 120 kVp and a pitch of 1.0. The aim
was to scan the phantom with the same range of CT-dose index (CTDI) settings [2.17,
3.26, 4.32, 5,43, 10, 20 mGy], but due to hardware (e.g., the risk of overheating) and
software limitations (i.e., not all exposures could be set) not all CTDIs could be obtained
for all scanners. Philips scans were reconstructed using the B kernel and Siemens scans
using the B31f or B31s kernel.
For test-retest purposes, two subsequent CT-scans were acquired on the ‘B’ and the
‘O’ scanner. The phantom was kept in place on the table without changing anything in
between, meaning that no other parameters than scanner output ﬂuctuations could have
inﬂuenced the images.
Feature extraction
A spherical region of interest (ROI) with a volume of 2.1 cm3 was contoured using
Mirada RTx (Mirada RTx 1.6, Mirada Medical, Oxford, UK) in the center of every insert.
Moreover, for test-retest purposes, the ROI was shifted to the right and downwards.
Supplementary Material Figure 5.7 shows an example CT image of the phantom in which
the ROIs are indicated in the rubber insert.
One hundred and fourteen radiomic features were extracted for the ROI in every
insert using software developed in-house. The histogram of voxel intensity values within
the ROI was described by nineteen ﬁrst order statistics (Stats) features. Textural
features were divided in ﬁve neighborhood gray-tone diﬀerence (NGTDM) features,
sixteen neighboring gray-level dependence matrix (NGLDM) features, sixteen gray-level
size zone matrix (GLSZM) features, sixteen gray-level run length matrix (GLRLM)
features, sixteen gray-level distance zone matrix (GLDZM) features and 26 gray-level
co-occurrence matrix (GLCM) features. The deﬁnitions of the radiomic features are
previously described in van Timmeren et al. [14].
The following pre-processing steps were applied prior to radiomic feature extracting:
gray-level discretization and voxel resampling. All features were calculated for ten bin
widths ranging from 5 to 50 Hounsﬁeld Units (HU), with a step size of 5 HU. Radiomic
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features were also calculated with and without applying resampling into voxel sizes of
1x1x3 mm3 using cubic, linear and nearest neighbor interpolation, which was only done
for a bin width of 25.
Analyses
The variation in feature values due to slice thickness and exposure, calculated per feature
for the rubber insert using a bin width of 25 HU, was deﬁned as the maximal diﬀerence
between scans with either the same exposure (variation due to unequal slice thicknesses)
or the same slice thickness (variation due to unequal exposures). The ratios between
the variations were calculated to investigate which features are most dependent on either
slice thickness or exposure. Features were ranked per scanner based on their ratios and
afterwards the rankings were summed, with a higher total rank indicating larger dependency
on slice thickness, and a lower total rank indicating a larger dependency on exposure.
We compared the radiomic feature values which were calculated using the three
diﬀerent resampling methods. Moreover, for ﬁve diﬀerent scanners we compared the
distribution of HU values in the rubber insert. For all scans we used in this analysis, the
phantom was scanned using a CTDI of 5.43 mGy and reconstructed with a slice
thickness of 1.5 mm. We also investigated the HU distributions after resampling into
voxel sizes of 1x1x3 mm3 using linear interpolation.
To investigate the inﬂuence of gray-level discretization on the feature values, each
feature was plotted against the bin width. Moreover, the pairwise concordance correlation
coeﬃcient (CCC) [15] was used to determine the agreement in feature values over all
inserts when comparing (1) a slice thickness of 1.5 mm with 3 mm, (2) an exposure of 60
mA with 80 mA, or (3) scanner ‘B’ with ‘O’ using the same scan protocol. The CCC ranges
from -1 (perfect negative agreement) to 1 (perfect positive agreement). A minimum CCC
of 0.85, which was used in previous studies [16, 17], was used to identify features that were
independent of the diﬀerent scanners or settings that were compared. The total number
of stable features per bin width was then used as a measure to investigate the inﬂuence
of bin width on feature stability.
Moreover, we performed a test-retest analysis to be able to compare results within
a controlled setting. For the three sets of scans that were used to perform the CCC
analyses described above: 1) B-60mA-3mm and B-60mA-1.5mm, 2) B-60mA-3mm and
B-80mA-3mm and 3) B-60mA-3mm and O-60mA-3mm, we also calculated the CCC for
the test-retest setting of both scans. The minimal CCC of these two test-retest scans
was then used to determine the number of stable features (CCC > 0.85) per bin width.
Moreover, we investigated the variability of radiomic features caused by shifted ROIs (see
‘Feature extraction’), by calculating the CCC between the radiomic features extracted from
the scan with the ROI in the center and from the same scan with the shifted ROI.
Finally, to test if the variability in tumor feature values is comparable to the variability
in feature values measured in the phantom, the results from the ten phantom inserts were
compared to two patient datasets. Patient dataset 1 consisted of 157 NSCLC patients for
which the CT-scans were acquired in diﬀerent hospitals in which the phantom was scanned
as well. Patient dataset 2 consisted of 168 NSCLC patients for which all CT-scans were
performed in a single hospital which is one of the hospitals in which the phantom was
scanned. All patient scans had a slice thickness ranging from 1 mm to 3 mm. To reduce
variability between scans, these were resampled to voxels of 1x1x3 mm3 prior to analysis
using cubic interpolation, as this corresponds to the voxel size of most the clinical images.
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Results
The feature ‘First order statistics (Stats) – Energy’ had the highest rank and thus showed
the highest dependency on slice thickness and ‘GLRLM – Run Length Nonuniformity
(RLN)’ the second highest dependency (Supplementary Material Figure 5.8). The feature
‘GLSZM – Small Area Emphasis (SAE)’ was least dependent on slice thickness and was
ranked last. In further analyses in this study, we focussed on the features ‘GLRLM –
RLN’ and ‘GLSZM – SAE’, since ‘Energy’ is independent of gray-level discretization by
deﬁnition. Figure 5.1 shows that the feature values for ‘GLRLM – RLN’ for 1.5 mm and
3 mm were more similar after resampling, which was not the case for the ‘GLSZM –
SAE’ feature values. The test-retest analysis demonstrated that the feature ‘GLRLM –
RLN’ is a stable feature (CCC > 0.85 for all bin widths), whereas the feature ‘GLSZM –
SAE’ is unstable (Supplementary Material Figure 5.10).
Figure 5.1: Scatterplots of feature values for all scanners. Per scanner, the data is sorted from
high to low exposure. Left: original data; Right: after resampling; Top: ’GLRLM-RLN’, highest
slice thickness dependency; Bottom: ’GLSZM-SAE’, lowest slice thickness dependency.
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For the feature ‘GLRLM – RLN’ the cubic, linear and nearest neighbor resampling
method resulted in very similar feature ranges after resampling (Figure 5.2). For ‘GLSZM
– SAE’, however, the nearest neighbor method resulted in a very wide range. When
comparing the three resampling methods for all features tested (n=114), for 34 (30 %)
features cubic interpolation resulted in the narrowest feature range, for 55 (48 %) features
this applied to linear interpolation, and the remaining 25 (22 %) features had the narrowest
feature range after nearest neighbor interpolation. Nearest neighborhood interpolation had
the widest range for the majority (61 %) of the features. For the feature that showed the
highest dependency on slice thickness, ‘Stats – Energy’, feature values over all scans
ranged from 6.3x108 to 1.9x109 (median 1.2x109), which reduced to a range from 5.5x108
to 6.9x108 (median 6.1x108) after resampling using cubic interpolation.
Figure 5.2: Bar plots of the spread of feature values of (A): ’GLRLM-RLN’ and (B): ’GLSZM-SAE’.
Bars range from the minimum to the maximum observed value, and the vertical lines indicate the
median. From top to bottom these bars are shown for all scans (n=90), all scans with an exposure
of 60 mA (n=6), all scans with an exposure of 80 mA (n=4), all scans with an increment of 1
mm (n=34), 2 mm (n=34) and 3 mm (n=13) and all scans after resampling the images into
1x1x3 mm3 using cubic (n=90), linear (n=90) and nearest neighbor (n=90) interpolation.
Figure 5.3 shows that the scans of the ﬁve diﬀerent scanners had a similar median HU
value: between 931 and 939 HU. When comparing the range in HU of those ﬁve scanners,
scanner ‘P’ had a much wider range than the other four scanners (160-1564 compared
to 437-1291). As shown in Figure 5.3 for the feature ‘GLCM cluster prominence’, this
also aﬀected radiomic feature values extracted from these images. The same histograms
were made after resampling, which show a similar shape as before resampling (shown in
Supplementary Material Figure 5.9).
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Figure 5.3: HU distribution of the rubber insert scanned with a ﬁxed CDTI of 5.43 mGy on
ﬁve diﬀerent Siemens and Philips scanners. From left to right and top to bottom [scanner -
tube current]: ’Fl-160mA’, ’L-161mA’, ’P-148mA’, ’S-143mA’, and ’V-162mA’. The scatterplot
in the bottom right displays the observed values of the feature ’GLCM cluster prominence’over
all scanners. The outlier in dark-green is scanner ’P’.
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Figure 5.4: Normalized feature values plotted against bin width. (A): GLCM features (n=26),
(B): GLDZM features (n=16), (C): GLRLM features (n=16), (D): GLSZM features (n=16), (E):
NGDLM features (n=16), (F): NGTDM (n=5) and ﬁrst order statistics features (n=2, dotted
lines). The red dashed lines indicate GLRLM RLN and GLSZM SAE.
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Figure 5.4 shows that every normalized feature had another bin width dependency.
Some features (e.g., ‘Energy’ and ‘Skewness’) were not dependent on bin width per
deﬁnition. In terms of feature stability, when comparing 1.5 mm scans with 3 mm scans
using an exposure of 60 mA, the total number of stable textural features hardly changed
over the diﬀerent bin widths (Figure 5.5). The median number of stable features was 49
(range 47-53). All CCC numbers for this comparison are shown in Supplementary
Material Figure 5.10, where the features that were not stable in either the test-retest of
‘B-60mA-1.5mm’ or ‘B-60mA-3mm’ are also indicated. Also, when comparing an
exposure of 60 mA with 80 mA on the same scanner, or scanner ‘B’ with ‘O’, no trend
indicating a dependency on bin width could be observed. In this case, the median
number of stable features was 66.5 (55-70) and 67.5 (56-72), respectively. Note that the
total number of stable features was much lower when comparing diﬀerent slice
thicknesses.
Figure 5.5: The total number of features with a CCC > 0.85 for each bin width when comparing
(A) a slice thickness of 1.5 mm with 3 mm (exposure 60 mA, scanner ’B’), (B) an exposure of
60 mA with 80 mA (slice thickness 3 mm, scanner ’B’), or (C) scanner ’B’ and ’O’ using the
same scan protocol (exposure 60 mA and slice thickness 3 mm). Test-retest ﬁgures are based on
minimal observed CCC in both test-retest sets that are compared.
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Figure 5.6: Bar plots of the spread of feature values over all phantom inserts and two independent
NSCLC datasets for (A): ’GLRLM-RLN’ and (B): ’GLSZM-SAE’. The bars indicate the minimum,
median, and maximum feature values. Scans were resampled to 1x1x3 mm3 voxels using cubic
interpolation and a bin width of 25 HU was used.
The images on the left side of Figure 5.5 show that approximately the same number
of features were stable for the test-retest compared to the scans with diﬀerent exposure or
acquired from diﬀerent scanners. On the other side, more features were stable in the test-
retest setting than when slice thicknesses were diﬀerent. The test-retest analysis of scan
‘B-60mA-3mm’ (bin width 25) shows that 5 out of 114 had a CCC below 0.85. When
shifting the ROI downwards (ROI ‘6s324’ in Supplementary Material Figure 5.7), there
were 8 features with CCC < 0.85, with 100 % overlap compared to the test-retest. When
shifting the delineation to the right (ROI ‘6s234’), 14 features were unstable, again with
a 100 % overlap.
The range of feature values for all inserts was compared to the range in two independent
datasets of NCSLC patients. As shown in Figure 5.6, the ‘GLRLM-RLN’ feature range
observed in the phantom is very limited and substantially lower in comparison with the
range observed in the clinical datasets, whereas the ‘GLSZM-SAE’ ranged in the same
order of magnitude. The same plots for all features are available in Supplementary Material
Figure 5.11.
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Discussion
The aim of this study was to investigate the impact of diﬀerent CT-scanners, slice
thicknesses, exposures, gray-level discretization and resampling of voxel sizes on feature
values and on their stability using a texture phantom. Moreover, we performed a
test-retest analysis. In short, we could show that CT-scanner, slice thickness and
gray-level discretization (i.e. bin width) inﬂuence feature values. A clear eﬀect of
exposure on feature values was not observed. Moreover, the stability of radiomic features
is hardly inﬂuenced by bin width, i.e. for each bin width the variability across diﬀerent
settings is similar.
Scatterplots of feature values showed that the distribution of feature values is diﬀerent
for each CT-scanner. Since scans were acquired with the same range of CTDI values, this
implies that the variability of feature values is aﬀected by diﬀerent scanners used in that
particular study. The feature ‘GLSZM – SAE’, which has the lowest rank in terms of slice
thickness dependency, appeared to be unstable in a test-retest analysis. In contrast the
feature ‘GLRLM – RLN’ had a CCC above 0.85 for all test-retest scans, whereas the CCC
was low in the comparison between 1.5 mm and 3 mm slice thickness (Supplementary
Material Figure 5.10).
A comparable eﬀect was observed in the HU histograms of ﬁve diﬀerent scans that
were acquired with the same CTDI of 5.43 mGy. The ‘Fl’, ‘L’, ‘V’, and ‘S’ scanners had
comparable HU distributions within the rubber insert. However, even though the same
radiation dose output of the CT-scanner and the same acquisition protocol was used,
scanner ‘P’ resulted in a CT-image with a much wider range of HU. The histograms
show the same pattern after resampling of the images was applied. The reason for the
discrepancy of scanner ‘P’ is unknown, but it might be the result of an incorrect calibration
of the scanner. So even with similar acquisition protocols, diﬀerent scanner types within
one dataset can inﬂuence radiomic feature values. Therefore, we recommend to take this
into account when performing radiomic studies with multiple heterogeneous datasets, i.e.,
to perform a study speciﬁc test-retest analysis [16] to eliminate features that are not robust
across diﬀerent scanners.
We also showed that a large proportion of features is inﬂuenced by the slice thickness
used for reconstruction. However, we could show that the variability in feature values
decreased after resampling was performed. This is in line with Shaﬁq-ul-Hassan et al.
[12], who showed that resampling reduced the feature variability from %COV > 70 %
to %COV < 30 %. Therefore, we recommend to always perform resampling prior to any
radiomic analysis. Despite the fact that resampling can greatly improve the robustness of
radiomic features [12], we recommend to keep the voxel size as consistent as possible, since
the variability in feature values is even lower when the voxel size is equal for all images
included in the study. This should also be taken into account when comparing training
and validation datasets that might be reconstructed into diﬀerent voxel sizes, which could
have increased the discrepancy between datasets in terms of distribution of radiomic feature
values although resampling was applied. In our study the data was resampled to a voxel
size of 1x1x3 mm3 using a cubic, linear and nearest neighbor interpolation, while in the
study of Shaﬁq-ul-Hassan et al. [12] the data was resampled to a voxel size of 1x1x2 mm3
using a linear interpolation. Our results demonstrated that linear interpolation resulted in
the narrowest feature value range for 48 % of the features and cubic interpolation for 30 %
of the features, whereas nearest neighbor interpolation had the widest range for 61 % of
the features. Therefore, cubic or linear interpolation are preferred over nearest neighbor
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interpolation when resampling to 1x1x3 mm3 voxels.
Furthermore, we investigated the inﬂuence of exposure on the feature values, as tube
current modulated CT-scans become more common. We only had data from a few scans
per CT-scanner, which made it diﬃcult to investigate the potential inﬂuence of exposure
on radiomic feature values. For none of the features, we could see a clear relationship
between feature value and the exposure. Mackin et al. [13] had quite a large range of
exposure values for the diﬀerent scanners, although the eﬀect of exposure on feature values
was not investigated, this might have inﬂuenced the scanner comparison results. In the
future, the inﬂuence of exposure should be explored on a larger dataset.
Finally, we investigated the inﬂuence of the pre-processing step of ‘gray-level
discretization’ on feature values and on their stability [18]. The main goal was to ﬁnd an
optimal bin width that could result in the highest reproducibility of radiomic features.
Almost all features change in value when choosing another bin width for gray-level
discretization. For a subset of features, a very small or very large bin width resulted in
very diﬀerent feature values across scans, whereas feature values are more similar with a
bin size in the order of 25 (Figure 5.4). Although the feature values change for diﬀerent
bin widths, we were not able to show that the stability of radiomic features is greatly
inﬂuenced by the choice of bin width (Figure 5.5 and Supplementary Material Figure
5.10). Our ﬁnding is the contrary of what Shaﬁq-ul-Hassan et al. [12] described. They
found that only seven out of 51 features were reproducible independent of the gray-level
discretization. Next to that, they found that seventeen out of 44 features showed a trend
with varying number of gray-levels, which could be a linear, quadratic or cubic-type
relation. Normalization of feature values by the number of gray-levels reduced the
variation in feature values. However, these results imply that the choice of bin width
could alter the prognostic value of a certain radiomic signature. The inﬂuence of
gray-level discretization on the prognostic value of radiomic features has not yet been
investigated and needs further research. Therefore, we cannot indicate a certain bin
width as being most optimal, but we strongly recommend to be consistent and always
clearly report which pre-processing steps have been used to improve the reproducibility
and validation of radiomic studies [9].
The test-retest analysis we have performed shows that, even when not changing
anything in between two subsequently acquired CT scans, some radiomic features were
not robust. When shifting the ROI within the same insert, even more features failed to
reach a CCC above 0.85. The only reason for the instability of features in the test-retest
setting could be the variability of scanner output, which is always present and cannot be
avoided. Therefore, these features would be too unstable even when imaging protocols
are completely standardized. We acknowledge that it is diﬃcult to deﬁne a CCC
threshold for eliminating the features, but we think that it is reasonable to exclude the
non-stable radiomic features with CCC < 0.85 in future radiomic studies.
One of the limitations of this study is the ignorance of convolution kernel used during
reconstruction. We considered the Philips ‘B’ kernel and the Siemens ‘B31s’ and ‘B31f’ as
interchangeable, but this was not investigated. We also did not investigate the inﬂuence
of iterative kernels or others commonly used in clinical practice, which might also aﬀect
the variability of radiomic features.
In this study, we investigated the inﬂuence of factors which we expected to have a major
eﬀect on radiomics. Nonetheless, other parameters inﬂuence image quality and therefore
could have inﬂuenced the results. For example, scanners from diﬀerent manufacturers have
diﬀerent possibilities for focal spot size and collimation width due to diﬀerences in technical
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design. These parameters do inﬂuence the image appearance: a smaller collimation width
results in increased noise and a larger focal spot size results in decreased image quality
(i.e. reduced sharpness). In the original design of the study we did not control for these
parameters and the values were only traced back after the study was performed. In future
studies, the inﬂuence of these parameters on radiomic features should be evaluated, and
we recommend to report as much parameters as possible.
Furthermore, the potential inﬂuence of change in volume of the spherical region of
interest was not investigated. Although all images were registered to the same reference
scan which was used for delineations, this always leads to slightly diﬀerent volumes.
Whereas the spherical volume should consistently be 2.1 cm3, we noticed deviations in
the order of 0.1 cm3. This could have inﬂuenced the results for radiomic features that
are correlated to volume.
Another limitation of current and former studies [12, 13] is the phantom itself. The
squared shape makes the phantom prone to scatter artefacts around the edges. A new
cylindrical version of the CCR phantom is therefore being produced and should be used in
future CT-scanner variability studies.
In our study we compared the distribution of radiomic features values compared to
two clinical NSCLC patient datasets. One possible explanation for the diﬀerences between
the two patient datasets is that patient dataset 1 was acquired from multiple hospitals
and dataset 2 from a single hospital, which might have resulted in a wider distribution of
feature values for dataset 1. Furthermore, the distribution of feature values shows that not
all inserts are very representative for clinical NSCLC datasets. Mackin et al. [13] already
showed that the mean and standard deviation in HU of the CCR phantom is diﬀerent than
for patient data. The distribution of HUs in the rubber insert was most comparable to the
distribution observed in the NSCLS datasets. However, radiomic features derived from any
of the phantom inserts typically had a very limited range when compared to the clinical
datasets, as well as a diﬀerent median value. Inserts with more representative textures are,
therefore, warranted for future phantom studies.
In conclusion, this study shows that feature values are inﬂuenced by CT-scanner, slice
thickness and bin width, whereas the inﬂuence of exposure could not be shown. Moreover,
the inﬂuence of bin width on feature stability was not clear, meaning that we could not
indicate an optimal bin width. The test-retest analysis shows that some radiomic features
are not robust in a strictly controlled setting: we recommend to exclude those in future
radiomic studies. Moreover, we strongly recommend to always perform the pre-processing
steps ‘resampling’ and ‘gray-level discretization’ for each radiomic study and to clearly
report the settings that have been used to improve consistency and reproducibility of
radiomic analyses.
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Figure 5.8 Feature ranking based on the ratio between variations due to slice thickness and due
to exposure. This ranking is the sum ranking over all scanners.
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Figure 5.9 HU distributions of the rubber insert scanned with a ﬁxed CTDI of 5.43 mGy on ﬁve
diﬀerent scanners, after resampling to voxels to 1 x 1 x 3 mm3 using linear interpolation. From
left to right and top to bottom [scanner - tube current]: ‘Fl-160 mA’, ‘L-161 mA’, ‘P-148 mA’,
‘S-143 mA’, and ‘V-162 mA’. The scatterplot in the bottom right displays the observed values of
the feature ‘GLCM cluster prominence’ over all scanners. The outlier in dark-green is scanner ‘P’.
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Figure 5.10 Feature stability comparing a slice thickness of 1.5mm with 3mm (scanner ‘B’,
exposure 60mA). CCC-values < 0.85 are indicated in red, and values ≥ 0.85 in green. The
cells marked in bold indicate features with a CCC < 0.85 in at least one of the test-retest scans
[scanner – tube current – slice thickness]: ‘B-60mA-3mm’ or ‘B-60mA-1.5mm’.
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Abstract
Purpose
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood ﬂow
and consequently decreases hypoxia. Therefore, changes in
18F-ﬂuorodeoxyglucose positron emission tomography (18F-FDG PET)
uptake pattern may occur. In this analysis, we investigated the feasibility of
18F-FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab
(PCB) treatment with and without NTG patches. And we compared the
18F-FDG PET response assessment to RECIST response assessment and
survival.
Methods
A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were
included in a phase II study (NCT01171170) randomizing between PCB
treatment with or without NTG patches. For 60 participating patients, a
baseline and a second 18F-FDG PET/computed tomography (CT) scan,
performed between day 22 and 24 after the start of treatment, were
available. Tumor response was deﬁned as a 30 % decrease in CT and PET
parameters, and was compared to RECIST response at week 6. The
predictive value of these assessments for progression free survival (PFS) and
overall survival (OS) was assessed with and without NTG.
Results
A 30 % decrease in SUVpeak assessment identiﬁed more patients as
responders compared to a 30 % decrease in CTdiameter assessment (73 % vs.
18 %), however, this was not correlated to OS (SUVpeak30 p=0.833;
CTdiameter30 p=0.557). Changes in PET parameters between the baseline and
the second scan were not signiﬁcantly diﬀerent for the NTG group compared
to the control group (p value range 0.159-0.634). The CT-based (part of the
18F-FDG PET/CT) parameters showed a signiﬁcant diﬀerence between the
baseline and the second scan for the NTG group compared to the control
group (CTdiameter decrease of 7 ± 23 % vs. 19 ± 14 %, p=0.016,
respectively).
Conclusion
The decrease in tumoral FDG uptake in advanced NSCLC patients treated with
chemotherapy with and without NTG did not diﬀer between both treatment
arms. Early PET-based response assessment showed more tumor responders
than CT-based response assessment (part of the 18F-FDG PET/CT); this was
not correlated to survival. This might be due to timing of the 18F-FDG PET
shortly after the bevacizumab infusion.
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Introduction
Molecular imaging with 18F-ﬂuorodexoyglucose positron emission tomography (18F-FDG
PET) has an established role in the staging of patients with non-small cell lung cancer
(NSCLC). In addition, an increasing number of studies have shown that 18F-FDG PET is
useful for early response assessment in NSCLC patients treated with cytotoxic
chemotherapy [1, 2, 3, 4].
Tumor hypoxia is a common phenomenon in lung cancer, and is related to poor
prognosis due to treatment resistance [5, 6, 7, 8, 9, 10, 11]. Preclinical studies have
shown that nitric oxide (NO)-donating drugs increase blood ﬂow and thereby decrease
hypoxia [12]. Nitroglycerin (NTG), a vasodilator, is such a drug. By increasing the tumor
blood ﬂow, NTG consequently augments antitumor drug delivery and inhibits hypoxia
inducible factor (HIF-1α) [13]. In preclinical models, administration of low doses of NTG,
at least partially, reverses the hypoxia-induced resistance to anticancer drugs [14].
Yasuda et al. [15] showed that the combination of platinum-based chemotherapy and
NTG improves overall survival (OS) in patients with stage IIIb/IV NSCLC. However, two
recent randomized studies, including the Dutch NVALT12 study, could not conﬁrm these
results and no clinical eﬀect was observed by the addition of NTG [16, 17].
Negative correlation between perfusion computed tomography (CT) and hypoxia PET
on a population basis were also described in literature [18], suggesting that hypoxia is
negatively correlated to tumor blood ﬂow. Consequently, if treatment with NTG improved
tumor perfusion, this could translate into a change in FDG uptake [13]. This concept was
tested in the context of the randomized NVALT12 study that sought to investigate whether
the addition of NTG to ﬁrst-line paclitaxel-carboplatin-bevacizumab (PCB) chemotherapy
would improve progression free survival (PFS).
In clinical practice, tumor response assessment is based on changes in tumor size,
according to response evaluation criteria in solid tumors (RECIST) at week 6 [19, 20].
However, response monitoring is complex because the tumor has to change signiﬁcantly
in size and shape before a response is reliably detected by CT [21, 22]. This leads to an
underestimation of the eﬃcacy of cytostatic therapeutic agents that stabilize the disease,
in contrast to conventional cytotoxic drugs, which induce shrinkage of tumor dimensions
in the case of tumor response [19]. Metabolic changes, measured by 18F-FDG PET, will
occur earlier than changes in size and may, therefore, be used for early treatment response
assessment. A decrease in metabolic activity of the primary tumor after one cycle of
chemotherapy treatment is predictive for better outcome [1, 18, 23, 24].
In this paper, we investigated the feasibility of 18F-FDG PET for response assessment to
PCB treatment with and without NTG patches. Furthermore, we compared the 18F-FDG
PET response with both the commonly used RECIST and survival.
Material and Methods
Patient characteristics
In the multicentric NVALT12 trial (NCT01171170), 223 patients with metastatic non-
squamous NSCLC were randomized between PCB with or without NTG (see [17] for
patient inclusion criteria and treatment speciﬁcations) with the primary endpoint of that
trial being PFS. Response was assessed every two cycles by the local investigator according
to RECIST 1.1 based on CT imaging [20]. In patients undergoing 18F-FDG PET/CT at
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baseline as part of the standard work-up (median number of days between baseline scan
and start treatment 17 days; range 73 days before treatment to 1 scan performed 1 after
the start of treatment), the protocol pre-speciﬁed a second 18F-FDG PET/CT between day
22 and 24 (after second chemotherapy infusion and with NTG application for patients in
the experimental group; Figure 6.1. To include more patients (17) in the analysis presented
here, scans acquired with a time interval between the ﬁrst chemotherapy and the second
18F-FDG PET/CT scan less than 35 days were accepted. This study was approved by the
medical ethical committee and all patients provided informed written consent prior to any
study handling.
Figure 6.1: NVALT12 trial timeline. At day one of the 21-day cycle, the paclitaxel-carboplatin-
bevacizumab therapy is administered (grey square). The patients in the experimental arm wear
the nitroglycerin (NTG) patch from day -3 to +2. The baseline 18F-FDG PET/CT is performed
before the start of chemotherapy and the second 18F-FDG PET/CT is performed between day 22
and 24 (black arrow). The baseline diagnostic CT is performed before the start of chemotherapy
and repeated after every two cycles of chemotherapy (grey arrow).
Scan protocol
Injected 18F-FDG activity depended on individual patient and scanner characteristics,
following the Netherlands protocol for standardization of 18F-FDG whole-body PET
studies in multi-center trials (NEDPAS) [25], which was the precursor of the EANM
guidelines, and images were reconstructed to institutional standards. Typically, a
low-dose CT scan as part of the 18F-FDG PET/CT was made, according to institutional
standards, and used for attenuation correction. Due to variations between the institutes,
for quality control purposes, a spherical volume of interest (VOI) with a diameter of 3 cm
was delineated in the right lobe of the liver [26]. This measurement was used as quality
index and scans with a mean standardized uptake value (SUV) of the liver below 1.3 or
above 3.0 were excluded from further analysis [27].
Early prediction of survival
The primary tumor was manually delineated by experienced radiation oncologists using
a treatment planning system (Eclipse Version 11.0, Varian Medical Systems, Inc.) and
used as the region of interest (ROI). A standard delineation protocol was used, which
included ﬁxed window/level settings of CT (lung: 1700/-300; mediastinum: 600/40).
Patients without a measurable primary tumor on the baseline 18F-FDG PET/CT scan
were excluded for analysis.
The maximum standardized uptake value (SUVmax), mean SUV (SUVmean), peak
SUV (SUVpeak; mean uptake in a sphere with a diameter of 1.2 cm [21], total lesion
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glycolysis (TLG; TLG was deﬁned by SUVmean multiplied by the tumor volume), maximal
CT diameter and CT volume (number of voxels within the delineated ROI multiplied by
the voxel size) were calculated in our institute on the 18F-FDG PET/CT scan (Matlab
R2013a, The Mathworks, Natrick, MA, USA) using an adapted version of CERR
(Computational Environment for Radiotherapy Research) extended with in-house
developed Radiomics image analysis software to extract imaging features [28, 29]. Early
metabolic response was deﬁned using relative changes in 18F-FDG PET uptake
parameters of the primary tumor expressed as a percentage change from baseline.
Patients were grouped according to a 30 % decrease in CT and PET parameters in the
primary tumor ROI of the 18F-FDG PET/CT scan [26, 30, 31]. For the PET response
assessment, SUVpeak was used and for the CT response assessment, CT diameter (CT
was part of the 18F-FDG PET/CT) was used [26, 30]. The RECIST analysis performed
during week 6 by the local investigators was used in the analysis to separate patients into
responders and non-responders. The 30 % CT and PET response assessments,
performed after 3 weeks of therapy, were compared against the RECIST response
assessment performed during week 6 by a speciﬁcity and sensitivity analysis.
Statistics
Since normality checks suggested an abnormal distribution for the changes in CT and
PET parameters from baseline, non-parametric tests were used for the analysis of these
variables. Comparison of the mean changes in CT and PET parameters from baseline for
responder vs. non-responders was carried out by an independent samples Mann-Whitney U
test. PFS was deﬁned as the interval from randomization to progressive disease or death,
whichever occurred ﬁrst, and OS was deﬁned as the interval from randomization to death
from any cause. Diﬀerences in PFS and OS were investigated using Cox regression. For
calculating the hazard ratio (HR), the diﬀerent response assessment criteria were used,
as a binary variable. To compare CT diameter and SUVmax response with survival, in
the waterfall plots a survival cut-oﬀ of 6 months was used. This is the median PFS of
the combined group (NTG group combined with control group). Statistical tests were
based on a two-sided signiﬁcance level, and the level of signiﬁcance was set at 0.05. All
statistics were performed in SPSS v.21 (IBM Corp. Released 2012, IBM SPSS Statistics
for Windows, Version 21.0, Armonk, NY, USA).
Results
Patients
87 out of the 223 included patients in the randomized phase II study had two 18F-FDG
PET/CT scans available with a measurable primary tumor; however, 27 patients were
subsequently excluded for analysis due to poor image quality (see Methods). Hence, 60
patients (characteristics in Table 16.1) had two evaluable consecutive 18F-FDG PET/CT
scans (Figure 6.2) with a median interval of 42 days. PFS and OS were similar for patients
treated with PCB and PCB + NTG (Table 6.1).
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Image characteristics
Experimental vs. control arm: does NTG leads to decreased FDG uptake
The mean decrease in SUVmax between the 131 patients treated with PCB (46 ± 27 %) and
the 29 patients treated with PCB + NTG (42 ± 29 %) was not statistically signiﬁcantly
diﬀerent (p=0.510). The other PET parameters (SUVmean, SUVpeak and TLG) showed
on average < 40 % decrease from baseline, but this was also not statistically signiﬁcantly
diﬀerent between the experimental arm and the control arm (Figure 6.3). Although for CT,
part of the 18F-FDG PET/CT, in the control arm, the CT diameter decreased signiﬁcantly
more than in the experimental arm (19 ± 14 % vs. 7 ± 23 %; p=0.028).
Early prediction of survival
According to the 30 % PET criteria, 74 % of patients in the control arm and 72 % of the
patients in the experimental arm showed response after 3 weeks (median time interval 42
days). According to the 30 % CT criteria, 26 % of the patients in the control arm and
Control Experimental
Patients analyzed 31 29
Gender Male 15 15
Female 16 14
Age (mean, range) [years] 59 (39-73) 59 (45-77)
WHO-PS 0 20 (65 %) 10 (34 %)
1 10 (32 %) 18 (62 %)
2 1 (3 %) 1 (3 %)
Smoker Current 13 (42 %) 14 (48 %)
Ex 14 (45 %) 12 (41 %)
Never 4 (13 %) 3 (11 %)
Histology Adeno 27 (86 %) 24 (83 %)
Large cell 2 (7 %) 1 (3 %)
Other 2 (7 %) 4 (14 %)
Survival (median, range) PFS [months] 7 (3-25) 4 (1-11)
OS [months] 13 (4-33) 9 (2-29)
RECIST response (week 6) Complete response 0 (0 %) 0 (0 %)
Partial response 9 (29 %) 5 (17 %)
Stable disease 20 (65 %) 17 (59 %)
Progressive disease 2 (6 %) 7 (24 %)
Baseline (mean, range) CT diameter [cm] 6.8 (2.5-12.1) 6.7 (2.4-16.4)
CT volume [cm3] 101.5 (4.4-474.5) 89.8 (3.0-468.8)
SUVmax 13.5 (3.4-28.9) 14.5 (3.6-44.6)
SUVmean 5.7 (2.5-11.8) 6.2 (2.1-22.3)
SUVpeak 11.0 (3.1-25.3) 12.1 (2.6-37.9)
TLG [SUV × cm3] 655.0 (23.4-4288.8) 638.4 (8.2-3467.2)
WHO-PS World Health Organization performance status, PFS progression free survival,
OS overall survival, RECIST response evaluation criteria in solid tumors,
SUV standardized uptake value, TLG total lesion glycolysis.
Table 6.1: Patient characteristics.
116
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 117
6
18F-FDG PET/CT-based response assessment of stage IV non-small cell lung cancer
Figure 6.2: CONSORT diagram.
10 % of the patients in the experimental arm had a response. According to the RECIST
analysis performed after 2 cycles (median time interval 56 days) by the local investigator,
29 % of the patients in the control arm had a response and 17 % of the patients in the
experimental arm had a response (Table 6.1).
The predictive value of the 30 % CT-based and 30 % PET-based response assessments
performed after 3 weeks (on the primary tumor) was assessed for response according to
RECIST after 2 cycles (Table 6.2). The 30 % PET-based response assessment had a higher
sensitivity compared to the 30 % CT-based response assessment but a lower speciﬁcity
(Table 6.2).
The 30 % CT-based and 30 % PET-based response assessments were for neither of
the arms predictive for PFS nor OS (Table 6.3).
The changes in CT diameter and SUVmax between baseline and early response
assessment were depicted in a waterfall plot showing that PET deﬁned more patients as
responders than CT (Figure 6.4 and Table 6.2). However, this decline was not predictive
for longer PFS (than 6 months).
Discussion
The hypothesis of the NVALT 12 trial was that the addition of NTG, by increasing tumor
blood ﬂow and oxygenation status, would improve outcome. While the clinical study of
the NVALT12 already showed that NTG did improve outcome, in the current study, we
investigated of we could predict outcome based on early response assessment using 18F-
FDG PET imaging [17]. This image analysis study of the NVALT12 trial could not show
a predictive value of 18F-FDG PET imaging for the evaluation of the addition of NTG to
bevacizumab-containing chemotherapy when compared to control patients. In a previous
study, the administration of NO donating drugs decreased hypoxia-induced resistance to
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anticancer drugs in cancer cell lines [14]. In the NVALT12 trial, this could not be conﬁrmed
based on 18F-FDG PET analysis. This could be due to a lower NTG dose than that used in
the Yasuda study [15], or to an interference with bevacizumab. From recent studies, it is
known that FDG is only a moderate surrogate for hypoxia [32]. The study of Zegers et al.
[33] showed that 42 ± 21 % of the primary tumor volume has a high FDG uptake (SUV <
50 % of SUVmax) of which 10 ± 12 % is hypoxic (high 18F-HX4 uptake TBR < 1.4), and
that 3 % of the primary tumor volume outside the high FDG uptake volume is hypoxic as
depicted by 18F-HX4 PET. In our study, we, therefore, only measure the eﬀects of NTG
on tumor metabolism and survival but not on hypoxia directly. Surprisingly, in nearly all
patients, irrespective of treatment arm, a major decrease in FDG uptake was observed in
the 18F-FDG PET scan performed after 3 weeks. Importantly, this 18F-FDG PET scan was
acquired within 3 days after the administration of the second cycle of chemotherapy. A
study by van der Veldt et al. [34] showed that bevacizumab reduces tumor perfusion and
11C-docetaxel uptake in NSCLC, which was accompanied by rapid reduction in circulating
levels of VEGF. This decrease in tumor blood ﬂow after bevacizumab administration may
explain the lower uptake of FDG in the tumor. Consequently, our results do not exclude
the possibility that NTG decreases hypoxia.
RECIST Responder RECIST non-responder Total
CT diameter decrease > 30 % 9 (15 %) 2 (3 %) 11 (18 %)
CT diameter decrease < 30 % 17 (28 %) 32 (54 %) 49 (82 %)
26 (43 %) 34 (57 %) 60 (100 %)
Sensitivity = 35 % Speciﬁcity = 94 %
SUV peak decrease > 30 % 23 (38 %) 21 (35 %) 44 (73 %)
SUV peak decrease < 30 % 3 (5 %) 13 (22 %) 16 (27 %)
26 (43 %) 34 (57 %) 60 (100 %)
Sensitivity = 88 % Speciﬁcity = 38 %
RECIST response evaluation criteria in solid tumors, SUV standardized uptake value.
Table 6.2: Comparison of 30 % CT-based and 30 % PET-based response assessment performed
after 3 weeks with the RECIST response assessment of week 6.
SUV parameter PFS OS
HR (95 % CI) p value HR (95 % CI) p-value
30 % SUVmax 1.048 (0.591-1.858) 0.874 1.025 (0.572-1.837) 0.934
response
assessment
SUVmean 0.941 (0.527-1.680) 0.838 0.901 (0.501-1.619) 0.726
SUVpeak 0.929 (0.514-1.679) 0.807 0.938 (0.515-1.706) 0.833
TLG 0.706 (0.355-1.406) 0.323 1.511 (0.722-3.160) 0.273
CTvolume 1.073 (0.617-1.866) 0.802 1.338 (0.740-2.419) 0.335
CTdiameter 0.718 (0.370-1.390) 0.325 0.805 (0.390-1.662) 0.557
SUV standardized uptake value, TLG total lesion glycolysis, PFS progression free survival,
OS overall survival, HR hazard ratio, CI conﬁdence interval.
Table 6.3: The hazard ratios (HR) for 30 % PET- and CT-based response assessment with 95 %
conﬁdence interval and corresponding p values for OS and PFS are shown per parameter.
118
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 119
6
18F-FDG PET/CT-based response assessment of stage IV non-small cell lung cancer
Figure 6.3: Mean values and standard deviations for the CT- and PET-derived image parameters
for the experimental arm and the control arm. p values of the independent samples Mann-Whitney
U test of the mean change from baseline of the control arm vs. the mean change from baseline of
the experimental arm (*signiﬁcantly diﬀerent for the experimental arm compared to the control
arm with a signiﬁcance level of 5 %). SUV: standardized uptake value; TLG: total lesion glycolysis.
A number of studies have demonstrated that changes in SUV parameters as early as
the third week after the start of treatment are predictive for response to chemotherapy
and PFS [1, 23, 24, 35]. A variety of approaches have been developed to measure the
response, starting with the World Health Organization (WHO) criteria and continuing to
RECIST and RECIST 1.1 [20, 26, 36]. These criteria refer to an anatomical decrease in
tumor diameter. However, this response must be viewed with some caution when one
is trying to predict outcomes in therapies that may be more cytostatic than cytotoxic.
With such therapies, lack of progression may be associated with a good improvement in
outcome, even in the absence of major shrinkage of tumors [37]. Newer metrics such as
PET may be more informative [38]. PET/CT-based response evaluation has proven to
be valuable in chemotherapy [39]. Currently, two sets of treatment response criteria for
PET are available: EORTC and PET response criteria in solid tumors (PERCIST) [30].
PERCIST operates with a ﬁxed region of interest (ROI) of 1 cm3 in the most 18F-FDG-avid
part of the single most metabolically active tumor in the patient at each PET/CT scan.
In the current study, a speciﬁc ROI, deﬁning the primary tumor, was used for response
evaluation. A consideration for anatomic and functional imaging is that many of the
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changes in response are at the border zones between response groups.
Figure 6.4: Change in CT diameter (upper) and SUVmax (lower) from baseline in individual
patients. Patients of the experimental arm are plotted in red, patients of the control arm in blue.
The pattern ﬁlled bars represent patients with a progression free survival longer than 6 months.
The black line represents the used response threshold of 30 %. SUV: standardized uptake value;
PFS: progression free survival.
These border zones are quite artiﬁcial, as changes in tumor size are on a continuous
scale (Figure 6.3). The comparison of 30 % CT-based and 30 % PET-based response
assessment performed after 3 weeks (median time interval between scans 42 days) with
the RECIST analysis performed in week 6 (median time interval between scans 56 days)
showed that the RECIST analysis deﬁned more patients as responders than the 30 %
CT-based analysis performed after 3 weeks. This can be caused by the diﬀerence in
timing but also due to the fact that for the 30 % CT-based analysis, only one lesion was
measured while in RECIST, multiple lesions were measured. The 30 % PET-based response
assessment performed after 3 weeks showed more responders than the RECIST analysis,
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which is probably caused by decreased perfusion due to the bevacizumab treatment, which
led to a decrease in FDG uptake for both treatment arms. The response assessment for
PET was not inﬂuenced by NTG. A previous study of our group showed that after 3 weeks
of treatment, ﬁve of nine patients were classiﬁed as responders by CT while six of nine
were classiﬁed as responders by 18F-FDG PET [40]. In the same study, patients with a
metabolic response (decrease in SUV < 20 %) at week 3 had a longer PFS than those
without (9.7 months vs. 2.8 months), while patients with a response on CT at week 3
did not have a signiﬁcantly longer PFS than those without. These two ﬁndings combined
showed that PET may be able to show treatment response earlier than CT. In the former
study, 18F-FDG PET scans were performed before bevacizumab infusion, while in our study
the 18F-FDG PET scan was performed shortly after bevacizumab infusion. This might have
impacted the uptake of FDG. A study of Hoekstra et al. [41], also shows that 18F-FDG
PET has additional value over conventional radiologic techniques for monitoring response
in locally advanced NSCLC patients.
The scans used for this study were made within the scope of the Dutch multicenter
NVALT12 phase II trial and 60/223 patients underwent 2 18F-FDG PET scans with the
second scan after cycle 2, but before day 35. For quality control purposes, only scans with
a mean SUV in the liver between 1.3 and 3 were used, reducing the number of assessed
patients in this analysis to only 60 of the 223 original patients. For the analysis, these 60
patients were also divided between the control and the experimental arm, which means
the study cohort was limited in size, hampering in-depth subgroup analyses.
Conclusion
The addition of NTG did not lead to enhanced reduction in FDG uptake compared to
the control arm. Although PET-based response assessment identiﬁed more responders
than CT-based response assessment, this did not correlate to progression-free survival or
overall survival. This might be due to the timing of the 18F-FDG PET shortly after the
bevacizumab infusion.
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Abstract
Objectives
Recently it has been shown that radiomic features of computed tomography
(CT) have prognostic information in stage I-III non-small cell lung cancer
(NSCLC) patients. We aim to validate this prognostic radiomic signature in
stage IV adenocarcinoma patients undergoing chemotherapy.
Materials and Methods
Two datasets of chemo-naive stage IV adenocarcinoma patients were
investigated, dataset 1: 285 patients with CTs performed in a single center;
dataset 2: 223 patients included in a multicenter clinical trial. The main
exclusion criteria were EGFR mutation or unknown mutation status and
non-delineated primary tumor. Radiomic features were calculated for the
primary tumor. The c-index of cox regression was calculated and compared
to the signature performance for overall survival (OS).
Results
In total CT scans from 195 patients were eligible for analysis. Patients
having a Prognostic Index (PI) lower than the signature median (n=92) had
a signiﬁcantly better OS than patients with a PI higher than the median
(n=103, HR 1.445, 95 % CI 1.07-1.95, p=0.02, c-index 0.576, 95 % CI
0.527-0.624).
Conclusion
The radiomic signature, derived from daily practice CT scans, has prognostic
value for stage IV NSCLC, however the signature performs less than
previously described for stage I-III NSCLC stages. In the future, machine
learning techniques can potentially lead to a better prognostic imaging based
model for stage IV NSCLC.
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Introduction
Medical imaging, such as computed tomography (CT) and positron emission tomography
(PET), is used in standard staging and response assessment procedures in patients with
non-small cell lung cancer (NSCLC). In contrast to pathological investigations, medical
imaging is non-invasive and able to capture the entire tumor volume at multiple time-
points prior to and during treatment [1]. Recent studies have shown that quantitative
imaging features, extracted from routine medical imaging, have prognostic value and may
predict clinical outcomes or allow for treatment monitoring in diﬀerent cancer types [2, 3,
4, 5, 6, 7].
Radiomics is a high-throughput approach to translate medical images into mineable
data by extracting a large number of quantitative features describing tumor intensity, shape
and texture [8, 9, 10]. A comprehensive and robust quantiﬁcation of imaging phenotypes
provides complementary and clinically relevant information, which may lead to imaging
biomarkers [11, 12, 13, 14, 15].
In 2014, our group published a prognostic radiomic signature for overall survival
(OS), consisting of 4 radiomic features (further referred to as ”the signature”), which is
exclusively based on pre-treatment CT imaging of the primary tumor volume [16]. The
signature consists of the following four features, derived from the primary tumor: 1)
“First order statistics: Energy”, describing the overall density of the tumor volume; 2)
“Shape: Compactness”, quantifying the compactness of the tumor volume relative to
that of a sphere (i.e. the most compact shape); 3) ”Gray level run length: Gray level
non-uniformity”, a measure of intra-tumor heterogeneity; and 4) Wavelet (HLH) “Gray
level run length: Gray level non-uniformity”, also describing intra-tumor heterogeneity,
but now after wavelet decomposition of the original CT image [17]. A detailed
mathematical description of the aforementioned features can be found in Aerts et al.
[16]. This signature was derived from stage I-III NSCLC patients treated with
radio(chemo)therapy and independently validated in both resected NSCLC (concordance
(c-) index 0.65), and stage I-IV head and neck squamous cell carcinoma (HNSCC)
patients (c-index 0.69). Next to that, this signature was validated in an oropharyngeal
squamous cell carcinoma cohort (c-index 0.63) [17].
Known prognostic clinical variables in stage IV NSCLC are WHO performance status
and cM-stage according to the 7th or 8th edition of the TNM staging in NSCLC [18]. Our
group showed before that next to lower cM-stage also younger age, female gender, and
low cTN-stage are favorable factors for OS in stage IV [19].
In this paper, we aimed to investigate the prognostic value of the signature in two large
independent cohorts of stage IV NSCLC patients, EGFR and ALK wildtype, and compared
this with prognostic value of clinical variables.
Material and Methods
Patient characteristics
The ﬁrst cohort consisted of 285 patients with incurable advanced stage non-squamous
NSCLC tested for epidermal growth factor receptor (EGFR) mutation/Kirsten rat sarcoma
(KRAS) mutation/anaplastic lymphoma kinase (ALK) translocation (see Rizzo et al. [20]
for patient inclusion criteria and treatment speciﬁcations). Patients were treated with
cisplatin or carboplatin in combination with pemetrexed. Written informed consent to
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the use of clinical and imaging data for scientiﬁc purposes was obtained from all patients
beforehand. This study was also approved by the local Ethical Committee (R 422/16).
The second cohort is a dataset of 223 non-squamous NSCLC patients, who were
included in a multicenter phase II trial (NVALT12; NCT01171170). In the NVALT12
trial patients were randomized between paclitaxel-carboplatin-bevacizumab with or without
nitroglycerin patches (see Dingemans et al. [21] for patient inclusion criteria and treatment
speciﬁcations). This study was approved by the medical ethical committee, and all patients
provided informed written consent prior to any study handling.
Eligiblity criteria were: stage IV non-squamous NSCLC, WHO-PS < 3, ALK and EGFR
wildtype (mutation status is only tested in advanced stage NSCLC). Next to that, patients
with a CT-scan without a deﬁnable primary tumor, a too small ﬁeld-of-view, an original
tumor volume that was separated by the resampling, or a non-standard patient position
were excluded.
Imaging
For the ﬁrst cohort all CT scans were performed, before treatment initiation, in the same
hospital using a 16-slice Lightspeed GE CT scanner or a 64-slice MSTC Optima 660 GE
CT scanner. Diagnostic CT scans with or without contrast were performed. A standard
thorax protocol was used with a mean slice thickness of 3 mm. The primary tumor was
manually delineated by EJ and checked by an experienced radiation oncologist (BR) using
Mirada (Mirada Medical, Oxford, UK) and used as the region of interest (ROI).
For the second cohort CT scans were performed in 16 diﬀerent hospitals and centrally
collected for analysis. Eleven diﬀerent CT scanners (Siemens, Philips, GE and Toshiba)
and seven diﬀerent PET/CT scanners (Siemens, Philips and GE) were used. Low-dose
CT scans as well as diagnostic CT scans, with and without contrast, were performed.
There was no speciﬁc CT protocol used, although all CT scans were used for response
evaluation criteria in solid tumors (RECIST) 1.1 response assessment, which recommends
a slice thickness of 10 mm or less and for spiral CT a slice thickness of 5 mm, therefore
the mean slice thickness was 3 mm. The primary tumor was manually delineated by EJ
and checked by an experienced radiation oncologist (ET) and a pulmonologist (LH) using
a radiation treatment planning system (Eclipse Version 11.0, Varian Medical Systems Inc.,
Palo Alto, CA) and used as the ROI. A standard delineation protocol was used, which
included ﬁxed window/level settings (lung: 1700/-300; mediastinum: 600/40).
Radiomics
Image features were calculated on the baseline CT scan using an adapted version of
Computational Environment for Radiotherapy Research (CERR) extended with in-house
developed radiomic image analysis software (Matlab R2014a, The Mathworks, Natrick,
MA) to extract the image features [14, 22]. A bin width of 25 Hounsﬁeld Units was
used. To minimize the possible eﬀect of the variation in image parameters, all scans were
resampled to a voxel size of 1×1×3 mm3 (same voxel size as in “the signature” dataset)
using a cubic interpolation as recommended in Larue et al. [23].
The signature was based on a Cox proportional hazards model with the following
feature coeﬃcients (β) : 1) “First order statistics: Energy”: 2.42 × 10-11; 2) “Shape:
Compactness”: -5.38 × 10-3; 3) ”Gray level run length: Gray level non-uniformity”: -1.47
× 10-4; 4) Wavelet (HLH) “Gray level run length: Gray level non-uniformity”: 9.39 ×
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10-6. The prognostic index (PI) for the radiomic signature, to be used for validation, is
then deﬁned as: PI=
∑
i βixi [17].
Clinical variables
We tested the prognostic value of the clinical variables age, gender, cT-stage, cN-stage,
cM-stage (restaged according to the 8th edition of the TNM classiﬁcation for lung cancer)
[18] and the WHO performance status.
Statistics
The performance of the signature in the cohort of stage IV NSCLC patients was
investigated by calculating the c-index using RStudio (Rstudio, Inc., Boston, MA, US)
and compared to the c-indices found by Aerts et al. [16].
The prognostic value of the clinical variables was investigated using a univariable and
multivariable cox regression in SPSS (IBM SPSS Statistics for Windows, Version 24.0,
Armonk, NY, US). A log-rank test was applied to test for signiﬁcant diﬀerences between
survival curves. For dataset 1, OS was deﬁned as the interval from start of treatment
for stage IV disease to death from any cause, and from randomization to death from any
cause for dataset 2. Patients without event or lost to follow-up were censored at last date
known to be alive. Statistical tests were based on a two-sided signiﬁcance level, and the
level of signiﬁcance was set at p < 0.05.
Results
For 261 out of 285 patients of the ﬁrst cohort a baseline CT scan could be retrieved. Since
203 patients were ineligible (10 patients were excluded for analysis due to the fact that the
primary tumor was indeﬁnable, 1 patient due to an incorrect patient position, 1 patient due
to a too small ﬁeld-of-view of the CT scan, 1 patient due to the resampling that caused
a separation of the original volume, 14 patients because of WHO-PS score higher than 2,
67 patients had cM0-stage and 109 patients had an EGFR mutation, ALK rearrangement
or unknown mutation status (see Figure 7.1 for the CONSORT diagram), a total of 58
scans was eligible for analysis. For the second cohort, baseline CT scans were available for
210 of the 223 patients. 71 patients were ineligible (28 patients due to a non-measurable
primary tumor, 1 patient due to an incorrect patient position, 1 patient due to a too small
ﬁeld of view of the CT scan, 2 patients due to the resampling that caused a separation of
the original volume, 1 patient due to missing survival data, 6 patients due to a M-stage of
zero, 5 patients with an EGFR mutation and 29 patients with an unknown mutation status
(see Figure 7.1 for the CONSORT diagram), leaving 137 CT scans suitable for analysis.
In Table 7.1, the patient characteristics of cohort 1, cohort 2 and the combined cohort
can be found. The median follow-up of cohort 1 was 52 months and at time of analysis 3
patients were censored for OS, for cohort 2 the median tumor volume was 28 months and
at the time of analysis 14 patients were censored for OS. The median tumor volume of the
ﬁrst cohort and second cohort were comparable (median 36 cc, range 2-507 cc vs. median
36 cc, range 1-769 cc). The median OS of the cohorts were comparable, 9 months (range
0-65 months) and 10 months (range 0-34 months), respectively.
Due to the relatively small number of eligible CT scans, both cohorts were combined
for the further analyses. The PI of the signature on this stage IV dataset had a c-index
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Figure 7.1: CONSORT diagram of cohort 1 (left) and cohort 2 (right).
of 0.576 (95 % CI 0.527-0.624, p=0.002). Patients with a PI lower than the median of
the signature cohort (n=92) had a signiﬁcant better OS than patients with a PI higher
than the median (n=103); Hazard ratio 1.445 (1.07-1.92, p=0.02); 13 vs. 8 months,
respectively (Figure 7.2).
In the univariable analysis, patients with WHO-PS 1 had a worse prognosis compared
to those with WHO-PS 0 (n=101 vs. n=69; HR 1.52, 95 % CI 1.10-2.11, p=0.012),
patients with cN3 disease had a worse prognosis compared to cN0 patients (n=76 vs.
n=28; HR 1.84, 95 % CI 1.15-2.93, p=0.01), and those with cM1c had a worse prognosis
compared to patients with cM1a disease (n=62 vs. n=75; HR 1.53, 95 % CI 1.07-2.19,
p=0.02; see Table 7.2). The PI was as well prognostic for OS in the univariable analysis
(HR 1.46, 95 % CI 1.02-2.10, p=0.04). In the multivariable analysis, the latter three tumor
characteristics retained their prognostic value showing (cN3 vs. cN0; HR 1.92, 95 % CI
1.18-3.12, p=0.01; cM1c vs. cM1a; HR 1.62, 95 % CI 1.11-2.36, p=0.01; and PI HR
1.56, 95 % CI 1.04-2.33, p=0.03; see Table 7.3). In Supplementary Material Table 7.4
the multivariable analysis excluding the PI can be found.
Discussion
We investigated a previous published prognostic radiomic signature consisting of four
quantitative image features calculated on baseline CT scans of the primary tumor. This
signature has prognostic value in patients with stage I-III NSCLC and HNSCC. In our
study we validated this signature in an independent cohort of 195 patients with
metastatic (stage IV), EGFR and ALK wildtype, NSCLC.
Aerts et al. [16] found that the signature had a good performance in an independent
validation cohort of stage I-III NSCLC patients (c-index 0.65). The signature showed in
addition prognostic value in our cohort of stage IV NSCLC, although the c-index was less
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prominent (c-index 0.58, p=0.002). However, our cohort of patients was well characterized
and in daily practice patients are viewed to have the same prognosis (stage IV, EGFR and
ALK wildtype, non-squamous histology, WHO PS <3, chemotherapy eligible), by applying
the signature and using a routine baseline CT scan we were able to select a group of patients
with poor outcome [HR 1.45 (1.07-1.92), p=0.02]. A reason for the less prominent c-index
in our cohort can be that the data from cohort 2 was part of a multicenter study. Although,
the CT scans of the diﬀerent cohorts were delineated using diﬀerent software packages, no
diﬀerences were expected in the radiomic features due to the diﬀerent delineation packages.
However, there was no dedicated CT image protocol speciﬁed as image speciﬁc endpoint,
therefore there was quite some variation in the image parameters. Recent publications
have shown that resampling of the voxel size leads to more reproducible CT features [24,
25]. Shaﬁq-Ul-Hassan et al. [24] showed that some radiomic features were even voxel
size dependent. To minimize the possible eﬀect of the variation in image parameters, all
scans were resampled, as recommended in Larue et al. [23], to a voxel size of 1 x 1 x
3 mm3, which is comparable to the voxel size of the signature dataset. Therefore the
median to split the cohort of patients as used in the signature cohort could be used as
well in our cohort of stage IV patients. Therefore in the future we would recommend to
perform resampling as recommended in Larue et al. [23] and for validation studies to use
Variable Cohort 1; Cohort 2; Combined;
n = 58 ( %) n = 137 ( %) n = 195 ( %)
Gender Male 37 (64 %) 72 (53 %) 109 (56 %)
Female 21 (36 %) 65 (47 %) 86 (44 %)
WHO-PS 0 8 (14 %) 61 (45 %) 69 (35 %)
1 31 (53 %) 70 (51 %) 101 (52 %)
2 19 (33 %) 6 (4 %) 25 (13 %)
cT-stage 1 5 (9 %) 27 (20 %) 32 (16 %)
2 17 (29 %) 36 (26 %) 53 (27 %)
3 8 (14 %) 26 (19 %) 34 (17 %)
4 26 (45 %) 38 (28 %) 64 (33 %)
x 2 (3 %) 10 (7 %) 12 (6 %)
cN-stage 0 8 (14 %) 20 (15 %) 28 (14 %)
1 2 (3 %) 8 (6 %) 10 (5 %)
2 28 (48 %) 43 (31 %) 71 (36 %)
3 18 (31 %) 58 (42 %) 76 (39 %)
x 2 (3 %) 8 (6 %) 10 (5 %)
cM-stage 1a 10 (17 %) 65 (47 %) 75 (38 %)
1b 13 (22 %) 45 (33 %) 58 (30 %)
1c 35 (61 %) 27 (20 %) 62 (32 %)
Mutation status wt 28 (48 %) 83 (61 %) 111 (57 %)
KRAS 30 (52 %) 54 (39 %) 84 (43 %)
Median OS [months] 9 (0-65) 10 (0-34) 10 (0-65)
Median Tumor volume [cc] 36 (2-507) 36 (1-769) 36 (1-769)
PS performance status, cT clinical Tumor-stage, cN clinical Nodal-stage,
cM clinical Metastases-stage, wt wildtype, KRAS Kirsten rat sarcoma,
OS overall survival.
Table 7.1: Patient and tumor characteristics of cohort 1, cohort 2 and the combined dataset.
133
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 134
7
Chapter 7
a resampling to a voxel size that is similar to the voxel size of the training dataset.
As the radiomic signature is based on analysis of the primary tumor, tumor volume
might have impact on the outcome. In the stage I-III NSCLC signature cohort of Aerts et
al. [16] the median tumor volume was 251 cm3 (2-489), while in our stage IV NSCLC cohort
the median tumor volume was only 36 cm3, (0-769). As can be seen in Supplementary
Material Figure 7.3, the variation in tumor volumes is much larger in the signature cohort
compared to cohort 1 and cohort 2, which have a comparable variation. As seen from
the coeﬃcients in the signature model, some parameters have a large correlation to tumor
size. In cohort 1 46 % of the tumors were staged as T4, while in the signature cohort only
28 % was staged as T4. A T4 staged tumor can be a large tumor but it can as well mean
that there are multiple nodules in the lung. In case of multiple nodules, the largest lesion
was used for the radiomic analysis, which can also explain the diﬀerence in tumor volumes
between the two cohorts.
Our cohorts have an equal distribution of cT-stage compared to Aerts et al. [16],
which conﬁrms that cT-stage is not an indicator of tumor volume. In stage IV NSCLC
mainly the cM-stage determines the prognosis of a patient. With radiomics image
characteristics of the primary tumor but also of the nodes and metastases can be easily
Figure 7.2: Kaplan Meier plot of overall survival showing the prognostic index of the radiomic
signature split at the median of the Nature signature.
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Clinical variables HR (95 % CI) p-value
Age 0.996 (0.980-1.012) 0.633
Gender 0.761 (0.565-1.025) 0.072
WHO-PS 0.038
WHO 1 1.521 (1.095-2.114) 0.012
WHO 2 1.159 (0.717-1.872) 0.547
cT-stage 0.454
T2 1.288 (0.800-2.075) 0.297
T3 1.226 (0.727-2.069) 0.444
T4 1.545 (0.971-2.460) 0.066
Tx 1.216 (0.599-2.468) 0.588
cN-stage 0.045
N1 1.363 (0.650-2.860) 0.412
N2 1.256 (0.783-2.014) 0.344
N3 1.837 (1.152-2.930) 0.011
Nx 2.159 (0.998-4.672) 0.051
cM-stage 0.016
M1b 0.929 (0.645-1.336) 0.690
M1c 1.534 (1.074-2.189) 0.019
PI 1.464 (1.021-2.101) 0.038
PS performance status, cT clinical Tumor-stage, cN clinical Nodal-stage,
cM clinical Metastases-stage, HR hazard ratio,
CI conﬁdence interval, OS overall survival, PI prognostic index.
Table 7.2: Hazard ratios with 95 % conﬁdence intervals of the univariable cox regression of the
clinical variables and the PI for OS, with uncorrected p-values.
used for prognostic models. To make better models in the future, large datasets are
needed, and therefore the tumor segmentation process should be automated. Using deep
learning, the image segmentation can be automated, which makes the process less time
consuming. A recent publication by Antropova et al. [26] used a mixed approach,
combining deep learning and radiomics, and showed that the combined approach
outperformed the individual approaches. Song et al. [27] developed and validated a
nomogram including radiomic features for predicting progression free survival in stage IV
EGFR-mutant NSCLC. They found a model performance of 0.71 (0.64-0.77) for the
training dataset and a comparable performance for the validation dataset 0.72
(0.65-0.78). A study of Coroller et al. [3] showed that a model consisting of CT-based
radiomic features was able to predict distant metastases in stage I-III NSCLC patients,
with a model performance of 0.61 in an independent validation cohort.
Our study shows that a radiomic signature applied on a routine baseline CT scan has
prognostic value for stage IV NSCLC patients. In the future, radiomics in combination
with machine learning or deep learning can potentially lead to better prognostic models in
stage IV NSCLC. Next to radiomics of the primary tumor, normal lung radiomics can give
additional information to existing clinical prognostic factors.
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Clinical variables HR (95 % CI) p-value
Age 0.993 (0.973-1.013) 0.497
Gender 0.738 (0.533-1.021) 0.067
WHO-PS 0.169
WHO 1 1.395 (0.976-1.995) 0.068
WHO 2 1.150 (0.652-1.937) 0.673
cT-stage 0.968
T2 1.193 (0.728-1.956) 0.483
T3 1.163 (0.658-2.057) 0.603
T4 1.170 (0.717-1.911) 0.529
Tx 1.197 (0.573-2.500) 0.632
cN-stage 0.035
N1 1.204 (0.555-2.610) 0.639
N2 1.231 (0.757-2.000) 0.402
N3 1.915 (1.175-3.121) 0.009
Nx 2.113 (0.924-4.833) 0.076
cM-stage 0.022
M1b 1.003 (0.678-1.484) 0.987
M1c 1.617 (1.110-2.357) 0.012
PI 1.556 (1.041-2.325) 0.031
PS performance status, cT clinical Tumor-stage, cN clinical Nodal-stage,
cM clinical Metastases-stage, HR hazard ratio,
CI conﬁdence interval, OS overall survival, PI prognostic index.
Table 7.3: Hazard ratios with 95 % conﬁdence intervals of the multivariable cox regression of the
clinical variables and the PI for OS, with uncorrected p-values.
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Supplementary Material
Figure 7.3: Boxplot of the tumor volumes of cohort 1, cohort 2 and the signature cohort [2].
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Clinical variables HR (95 % CI) p-value
Age 0.991 (0.972-1.011) 0.380
Gender 0.713 (0.514-0.988) 0.042
WHO-PS 0.199
WHO1 1.380 (0.965-1.973) 0.078
WHO2 1.157 (0.672-1.993) 0.598
cT-stage 0.896
T2 1.229 (0.751-2.008) 0.412
T3 1.326 (0.761-2.309) 0.319
T4 1.251 (0.769-2.035) 0.368
Tx 1.181 (0.566-2.466) 0.657
cN-stage 0.064
N1 1.129 (0.523-2.435) 0.758
N2 1.228 (0.757-1.993) 0.406
N3 1.802 (1.114-2.915) 0.016
Nx 2.068 (0.904-4.730) 0.085
cM-stage 0.015
M1b 1.014 (0.686-1.499) 0.944
M1c 1.668 (1.145-2.430) 0.008
Table 7.4: Hazard ratios with 95 % conﬁdence intervals of the multivariable cox regression of the
clinical variables for OS, with uncorrected p-values.
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Can radiomic features describe lung semantic features in
non-small cell lung cancer patients?
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Abstract
Qualitative image characteristics, such as cavitation or air bronchogram,
have been shown to be prognostic for treatment outcome in non-small cell
lung cancer (NSCLC). However, scoring of these features manually might
suﬀer from inter-observer variability. We hypothesized that automatically
calculated radiomic features could objectively describe these semantic
features. Therefore, in this study the correlation between 15 qualitative
semantic features and 160 quantitative radiomic features of the primary
tumor and 201 of the ipsilateral lung, was investigated in 218 NSCLC
patients. In addition, we developed models to describe these semantic
features, based on combinations of radiomic features, which were validated in
an independent cohort of 98 NSCLC patients. Tumor radiomic features,
could predict the semantic features air bronchogram, necrosis and pleural
eﬀusion (AUC 0.71, 0.68, and 0.65, respectively). Lung radiomic features
could predict pleural thickening, satellite nodules and pleural eﬀusion (AUC
0.62, 0.64, and 0.87, respectively). For combinations of tumor and lung
radiomic features the performance was for air bronchogram, pleural
thickening, necrosis, satellite nodules and pleural eﬀusion respectively AUC
0.68, 0.66, 0.72, 0.65 and 0.83. Although there are associations between
semantic and radiomic features, larger training datasets with new
approaches, like deep learning, are needed to further improve performance.
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Introduction
Medical imaging, like computed tomography (CT), is routinely used for diagnosis and
response assessment procedures in patients with non-small cell lung cancer (NSCLC).
Medical imaging is, in contrast to pathological investigations, non-invasive and can be
applied at multiple time-points before and during treatment [1].
The survival rate of NSCLC patients is still unsatisfactory and dependent on stage.
However, even within a certain stage, survival varies. Prognostic models, consisting of
clinical parameters and genetic information, can make treatment more personalized and
potentially increase the survival rate [2].
More and more targetable molecular alterations are being discovered. Examples are
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1,
BRAF, for which tyrosine kinase inhibitors (TKIs) have been approved [3]. However, tissue
acquisition through invasive biopsies cannot represent the complete tumor genotype.
A study of Rizzo et al. [4] showed, in a dataset of 285 patients with lung
adenocarcinoma that were tested for EGFR, ALK and KRAS mutations, that single
qualitative image features as cavitation, emphysema, ground glass opacity, air
bronchogram, necrosis, pleural retraction, pleural eﬀusion, pleural thickening, pleural
contact, ﬁbrosis and satellite nodules are shown to be predictive for mutation status.
Other studies showed that those semantic features are also prognostic for survival [5, 6].
However, these semantic features are scored by a visual assessment of radiologists and
might be inter-observer dependent and time consuming when applied to large datasets.
Radiomics, which is a high-throughput approach to automatically extract a large
number of quantitative image features, is as well shown to be prognostic [7]. A radiomic
signature, existing of four radiomic features, developed in 422 stage I-III NSCLC patients,
which was prognostic for overall survival, could be externally validated in a cohort of 225
stage I-III NSCLC patients. Next to that, this signature was also prognostic for overall
survival in head and neck cancer [7]. Using radiomics the image phenotype can be
quantiﬁed, which is diﬀerent for tumors with somatic mutations [8, 9]. A study of Yip et
al. [10] recently found, in a cohort of 183 early stage and 75 advanced stage NSCLC
patients, associations between qualitative semantic features and radiomic features. They
focused on semantic and radiomic features scored for the tumor while it is known that
patients with lung abnormalities usually have a worse prognosis [10]. Tumors that are
attached to vessels, an unclear border deﬁnition but as well pleural retraction are
associated with a worse overall survival [11].
In the current study, we investigated associations between semantic features and
radiomic features of the tumor in a cohort of NSCLC patients and investigated the
correlation between semantic features and radiomic features of the ipsilateral lung. By
using combinations of radiomic features we hypothesize that the models improved by
describing the semantic features. The developed models are validated using an
independent cohort of stage IV NSCLC patients.
Methods
Patient characteristics
For training, a cohort of 285 advanced stage NSCLC patients (cohort A), which were
retrospectively selected from a database with lung adenocarcinoma patients tested for
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EGFR mutation/KRAS mutation/ anaplastic lymphoma kinase (ALK) translocation, was
used (see Rizzo et al. [4] for patient inclusion criteria and treatment speciﬁcations).
Written informed consent to the use of clinical and imaging data for scientiﬁc purposes
was obtained from all patients beforehand.
For validation, a cohort of 271 advanced stage NSCLC patients (cohort B), was
retrospectively selected from a database with lung adenocarcinoma patients tested for
EGFR mutation/KRAS mutation/ALK translocation. The data was retrospectively
collected with approval of the Institutional Review Board of the Department of Radiation
Oncology of Maastricht University Medical Center (MAASTRO Clinic) in accordance
with the informed consent form and/or the applicable Dutch and international rules and
legislation for handling of medical and personal data. Data was processed by the
investigator in an anonymized manner. All procedures performed in this study were in
accordance with the ethical standards of the institutional and national research
committee and with the 1964 Helsinki Declaration and its later amendments.
Patients that had an unknown status for one or more semantic features were excluded,
as were patients with a CT-scan without a deﬁnable primary tumor, a too small ﬁeld
of view, an original tumor volume that was separated by the resampling procedure or a
non-standard patient position.
Imaging
For the training cohort all CT scans were performed in the same hospital using a 16-slice
Lightspeed GE CT scanner or a 64-slice MSTC Optima 660 GE CT scanner. Diagnostic
CT scans with or without contrast were performed. A standard thorax protocol was used
with a mean slice thickness of 3 mm.
For the validation cohort the CT scans were performed in nine diﬀerent centers, using
four diﬀerent CT scanner brands (Philips, Siemens, Toshiba, GE) and 14 diﬀerent CT
scanner types. The slice thickness varied from 2 to 5 mm with a mean slice thickness of
4.5 mm.
For all scans the primary tumor was manually delineated by an experienced radiation
oncologist (BR) using Mirada (Mirada Medical, Oxford, UK) and used as the region of
interest. The lungs were delineated using atlas based contouring (Workﬂowbox Mirada
Medical, Oxford, UK) and were manually adjusted if needed. On the scans where the lungs
could not be delineated using atlas based contouring, threshold based contouring was used
with a threshold from -1000 to -200 HU and manually adjusted afterwards if needed.
Semantic features
Qualitative features were scored as described in Rizzo et al. [4]. For each CT, the following
qualitative features were scored:
i presence (1) or absence (0) of a ground-glass opacity;
ii lesion density, indicated as sub-solid (0) or solid (1);
iii presence (1) or absence (0) of cavitation;
iv presence (1) or absence (0) of air bronchogram;
v thickening of the adjacent pleura (yes=1, no=0);
vi presence (1) or absence (0) of intra-tumoral necrosis;
vii presence (1) or absence (0) of satellite nodules in primary tumor lobe;
viii presence (1) or absence (0) of nodules in non-tumor lobes;
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ix presence (1) or absence (0) of pleural retraction;
x location of the lesion, as central (1) or peripheral (0);
xi presence (1) or absence (0) of intra-nodular calciﬁcations;
xii presence (1) or absence (0) of ﬁbrosis;
xiii presence (1) or absence (0) of pleural contact;
xiv presence (1) or absence (0) of pleural eﬀusion.
All semantic features were scored on a binary scale (see Table 8.1).
Semantic feature Cohort A n=218 ( %) Cohort B n=98 ( %)
GGO Absence 175 (80 %) 87 (89 %)
Presence 43 (20 %) 11 (11 %)
Density Subsolid 25 (11 %) 7 ( 8 %)
Solid 193 (89 %) 90 (92 %)
Cavitation Absence 186 (85 %) 90 (92 %)
Presence 32 (15 %) 8 ( 8 %)
Air bronchogram Absence 126 (58 %) 63 (64 %)
Presence 92 (42 %) 35 (36 %)
Pleural thickening Absence 114 (52 %) 42 (43 %)
Presence 104 (48 %) 56 (57 %)
Necrosis Absence 172 (79 %) 77 (79 %)
Presence 46 (21 %) 21 (21 %)
Satellite nodules Absence 148 (68 %) 61 (62 %)
Presence 70 (32 %) 37 (38 %)
Suspect nodules Absence 135 (62 %) 52 (53 %)
Presence 83 (38 %) 46 (47 %)
Pleural retraction Absence 105 (48 %) 24 (24 %)
Presence 113 (52 %) 74 (76 %)
Tumor location Peripheral 137 (63 %) 52 (53 %)
Central 81 (37 %) 46 (47 %)
Calciﬁcations Absence 191 (88 %) 95 (97 %)
Presence 27 (12 %) 3 ( 3 %)
Emphysema No 184 (84 %) 69 (70 %)
Yes 34 (16 %) 29 (30 %)
Fibrosis Absence 190 (87 %) 85 (87 %)
Presence 28 (13 %) 13 (13 %)
Pleural contact Absence 78 (36 %) 26 (27 %)
Presence 140 (64 %) 72 (73 %)
Pleural eﬀusion Absence 186 (85 %) 71 (72 %)
Presence 32 (15 %) 27 (28 %)
GGO ground glass opacity.
Table 8.1: Number of events per semantic feature for cohort A en cohort B.
Radiomic features
Image features were calculated on the baseline CT scan using an adapted version of
Computational Environment for Radiotherapy Research (CERR) extended with in-house
developed radiomic image analysis software (Matlab 2014a, The Mathworks, Natick,
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MA) to extract the image features [12, 13]. A bin width of 25 Hounsﬁeld Units was
used. To minimize the possible eﬀect of the variation in image parameters, all scans were
resampled to a voxel size of 1 x 1 x 3 mm3 using a cubic interpolation as recommended
in Larue et al. [14]. In total 1322 features, 24 shape features, 19 statistics features and
127 textural features (26 GLCM, 16 GLDZM, 16 GLRLM, 16 GLSZM, 26 IH, 17
NGLDM, 5 NGTDM, 2 Local Intensity and 3 Fractal features) were extracted for the
primary tumor and for the tumor lung. Next to that, 1152 features were calculated after
applying a wavelet ﬁlter. A mathematical description of all features can be found in the
Supplementary Material Figure 8.5.
Radiomic feature selection
Spearman’s correlation coeﬃcient (ρ) was used to assess the correlation between all
radiomic features. Features with |ρ| ≥ 0.85 were considered to be strongly correlated and
likely to provide redundant information about the tumor phenotype. In these strongly
correlated pairs, the feature with the highest average |ρ| was excluded. Next to that,
features with unique values and with missing values were excluded.
Statistics
Univariable
The univariable analysis is performed in RStudio (version 3.4.1). The association between
radiomic features and semantic features was assessed using the area under the receiver
operating curve (AUC). Noether’s test was used to determine signiﬁcance of the AUC
from a random relationship (AUC = 0.5). All p-values were corrected for multiple testing
by adjusting the false discovery rate according to the Benjamini and Hochberg procedure,
where a q-value < 0.05 suggested statistical signiﬁcance.
Multivariable
The multivariable analysis is performed in Matlab R2018a (The Mathworks, Natick, MA).
The analysis is conducted separately for each of the 15 semantic features, and repeated
for three sets of predictors: for radiomic features of the primary tumor, radiomic features
of the ipsilateral lung, and the combination of radiomics features of the primary tumor and
the ipsilateral lung. This results in a total of 45 separate analyses. Each time, a random
forest model is trained on the training dataset and validated on the validation dataset. The
default hyper parameter set was used and the number of trees was set to 200. Missing
radiomic feature values in the validation set were imputed by the training set mean.
Performance was expressed in the AUC with a 95 % conﬁdence interval computed
from 100 bootstraps. ROC curves were plotted for pleural eﬀusion, for radiomic features
of the tumor, lung and a combination of radiomic features. For every analysis, the top
ten ranked radiomic features were listed. The radiomic features selected in the tumor and
lung analysis were compared to the radiomic features selected in the combined analysis.
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Results
Patient selection
For 249 out of 285 patients from the training cohort a baseline CT scan could be retrieved.
Thirty-one scans were excluded from analysis, reasons were: a non-measurable primary
tumor (n=4), an incorrect patient position (n=1), a too small ﬁeld of view (n=5), a
separated volume due to the resampling (n=13) and an unknown semantic feature status
for at least one semantic feature (n=8). In total 218 scans could be analyzed.
For the validation cohort a baseline CT scan was received from 131 patients. Thirty-
three scans were excluded, reasons were: a too small ﬁeld of view (n=1), a non-measurable
primary tumor (n=2), a separated volume due to the resampling (n=13) and an unknown
semantic feature status for at least one semantic feature (n=17). In total 98 scans could
be used for the analysis (see Figure 8.1 for the CONSORT-diagram).
Figure 8.1: CONSORT diagram of cohort A (left) and the cohort B (right).
Feature selection
Excluding the radiomic features that contained redundant information or unique values,
left for the primary tumor 18 unﬁltered radiomic features (7 shape, 2 statistics, 1 GLCM,
1 GLDZM, 2 GLSZM, 1 fractal, 1 IH, 2 Local Intensity, 1 NGLDM), and 142 ﬁltered
radiomic features for the analysis.
Excluding the radiomic features that contained redundant information or unique values,
left for the ipsilateral lung 36 unﬁltered radiomic features (11 shape, 2 statistics, 3 GLCM,
4 GLDZM, 2 GLSZM, 1 GLRLM, 1 fractal, 5 IH, 2 local intensity, 4 NGLDM, 1 NGTDM),
and 165 ﬁltered radiomic features for the analysis.
Univariable analysis
There was a clear association between unﬁltered radiomic features of the primary tumor and
the semantic features: density, cavitation, air bronchogram, pleural thickening, necrosis,
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satellite nodules, and pleural eﬀusion (see Figure 8.2). For the ipsilateral lung unﬁltered
radiomic features were associated with the semantic features: density, pleural contact
and pleural eﬀusion (see Figure 8.3). Due to the large number of ﬁltered features, the
associations between the ﬁltered radiomic features of the tumor as well as the ipsilateral
lung with the semantic features can be found in Supplementary Material Figure 8.6 and
Figure 8.7.
Figure 8.2: Associations between the binary semantic and unﬁltered radiomic features assessed
with the AUC for the primary tumor. * indicates q-values < 0.05. AUC: area under the curve,
GGO: ground glass opacity.
Multivariable analysis
The model performance per semantic feature for a combination of radiomic features of
the primary tumor, the ipsilateral lung and a combination of tumor and lung features is
shown in Table 8.2. The semantic features air bronchogram (AUC 0.71, 95 % CI 0.57-
0.81), necrosis (0.68, 0.52-0.77) and pleural eﬀusion (0.65, 0.52-0.79) were described by a
combination of radiomic features of the tumor (see Supplementary Material Table 8.3 for
the top ten selected features). The semantic features pleural thickening (AUC 0.62, 95 %
CI 0.51-0.69), satellite nodules (0.64, 0.53-0.74) and pleural eﬀusion (0.87, 0.72-0.92) were
described by a combination of radiomic features of the ipsilateral lung (see Supplementary
Material Table 8.3 for the top ten selected features). Using a combination of radiomic
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features of the tumor and the ipsilateral lung air the performance is slightly diﬀerent, air
bronchogram AUC 0.68 (95 % CI 0.56-0.78), pleural thickening 0.66 (0.52-0.73), necrosis
0.72 (0.61-0.83), satellite nodules 0.65 (0.53-0.77) and pleural eﬀusion 0.83 (0.69-0.88).
Figure 8.3: Associations between the binary semantic and unﬁltered radiomic features assessed
with the AUC for the ipsilateral lung. * indicates q-values < 0.05. AUC: area under the curve,
GGO: ground glass opacity.
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In Figure 8.4, the ROC curve for pleural eﬀusion for tumor features, lung features and a
combination of features is shown.
Tumor Lung Combined
Semantic feature AUC 95 % CI AUC AUC 95 % CI AUC AUC 95 % CI AUC
GGO 0.56 0.43-0.71 0.52 0.28-0.71 0.56 0.38-0.71
Density 0.66 0.30-0.88 0.53 0.16-0.69 0.67 0.34-0.91
Cavitation 0.72 0.42-0.86 0.49 0.22-0.72 0.65 0.49-0.80
Air bronchogram 0.71* 0.57-0.81 0.56 0.46-0.70 0.68* 0.56-0.78
Pleural thickening 0.56 0.46-0.69 0.62* 0.51-0.69 0.66* 0.52-0.73
Necrosis 0.68* 0.52-0.77 0.60 0.42-0.72 0.72* 0.61-0.84
Satellite nodules 0.56 0.46-0.67 0.64* 0.53-0.74 0.65* 0.53-0.77
Suspect nodules 0.48 0.36-0.57 0.55 0.42-0.66 0.54 0.40-0.65
Pleural retraction 0.45 0.36-0.58 0.58 0.45-0.70 0.55 0.40-0.69
Tumor location 0.52 0.38-0.62 0.47 0.35-0.59 0.56 0.44-0.67
Calciﬁcations 0.74 0.41-0.97 0.50 0.06-0.75 0.63 0.26-0.99
Emphysema 0.44 0.28-0.53 0.59 0.46-0.71 0.52 0.40-0.65
Fibrosis 0.48 0.36-0.62 0.40 0.25-0.57 0.39 0.22-0.52
Pleural contact 0.61 0.48-0.75 0.57 0.45-0.74 0.56 0.42-0.68
Pleural eﬀusion 0.65* 0.52-0.79 0.87* 0.72-0.92 0.83* 0.69-0.88
GGO ground glass opacity, AUC area under the curve, CI conﬁdence interval.
Table 8.2: AUC of the random forest for the validation cohort per semantic feature. The stars
represent the signiﬁcant AUC values (lower bound 95 % CI above 0.5) (Random Forest, ﬁtted on
training set, validated on validation set).
Discussion
Previous studies have shown that qualitative image characteristics such as cavitation,
ground glass opacity or air bronchogram, are prognostic for treatment outcome in NSCLC
[4, 10, 11, 15, 16]. However, these semantic features suﬀer from inter-observer variability,
because they are scored by a human and not automatically calculated 14. In this study, we
investigated the correlation between visually classiﬁed semantic features and quantitative
radiomic features. This correlation is investigated for radiomic features of the tumor and
for radiomic features of the ipsilateral lung, as we hypothesized that lung features can also
describe tumor characteristics and vice-versa.
In the univariable analysis we found like Yip et al. [10] that there is an association
between air bronchogram and the tumor radiomic feature shape_sphericity. In the study
of Yip et al. [10] as well as in our study the radiomic features that are highly correlated to
each other were removed. Comparing the features that are left after removing the highly
correlated features shows similar features. Another method to select robust radiomic
features is by using a test-retest dataset or a multiple delineation dataset as shown by van
Timmeren et al. [17]. This can be performed using an open source test-retest dataset,
which makes the results of diﬀerent studies more comparable. Although in our univariable
analysis, diﬀerent radiomic features were signiﬁcant for the semantic features compared to
Yip et al. [10]. This can be due to a diﬀerent number of events per semantic feature in both
datasets. Collins et al. [18] showed that to reliably validate a prognostic model a minimum
of 100 events and ideally 200 or more events are required, which was unfortunately not
the case in our study. For validation of models it is therefore important that the number
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of events of the training and validation cohort match.
Some semantic features are lesion speciﬁc (e.g. cavitation and necrosis), while other
semantic features describe lung characteristics (e.g. pleural eﬀusion and satellite
nodules). The univariable analysis clearly shows that tumor radiomic features contain
information about tumor semantic features (e.g. density, air bronchogram, necrosis),
while lung radiomic features contain information about lung semantic features (e.g.
Figure 8.4: Example of the ROC curves of the validation dataset for pleural eﬀusion with A)
tumor radiomic features, B) lung radiomic features and C) combination of radiomic features.
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pleural contact and pleural eﬀusion). No radiomic feature contained information to
describe calciﬁcations, but only a small proportion of 12 % of the patients of the training
cohort had calciﬁcations and these calciﬁcations were visually hard to detect, with the
validation cohort only 3 % showing calciﬁcations. Furthermore, tailored radiomic features
or other pre-processing techniques could improve detection of these semantic features.
The multivariable analysis showed that a combination of tumor radiomic features could
detect the semantic features air bronchogram, necrosis and pleural eﬀusion. A combination
of lung radiomic features could detect the semantic features pleural thickening, satellite
nodules and pleural eﬀusion. This shows that there is an added value of combining radiomic
features containing complementary information for prediction purposes.
The validation data in our study is part of a multicentric trial and therefore a large
variability in image acquisition and reconstruction parameters exists. Although, we
performed resampling of the voxel sizes, datasets with equal voxel sizes have more robust
radiomics features [19]. This makes the semantic feature scoring as well as the radiomic
features less reliable [20, 21]. Modelling semantic features using single center data is
expected to result in higher AUC values. Phantom studies potentially lead to optimal
post-processing settings and eventually correction factors, to overcome the variability of
image acquisition in reconstruction settings in large datasets [19, 14, 22, 23].
A study of Liu et al. [24] showed that semantic features as well as radiomic features
of the primary lung can predict pathological node involvement. A study of Wei et al. [25]
showed that using semantic features malignancy of a lesion can be predicted. A study
of Li et al. [16] used a combination of clinical variables, radiomic features and semantic
features to predict recurrence after therapy. All these studies show that combining clinical
variables, semantic features and radiomic features can be used to stratify patients.
For radiomic feature extraction the region of interest needs to be
delineated/segmented, which is currently mostly done semi-automatically or manually. In
our study the lungs are segmented using automatic atlas based segmentation, and
manually adjusted if needed. This method was quite accurate and can therefore, in the
future, easily be used for segmentation of large datasets [26]. Our study showed that
some semantic features, for example necrosis, can be described by a combination of
radiomic features, which by using automatic segmentation can reduce the inter-observer
variability as well as the time factor. Deep learning in combination with radiomics
overcomes this issue as well. A combination of deep learning and radiomics was shown to
have predictive power which nodules are malignant [27].
To conclude, semantic features like pleural eﬀusion and necrosis can be described using
a single radiomic feature. Using a combination of radiomic features, the performance can
be improved. While there are correlations between radiomic and semantic features, new
approaches such as deep learning approaches with more training data are needed to describe
better qualitiative semantic features.
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Figure 8.6 Associations between semantic and filtered radiomic features
for the tumor.
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Figure 8.7 Associations between semantic and filtered radiomic features
for the ipsilateral lung.
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Wavelet_LLL_GLCM_infoCorr1_gtv Wavelet_LHH_Stats_mean_lung Wavelet_HLL_Stats_min_lung
Wavelet_LHL_Fractal_sd_gtv Wavelet_HHH_GLDZM_LILDE_lung GLDZM_LILDE_gtv
Pleural GLDZM_HILDE_lung Wavelet_HLL_IH_skewness_gtv
thickening Wavelet_LLL_Stats_qcod_lung Wavelet_LLH_GLCM_maxCorr_lung
Wavelet_HLH_GLDZM_LILDE_lung Wavelet_LLL_Stats_qcod_lung
Wavelet_HLH_Stats_median_lung Shape_volumeDensityBE_lung
Wavelet_LHL_Stats_cov_lung Wavelet_LLH_Stats_mean_lung
Wavelet_LLH_GLRLM_RE_lung Wavelet_LLH_NGLDM_DV_lung
Wavelet_HLL_Stats_mean_lung Wavelet_LLL_IH_qcod_lung
NGLDM_DN_lung Wavelet_LHH_GLCM_maxCorr_gtv
Wavelet_HLL_GLDZM_HISDE_lung Wavelet_LLL_GLCM_inverseVar_lung
Wavelet_HLH_Stats_min_lung Wavelet_HHL_Stats_min_lung
Satellite Wavelet_HHL_Stats_mean_lung Wavelet_HLH_NGTDM_complexity_gtv
Nodules Wavelet_HLL_Stats_min_lung Wavelet_LLH_GLDZM_LILDE_gtv
Wavelet_LHH_NGLDM_LGSDE_lung Wavelet_LHH_GLCM_clusShade_gtv
Wavelet_HLL_Stats_median_lung Wavelet_HLL_IH_cov_lung
Wavelet_LHH_GLDZM_DZN_lung Wavelet_LLL_GLDZM_LILDE_lung
Wavelet_LHH_GLCM_infoCorr1_lung Shape_ﬂatness_gtv
Wavelet_LHH_Stats_mean_lung Wavelet_HLL_GLCM_maxCorr_gtv
Wavelet_HLL_GLCM_infoCorr2_lung NGLDM_DV_lung
Wavelet_HLH_IH_qcod_lung GLDZM_HILDE_lung
Wavelet_HLH_Stats_median_lung Wavelet_HLH_GLSZM_SZNN_lung
Table 8.3: Top 10 ranked radiomic features for the tumor, lung and the combination for air
bronchogram, necrosis, pleural eﬀusion, pleural thickening and satellite nodules.
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Abstract
Background
Skeletal muscle loss associates with low quality of life, diminished treatment
eﬃcacy and poor survival rates in cancer patients. Prevention and timely
treatment of muscle loss requires prediction of patients at risk. Therefore,
the main goal of the present study was to assess whether baseline skeletal
muscle radiomic features can predict future muscle loss. We furthermore
investigated if longitudinal changes in muscle radiomic features correlate to
computed tomography (CT)-derived muscle loss.
Methods
CT scans of 116 stage IV non-small cell lung cancer patients included in a
randomized controlled trial (NCT01171170) were analysed. Skeletal muscle
cross-sectional area and radiomic features were assessed at the third lumbar
level on CT images obtained before initiation of chemotherapy and shortly
after administration of the second cycle. For internal cross-validation of the
radiomics modelling approach, the cohort was randomly split in a training set
and validation set 100 times. A least absolute shrinkage and selection operator
(LASSO) feature selection was performed. The area under the curve (AUC)
was used to show model performance. This was done using radiomic features
of the baseline scan as well as the diﬀerence in radiomic features between the
baseline scan and the follow-up scan, so called delta radiomic features.
Results
75 Patients (65 %) exhibited loss of skeletal muscle. A total of 1298 radiomic
features were extracted. After elimination of correlated features, 193 radiomic
features of the baseline scan were used to construct a prediction model with
muscle loss as outcome. The average AUC was 0.49 (95 % CI: 0.36, 0.62).
Diﬀerences in intensity and texture radiomic features over time were seen
between patients with and without muscle loss. The AUC for delta radiomics
was 0.68 (95 % CI: 0.51, 0.84).
Conclusions
The present study shows that skeletal muscle radiomics at baseline cannot
predict future muscle loss during chemotherapy in metastatic NSCLC
patients. Diﬀerences in radiomic features over time might reﬂect
myosteatosis. Future imaging analysis combined with muscle tissue analysis
in patients and in experimental models is needed to unravel the biological
processes linked to the radiomic features.
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Introduction
Cachexia is a frequently observed phenomenon of skeletal muscle and adipose tissue
depletion among non-small cell lung cancer (NSCLC) patients [1, 2]. The progressive loss
of muscle has a devastating impact on quality of life [3] and survival rates in NSCLC
patients [2, 4, 5, 6]. Although both muscle and fat become depleted, there is evidence
that body fat is lost more rapidly than muscle [7, 8]. Cancer may therefore shift lipid
metabolism to a catabolic state, which in turn may aﬀect skeletal muscle. In cancer
cachexia depletion of subcutaneous fat is driven by increased lipolysis [9, 10].
Experimental research has shown that lipolysis generates fatty acids which are able to
transport into myocytes and stimulate protein degradation [11]. Indeed, skeletal muscle
of cancer patients contained more intramyocellular fat compared to age- and gender
matched controls [12]. However, the exact role of intramyocellular fat and its prognostic
signiﬁcance in cachexia progression needs to be elucidated.
Radiomics is a method to quantitatively characterise regions of interest in medical
images. The method extracts a large number of quantitative imaging features. These
features describe shape, size, intensity, and texture [13, 14, 15]. The underlying idea is
that medical images contain information that reﬂects elemental pathophysiology, which
can be revealed via quantitative analyses [16, 17]. Until now, radiomics has mainly been
applied to extract tumour features in oncologic patients to visualize tumour heterogeneity
or predict radiation pneumonitis [17, 18]. The obtained features are predictive for clinical
outcomes, including tumour aggressiveness and prognosis [19, 20, 21]. It is therefore
argued that radiomic features can help to better understand biological and pathological
processes [16, 17].
There are currently no methods available to identify patients at risk, which would be
very helpful for timely treatment decisions. To date, analysis of muscle characteristics
using radiomics has never been used to predict muscle loss. The primary goal of this
exploratory study is to investigate whether baseline skeletal muscle radiomic features are
diﬀerent between patients who develop muscle loss and those who maintain their muscle
mass after chemotherapy. We furthermore investigated if longitudinal changes in muscle
radiomic features are associated to muscle loss.
Material and Methods
Patient cohort
CT scans derived from the multicentre randomized phase II trial (NVALT12 trial,
NCT01171170) were investigated. In this trial the eﬀect of nitroglycerin added to
paclitaxel-carboplatin-bevacizumab on progression free survival in chemotherapy naïve
stage IV non-squamous NSCLC was investigated. The methodology and results of this
trial have been published previously [22].
Image analysis
CT scans made at baseline and after the second cycle of chemotherapy were used. To
evaluate whether or not patients lost skeletal muscle, cross-sectional measurements of
skeletal muscle areas were made on transverse images at the third lumbar level with Slice-
O-Matic software v5.0 (Tomovision, Montreal, Canada). One slice at the third lumbar
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level in each scan was selected for each patient. Skeletal muscle cross-sectional area was
quantiﬁed on the basis of pre-established thresholds of Hounsﬁeld units (-29 to 150). It is
of note, that this delineation excludes intramuscular fat. Changes in muscle cross-sectional
areas between CT scans were expressed as a percentage, which was normalized for the time
interval between scans (percentage change per 100 days). A measurement error of 1.3 %
was adopted, based on previous reported literature [2, 4]. Changes greater than or equal
to -1.3 % were considered as ‘loss of skeletal muscle’, while changes less than -1.3 % were
considered ‘maintenance of skeletal muscle’. Additionally, the mean Hounsﬁeld units of
the muscle CSA were assessed, as a measure for muscle fat deposits. Low values reﬂect
increased muscle fat.
Next, to evaluate radiomic features, skeletal muscle cross-sectional area was
delineated at the third lumbar level using the same thresholds of Hounsﬁeld units as
described above. Now it was extended one slice in the cranial direction and one slice in
the caudal direction using Mirada software (Mirada Medical, Oxford, UK), to be able to
calculate three-dimensional image features. Image features were calculated on both
baseline and follow-up scans, using an adapted version of Computational Environment for
Radiotherapy Research extended with in-house developed radiomic image analysis
software (Matlab 2014a, The Mathworks, Natick, MA). Prior to the extraction of
features a grey-level discretisation using a bin width of 25 Hounsﬁeld units was applied.
To minimize the possible eﬀect of the variation in image parameters, all scans were
resampled to a voxel size of 1×1×3 mm3 using a cubic interpolation as recommended in
Larue et al. [23].
Radiomic feature selection and statistics
Intensity and texture features were analysed. Shape and size features were excluded
because the volumes of interest has been segmented manually, which might inﬂuence the
outcome of these feature categories. In addition, a three-dimensional wavelet
transformation was applied to the CT scan to create ﬁltered, next to the unﬁltered
intensity and texture features. Features without a range (i.e. features with an exact
similar value in all patients), which were not able to discriminate patients, were excluded.
Spearman’s correlation coeﬃcient (ρ) was used to assess the correlation between all
texture and intensity radiomic features. Feature pairs with |ρ| ≥ 0.85 were excluded. Of
each feature pair with |ρ| ≥ 0.85, the feature that was strongest correlated to all other
features was excluded. This process was repeated until no feature pair with all |ρ| ≥ 0.85
was remaining.
To calculate to which extent the variation among the radiomic features on baseline
scans is explained by muscle loss, a logistic Least Absolute Shrinkage and Selection
Operator (LASSO) regression model adopting a 100-fold Monte Carlo cross-validation in
Matlab 2017b was applied (The Mathworks, Natick, MA).
The cohort was randomly split in a training set (approximately 2/3) and validation
set (approximately 1/3). Patients were randomized such that the ratio between patients
with and without skeletal muscle loss was similar in each group. Features in the training
and validation sets were standardized by subtracting the respective mean feature value in
the training set and dividing by the feature standard deviation in the training set. The
logistic LASSO model was used to reduce the number of features and estimate regression
coeﬃcients for the remaining features. The model-intrinsic parameter λ was estimated
using an internal 5-fold cross-validation on the training set. The out-of-sample area
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under the curve (AUC) of the Receiver operating characteristic curve (ROC) was
computed on the validation set to assess the prognostic power. This process was
repeated 100 times, each time with a diﬀerent randomization of the patients into
training and validation sets, and the average AUC over the hundred diﬀerent models was
calculated. This analysis was done for the radiomic texture and intensity features of the
baseline and for the absolute diﬀerence in feature values between the baseline scan and
the follow-up scan (delta features). For all radiomic features that were at least selected
once in the LASSO feature selection procedure the diﬀerence in feature value between
patients with and without muscle loss were compared by plotting a heatmap. For the
heatmap all radiomic features were normalized to have values between 0 and 1. A
hierarchical clustering was applied on the same heatmap to identify clusters of patients
with diﬀerent radiomic texture and intensity values.
Results
Patients and characteristics
In total 223 patients were enrolled in the randomized controlled trial. The inclusion of
the present paper is based on previous analysis of change in muscle mass and its
association to overall survival [6]. Therefore, one hundred three patients were excluded
due to unavailability of one or both CT scans, two patients were excluded because L3
was not evaluable, one patient was excluded due to lacking overall survival (OS) data
and one was excluded for insuﬃcient quality of the scans. After exclusion, CT scans from
116 patients were eligible. The mean age was 61 years and sixty-four patients (55 %)
were male.
Muscle maintenance and muscle loss
Delineations of skeletal muscle cross-sectional area made with Slice-O-Matic for cross-
sectional area and with Mirada for extraction of radiomic features are shown in Figure 9.1.
Analysis of skeletal muscle cross-sectional area at baseline and during follow-up revealed
that in the whole cohort skeletal muscle decreased with mean (± standard deviation) -5.4
± 14.0 % per 100 days. Of those, 75 patients (65 %) exhibited loss of skeletal muscle.
Figure 9.1: Skeletal muscle area on transverse CT images at the third lumbar level, using (a)
Slice-O-Matic for evaluation of cross-sectional area and (b) Mirada software for extraction of
radiomic features.
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Radiomic features
A total of 1298 radiomic features were extracted. For analysis of baseline radiomic features,
those which had no range (n=9) were excluded. After removing the redundant features
using the spearman correlation method, 193 radiomic features, 11 unﬁltered and 182
ﬁltered, could be used for the analysis. The average AUC over 100 repetitions for radiomic
features of the baseline scan, with muscle loss as outcome, is 0.49 (95 % CI: 0.36, 0.62).
For analysis of the delta features (diﬀerence in feature values between the baseline scan
and the follow-up scan), eight features without a range were excluded. After removing
the redundant features using the spearman correlation method, 349 radiomic features, 33
unﬁltered and 316 ﬁltered, were used to construct an AUC. For the delta radiomic features,
with muscle loss as outcome, the average AUC is 0.68 (95 % CI: 0.51-0.84).
The 20 most frequently selected delta radiomics features in LASSO models for muscle
loss in a 100-fold Monte Carlo cross-validation were plotted in Figure 9.2, it can be seen
that features from the grey-level co-occurrence matrix (GLCM) were most often selected.
Most features selected in the models were wavelet ﬁltered features, 17 of the top 20 mostly
selected features.
Figure 9.2: The 20 most frequently selected delta radiomics features in LASSO models for muscle
loss in a 100-fold Monte Carlo cross-validation. The solid bars represent unﬁltered radiomic
features and the textured bars represent wavelet ﬁltered features.
In Figure 9.3 a heatmap is shown in which radiomic features that are selected at least
once in the LASSO models, are clustered according Ward’s minimum variance method.
Two clusters of patients based on diﬀerences in radiomic texture and intensity values
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Figure 9.3: Clustered heatmap of selected delta radiomic features.
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could be deﬁned. The clusters were similar regarding age, percentage of muscle loss,
change in mean Hounsﬁeld units, Charlson comorbidity index, treatment arm, smoking
status, and overall survival. A diﬀerence was found in gender distribution, as cluster 2
contained 71 % male patients compared to 44 % male patients in cluster 1 (p=0.004).
We therefore evaluated potential gender diﬀerences regarding clinical response and change
in body composition in the whole cohort, but found none [data not shown]. Figure 9.4
shows a heatmap in which radiomic features that are selected at least once in the LASSO
models were plotted against the patients ranked in descending order of the decrease in
muscle mass. The upper half of the graph shows the patients with muscle loss, the lower
half of the graph the patients with a stable muscle mass. No diﬀerence in radiomic features
is seen between those with maintenance of muscle and those with muscle loss. A list with
the selected radiomic features in alphabetic order can be found in the Supplementary
Material Table 9.1.
Figure 9.4: Heatmap of the normalized selected delta radiomic features in alphabetic order (list of
features can be found in supplementary material). Patients are ranked according to the descending
diﬀerence in muscle mass; upper half are the patients with muscle depletion, lower half patients
with stable muscle mass.
Discussion
To the best of our knowledge, this is the ﬁrst exploratory study evaluating the potential of
skeletal muscle radiomics to predict skeletal muscle loss. Some cross-sectional studies show
that baseline low CT-derived muscle mass is an important prognostic factor for OS [4, 24],
which contradicts to other studies [25, 26]. The lack of properly validated and population
speciﬁc cut-oﬀ values for CT-derived low muscle mass may explain this discrepancy. We
therefore were interested if radiomic features of baseline skeletal muscle are prognostic for
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longitudinal muscle loss. In this study, baseline radiomic features had no discriminatory
value with regard to longitudinal skeletal muscle changes. However, longitudinal diﬀerences
in radiomic features were seen between those who lost muscle and those who maintained
muscle mass.
The most distinct delta radiomic feature was a feature in the grey-level co-occurrence
matrix (GLCM) category. To calculate the GLCM, each pixel in an image is assigned
a numerical value depending on the combination of grey-level intensity values in two
neighbouring pixels. Second order statistics calculate mathematical algorithms to derive
textural homogeneity, contrast, variance etc. [27]. GLCM features depend on the grey
level pattern, which might implicate that patients with muscle loss develop more muscle
fat deposits, leading to a more heterogeneous grey level intensity pattern (as low grey
levels reﬂect increased intramuscular fat). Indeed analysis of muscle biopsies demonstrated
that compared to controls, cancer patients exhibited increased numbers of lipid droplets
in skeletal muscle. Moreover, the amount of lipid droplets increased with progression
of weight loss [28]. Muscle fat depots assessed by muscle radiation attenuation on CT
are associated with poor survival in cancer [4]. A phantom study showed concordance
between radiation attenuation and muscle lipid content [29], therefore, reduced muscle
radiation attenuation is believed to reﬂect fat inﬁltration. However, it is unclear if this
radiation attenuation indicates intra- or extramyocellular lipids. Therefore, the etiology
and prognostic signiﬁcance of muscle lipids in cachexia progression is object for further
research.
While the strength of our study comes from the well-deﬁned randomized patient cohort,
with CT scans executed according to study protocol predeﬁned time points, there are
some limitations. Pre-treatment changes in muscle mass are unknown. Patients currently
identiﬁed as ‘muscle maintenance’, could have exhibited muscle loss prior to the ﬁrst CT
scan, which may inﬂuence radiomic features. The NVALT12 trial is a multicentre study.
Consequently, the CT scans included in this analysis are performed in diﬀerent hospitals
on diﬀerent CT scanners with possible diﬀerent scan protocols. We showed in a phantom
study that slice thickness variability inﬂuences radiomic features. However, this variability
in radiomic feature values can be reduced by resampling to a standardized voxel size. In
addition, it was shown that diﬀerent exposures do not inﬂuence the radiomic feature values
[23]. Although most CT scans included in our analysis were low dose, some CT scans were
performed with use of contrast. The inﬂuence of CT contrast on radiomic features is still
unclear.
In conclusion, the present study shows that baseline skeletal muscle radiomics is not
able to predict muscle loss in metastatic NSCLC patients. Nevertheless, longitudinal
diﬀerences in texture muscle radiomic features can distinguish patients with muscle loss
from patients without muscle loss. Future research in experimental models and human
radiomics combined with muscle tissue analysis is required to unravel the biological
processes linked to the radiomic features.
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1. Fractal_average
2. GLCM_inverseVar
3. GLRLM_RLN
4. GLSZM_IN
5. GLSZM_IV
6. GLSZM_LILAE
7. GLSZM_SAE
8. IH_iqr
9. IH_mingrad
10. IH_qcod
11. LocInt_peakGlobal
12. LocInt_peakLocal
13. NGLDM_DV
14. NGTDM_coarseness
15. Wavelet_HHH_Fractal_lacunarity
16. Wavelet_HHH_GLCM_clusShade
17. Wavelet_HHH_GLCM_correl1
18. Wavelet_HHH_GLCM_infoCorr2
19. Wavelet_HHH_GLDZM_LISDE
20. Wavelet_HHH_GLSZM_HILAE
21. Wavelet_HHH_GLSZM_IN
22. Wavelet_HHH_GLSZM_SAE
23. Wavelet_HHH_IH_cov
24. Wavelet_HHH_IH_qcod
25. Wavelet_HHH_NGTDM_coarseness
26. Wavelet_HHH_Stats_cov
27. Wavelet_HHH_Stats_max
28. Wavelet_HHH_Stats_mean
29. Wavelet_HHH_Stats_median
30. Wavelet_HHH_Stats_qcod
31. Wavelet_HHL_Fractal_lacunarity
32. Wavelet_HHL_GLCM_clusShade
33. Wavelet_HHL_GLCM_correl1
34. Wavelet_HHL_GLCM_infoCorr1
35. Wavelet_HHL_GLCM_infoCorr2
36. Wavelet_HHL_GLDZM_DZE
37. Wavelet_HHL_GLDZM_LDE
38. Wavelet_HHL_GLRLM_GLN
39. Wavelet_HHL_GLRLM_RE
40. Wavelet_HHL_GLRLM_SRLGE
41. Wavelet_HHL_GLSZM_HILAE
42. Wavelet_HHL_GLSZM_IN
43. Wavelet_HHL_GLSZM_SZNN
44. Wavelet_HHL_IH_iqr
45. Wavelet_HHL_IH_qcod
46. Wavelet_HHL_NGLDM_DE
47. Wavelet_HHL_NGLDM_DNN
48. Wavelet_HHL_NGLDM_DV
49. Wavelet_HHL_NGLDM_LGSDE
50. Wavelet_HHL_NGTDM_coarseness
51. Wavelet_HHL_NGTDM_contrast
52. Wavelet_HHL_NGTDM_strength
53. Wavelet_HHL_Stats_cov
54. Wavelet_HHL_Stats_max
55. Wavelet_HHL_Stats_median
56. Wavelet_HHL_Stats_qcod
57. Wavelet_HLH_Fractal_average
58. Wavelet_HLH_GLCM_infoCorr2
59. Wavelet_HLH_GLCM_invDiﬀnorm
60. Wavelet_HLH_GLCM_maxCorr
61. Wavelet_HLH_GLSZM_LISAE
62. Wavelet_HLH_IH_cov
63. Wavelet_HLH_IH_iqr
64. Wavelet_HLH_IH_mediand
65. Wavelet_HLH_IH_min
66. Wavelet_HLH_IH_qcod
67. Wavelet_HLH_NGLDM_LGSDE
68. Wavelet_HLH_NGTDM_contrast
69. Wavelet_HLH_Stats_cov
70. Wavelet_HLH_Stats_max
71. Wavelet_HLH_Stats_mean
72. Wavelet_HLH_Stats_median
73. Wavelet_HLH_Stats_qcod
74. Wavelet_HLH_Stats_skewness
75. Wavelet_HLL_GLCM_infoCorr1
76. Wavelet_HLL_GLCM_maxCorr
77. Wavelet_HLL_GLDZM_DZV
78. Wavelet_HLL_GLRLM_GLN
79. Wavelet_HLL_GLRLM_LRHGE
80. Wavelet_HLL_GLRLM_RLN
81. Wavelet_HLL_GLSZM_HILAE
82. Wavelet_HLL_GLSZM_SZV
83. Wavelet_HLL_IH_cov
84. Wavelet_HLL_IH_iqr
85. Wavelet_HLL_IH_mediand
86. Wavelet_HLL_IH_qcod
87. Wavelet_HLL_IH_skewness
88. Wavelet_HLL_NGLDM_DN
89. Wavelet_HLL_NGLDM_DV
90. Wavelet_HLL_NGTDM_coarseness
91. Wavelet_HLL_NGTDM_strength
92. Wavelet_HLL_Stats_cov
93. Wavelet_HLL_Stats_qcod
94. Wavelet_LHH_Fractal_average
95. Wavelet_LHH_Fractal_lacunarity
96. Wavelet_LHH_GLCM_correl1
97. Wavelet_LHH_GLCM_infoCorr1
98. Wavelet_LHH_GLCM_infoCorr2
99. Wavelet_LHH_GLCM_invDiﬀnorm
100. Wavelet_LHH_GLCM_maxCorr
101. Wavelet_LHH_GLDZM_DZV
102. Wavelet_LHH_GLSZM_IN
103. Wavelet_LHH_GLSZM_SZNN
104. Wavelet_LHH_GLSZM_SZV
105. Wavelet_LHH_IH_cov
106. Wavelet_LHH_IH_mediand
107. Wavelet_LHH_IH_qcod
108. Wavelet_LHH_IH_skewness
109. Wavelet_LHH_NGLDM_LGSDE
110. Wavelet_LHH_NGTDM_contrast
111. Wavelet_LHH_Stats_qcod
112. Wavelet_LHL_Fractal_average
113. Wavelet_LHL_GLCM_correl1
114. Wavelet_LHL_GLCM_infoCorr1
115. Wavelet_LHL_GLCM_infoCorr2
116. Wavelet_LHL_GLCM_maxCorr
117. Wavelet_LHL_GLDZM_SDE
118. Wavelet_LHL_GLRLM_GLN
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119. Wavelet_LHL_GLRLM_LRLGE
120. Wavelet_LHL_GLRLM_RLN
121. Wavelet_LHL_GLRLM_SRLGE
122. Wavelet_LHL_GLSZM_HILAE
123. Wavelet_LHL_GLSZM_IN
124. Wavelet_LHL_GLSZM_ZE
125. Wavelet_LHL_IH_cov
126. Wavelet_LHL_IH_iqr
127. Wavelet_LHL_IH_mediand
128. Wavelet_LHL_NGLDM_DN
129. Wavelet_LHL_NGTDM_strength
130. Wavelet_LHL_Stats_cov
131. Wavelet_LHL_Stats_kurtosis
132. Wavelet_LHL_Stats_max
133. Wavelet_LHL_Stats_mean
134. Wavelet_LLH_Fractal_sd
135. Wavelet_LLH_GLCM_correl1
136. Wavelet_LLH_GLCM_infoCorr2
137. Wavelet_LLH_GLCM_maxCorr
138. Wavelet_LLH_GLSZM_IN
139. Wavelet_LLH_IH_cov
140. Wavelet_LLH_NGLDM_SM2
141. Wavelet_LLH_Stats_kurtosis
142. Wavelet_LLH_Stats_max
143. Wavelet_LLH_Stats_median
144. Wavelet_LLH_Stats_skewness
145. Wavelet_LLL_GLCM_correl1
146. Wavelet_LLL_GLCM_infoCorr2
147. Wavelet_LLL_GLDZM_DZNN
148. Wavelet_LLL_GLRLM_RE
149. Wavelet_LLL_GLSZM_INN
150. Wavelet_LLL_GLSZM_SZNN
151. Wavelet_LLL_GLSZM_SZV
152. Wavelet_LLL_IH_iqr
153. Wavelet_LLL_IH_maxgrad
154. Wavelet_LLL_NGLDM_DN
155. Wavelet_LLL_NGLDM_SM2
156. Wavelet_LLL_NGTDM_contrast
157. Wavelet_LLL_Stats_p10
158. Wavelet_LLL_Stats_p90
Table 9.1 Selected radiomic features in alphabetic order
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Imaging in non-small cell lung cancer
Imaging plays a crucial role in the diagnosis, staging, treatment and follow-up of lung
cancer. Imaging modalities used in routine daily care in lung cancer are computed
tomography (CT), 18F-ﬂuodeoxyglucose positron emission tomography (FDG-PET),
magnetic resonance imaging (MRI) and ultrasound. A PET/CT scan has a higher
sensitivity than a CT scan in the detection of malignancies, however at the cost of a
lower speciﬁcity [1]. Next to that, the higher sensitivity of the PET does not always have
therapeutic consequences, e.g. if the PET scan detects more metastases compared to the
CT, the patient is still diagnosed with a stage IV disease and its intended treatment [1].
While PET/MR has a higher sensitivity than PET/CT in non-small cell lung cancer
(NSCLC), this does also not always lead to a diﬀerent treatment. A recent study showed
that 18F-FDG PET/MR and 18F-FDG PET/CT agreed 100 % on the T-stage and that
there were no signiﬁcant diﬀerences between both modalities for the detection of lymph
node metastases[2].
Response assessment using CT and PET
A variety of approaches have been developed to measure treatment response, starting
with the World Health Organization (WHO) criteria and continuing to Response Criteria
In Solid Tumors (RECIST) and RECIST 1.1 [3, 4]. These criteria refer to an anatomical
decrease in tumor diameter. However, this response assessment must be viewed with
some caution when assessing treatment outcomes in therapies that may be more
cytostatic than cytotoxic. With cytostatic therapies, lack of progression may be
associated with an improvement in outcome, even in the absence of major shrinkage of
tumors [5]. Therefore, newer metrics such as PET-based imaging biomarkers may be
more informative [6]. Currently, two sets of treatment response criteria for PET are
available: European Organization for Research and Treatment of Cancer (EORTC) [7]
and PET response criteria in solid tumors (PERCIST) [8]. Next to quantitative response
criteria, there also exist visual response criteria. The ﬁrst visual response criteria for PET
were published in 2003 [9]. In 2012 visual response criteria speciﬁc for lymphoma were
published [10]. In a recent study, the quantitative PET response criteria of the EORTC
and PERCIST, were compared to the visual response criteria of Peter Mac and Deauville
in NSCLC [11]. Although all four response criteria were highly predictive for overall
survival, the visual response criteria showed a better discrimination between complete
metabolic responders and non-responders [11]. The EORTC criteria and PERCIST
showed similar results. Another recent study showed that the EORTC response criteria
and the PERCIST criteria gave similar prognostic stratiﬁcation [12]. Therefore, for PET
response assessment the visual response criteria of Deauville or Peter Mac are preferred
over the quantitative response criteria of the EORTC and PERCIST. A recent study
compared the anatomical CT-based response criteria RECIST with the metabolic
PET-based response criteria PERCIST [13]. They showed that in only 45 % of the
patients there was concordance between both response criteria, in which PERCIST
response criteria had a higher agreement with pathological response (94 %) than
RECIST response assessment (72 %). Nevertheless, PET response assessment had a
higher sensitivity (77.8 %) and speciﬁcity (75 %) than CT response assessment (66.7 %
and 70.5 %, respectively) [13]. In the Dutch multicenter randomized phase II clinical trial
NVALT12 (NCT01171170), patients were randomized between
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paclitaxel-carboplatin-bevacizumab with or without the addition of nitroglycerin (NTG),
to investigate the added value of NTG on progression free survival (PFS) [14]. For all
patients that had a baseline PET/CT-scan a second PET/CT-scan after three weeks was
performed. In this thesis we compared CT-based response assessment and PET-based
response assessment for patients included in the NVALT12 study, on the primary tumor
only, while RECIST and PERCIST are based on the total tumor load. Early metabolic
response was deﬁned as a 30 % decrease in the maximum standardized uptake value
(SUVmax), SUVmean or SUVpeak relative to the baseline scan. The early anatomic
response was deﬁned as a 30 % decrease in CT diameter or CT volume relative to the
baseline scan. The comparison of 30 % CT-based and 30 % PET-based response
assessment performed after 3 weeks (median time interval between scans 42 days) with
the RECIST analysis performed in week 6 (median time interval between scans 56 days)
showed that the RECIST analysis deﬁned more patients as responders than the 30 %
CT-based analysis performed after 3 weeks. This can be caused by the diﬀerence in
timing, but also due to the fact that for the 30 % CT-based analysis only one lesion was
measured while in RECIST multiple lesions were measured. The 30 % PET-based
response assessment performed after 3 weeks showed more responders than the RECIST
analysis, which is probably caused by decreased perfusion due to the bevacizumab
treatment, which led to a decrease in FDG uptake for both treatment arms. In another
study, in which PET-based response assessment in NSCLC patients treated with erlotinib
and bevacizumab was performed after 3 weeks of treatment, showed that ﬁve of nine
patients were classiﬁed as responders by CT while six of nine were classiﬁed as
responders by 18F-FDG PET [15], which is in line with the study that compared RECIST
response assessment with PERCIST response assessment. In the same study, patients
with a metabolic response (decrease in SUV > 20 %) at week 3 had a longer PFS than
those without (9.7 months vs. 2.8 months), while patients with a response on CT at
week 3 did not have a signiﬁcantly longer PFS than those without. These two ﬁndings
combined showed that PET may be able to show treatment response earlier than CT. In
the study of Dingemans et al. [15], 18F-FDG PET scans were performed before
bevacizumab infusion, while in the NVALT12 study the 18F-FDG PET scan was
performed shortly after bevacizumab infusion. This might have impacted the uptake of
FDG. Response assessment using 18F-FDG PET can detect responders earlier (from three
weeks after the start of chemotherapy treatment) than a CT based response assessment,
however caution needs to be taken with treatments that inﬂuence tumor perfusion, while
this may lead to false positives. While tumors, lymph nodes and metastases can respond
diﬀerently on treatment, it is recommended to perform PERCIST response assessment of
total tumor load instead of only focusing on the primary tumor. Ultimately, it would be
even better to select patients before the start of treatment. Outcome prediction models
(either prognostic or predictive) can be used to up front estimate if a patient will respond
on a speciﬁc treatment. Prognostic models give information about a likely outcome, for
example survival, independent of treatment received [16]. Medical imaging can as well be
used in predictive models by changing therapy options during the course of treatment.
Images should therefore be processed in such a way that imaging biomarkers can be
extracted and interpreted for such purpose.
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Image biomarkers
Simple image features
An imaging biomarker is a measured indicator of normal biological processes, pathogenic
processes or responses to treatment [17]. Simple PET derived metrics like the SUVmax,
SUVmean, SUVpeak or the total lesion glycolysis have been described to determine the
prognosis of NSCLC patients [18, 19, 20]. Many studies have shown that by using these
18F-FDG PET SUV metrics, response to chemotherapy can be assessed as early as three
weeks after the start of therapy [21, 22, 23, 24, 25]. In the NVALT12 trial, the added value
of NTG to paclitaxel-carboplatin-bevacizumab was investigated. Many factors inﬂuence
tumor resistance and response to treatment. Tumor hypoxia is a negative prognostic factor
in lung cancer and seems to be related to treatment resistance. Both at cellular level as
well as on a population level, a negative correlation between perfusion CT and hypoxia
PET is described [26, 27], suggesting that hypoxia is negatively correlated to tumor blood
ﬂow. NTG, which is a vasodilator, increases tumor blood ﬂow, consequently augments
antitumor drug delivery and inhibits hypoxia inducible factor (HIF-1α). When hypoxia is
negatively correlated to tumor blood ﬂow and NTG increases tumor perfusion, this could
translate into a change in FDG uptake [28]. The feasibility of PET response assessment to
paclitaxel-carboplatin-bevacizumab treatment with and without NTG is investigated in this
thesis. Changes in PET derived imaging parameters such as SUVmax, SUVpeak, SUVmean
and the total lesion glycolysis (TLG: SUVmean x metabolic tumor volume) between the
baseline and the second scan, were not signiﬁcantly diﬀerent, for the NTG group compared
to the control group. In a previous study by Matthews et al. [29], the administration of
nitric oxide (NO) donating drugs decreased hypoxia-induced resistance to anticancer drugs
in cancer cell lines. In our study, this could not be conﬁrmed based on PET analysis. This
could be due to a lower NTG dose or to an interference with bevacizumab. However from
recent studies, it is known that FDG is only a moderate surrogate for hypoxia [30]. The
study of Zegers et al. [31] showed that 42 ± 21 % of the primary tumor volume has a high
FDG uptake of which 10 ± 12 % is hypoxic and that 3 % of the primary tumor volume
outside the high FDG uptake volume is hypoxic depicted by 18F-HX4. For the NVALT 12
study, we therefore only quantiﬁed/correlated the eﬀects of NTG on tumor metabolism
and survival but not on hypoxia directly. The NVALT12 study showed that the addition of
NTG to paclitaxel-carboplatin-bevacizumab therapy did not improve PFS or overall survival
(OS). Surprisingly, we could show that nearly all patients, irrespective of the addition of
NTG, had a major decrease in FDG uptake in the 18F-FDG PET scan performed after
3 weeks. Importantly, this 18F FDG PET scan was acquired within 3 days after the
administration of the second cycle of chemotherapy. A study by van der Veldt et al. [32]
showed that bevacizumab reduces tumor perfusion and 11C docetaxel uptake in NSCLC,
which was accompanied by rapid reduction in circulating levels of VEGF. This decrease in
tumor blood ﬂow after bevacizumab administration may explain the lower uptake of FDG
in the tumor. Consequently, our results do not exclude the possibility that NTG decreases
hypoxia. To conﬁrm this eﬀect a hypoxia PET imaging study needs to be performed. In
conclusion, because FDG may not be a good surrogate for hypoxia, studies investigating the
eﬀect of hypoxia treatment preferably use hypoxia tracers as 18F-HX4, 18F-ﬂuoroazomycin-
arabinoside (FAZA) or 18F-ﬂuoromisonidazole (MISO). When 18F-FDG-PET is used for
response assessment of paclitaxel-carboplatin-bevacizumab treatment the 18F-FDG PET
scan should be performed minimal ﬁve days after bevacizumab infusion. For response
232
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 233
10
General discussion and future perspectives
assessment it is advised to use SUVpeak or SUVmean as they show less variability compared
to SUVmax [33]. Potentially a more detailed investigation of the full image dataset and
tumors complemented with more complex image biomarkers can give additional information
about tumor heterogeneity and therefore aggressiveness of the tumor.
Semantic features
Next to simple SUV metrics, also visually scored image characteristics, so called semantic
features, may yield prognostic information. A recent study showed that semantic features
could predict disease progression [34]. A study in sarcoma patients showed that simple SUV
metrics combined with semantic features predicts treatment outcomes [35]. A decreased
volumetric muscle CT attenuation was associated with increased distant cancer recurrence,
and increased PET SUV of muscle was associated with decreased overall survival. Muscles
with on average higher HUs may have less intramuscular fat. A higher level of IMAT
has been associated with lower muscle quality and a worse prognosis. Patients with lower
levels of IMAT are therefore suggested to have a better outcome. The SUV measures
were associated with lower serum albumin and lower hemoglobin, which shows that PET
can potentially be a biomarker for serum markers related to cachexia [35]. A study of
Segal et al. [36] has shown that non-invasive imaging can decode genomic activity of
human liver cancers. A study of Rizzo et al. [37] has shown that semantic features, like
lesion cavitation, air bronchogram and pleural eﬀusion are associated with alterations of
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and Kirsten
rat sarcoma (KRAS) genes. Current methods of molecular proﬁling require invasive biopsies
for tissue procurement, which may limits the routinely use, especially in repeated testing.
Next to that, it provides only a sample of a usually heterogeneous lesion at a speciﬁc
time point. While imaging can reﬂect the dynamic status of tissue, it can be helpful
predicting gene expression patterns [36]. However, these semantic features are scored by
visual assessment of radiologists and are therefore inter-observer dependent. Therefore, we
investigated if there are correlations between semantic features and quantitative radiomic
features. A study of Yip et al. [38] already looked into possible correlations between
semantic features and radiomic features of the tumor. Like Yip et al., we conﬁrmed that
there is an association between air bronchogram and the tumor radiomic feature “shape
sphericity”. Additionally, we found overlap of the non-redundant features by Yip et al.,
but also some other radiomic features that were not signiﬁcant in the previous study. This
can be due to a diﬀerent number of events per semantic feature in the both datasets, but
highlights the possibility of using quantitative radiomic based features to describe visual
semantic features.
We also showed that some semantic features are lesion speciﬁc (e.g. cavitation and
necrosis), while other semantic features describe lung characteristics (e.g. pleural
eﬀusion and satellite nodules). As the univariate analysis clearly showed, as expected,
that tumor radiomic features contain information about tumor semantic features (e.g.
density, air bronchogram, necrosis), the lung radiomic features contain information about
lung semantic features (e.g. pleural contact and pleural eﬀusion). To ﬁnd these
correlations is not straightforward, for example no radiomic feature contained information
to describe calciﬁcations, but this might be also due to the fact that only 12 % of the
patients of the training cohort and 3 % of the patients of the validation cohort had
calciﬁcations, and also that those calciﬁcations were visually hard to detect. For
validation of models, it is therefore important that in both cohorts the number of events
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are large enough. A study of Collins et al. [39] showed that the minimum number of
events is 100 and ideally, 200 or more events are required. Current datasets are hence
too small to accurately classify rare events, larger datasets are needed for model building.
Our multivariate analysis showed that a combination of tumor radiomic features
could detect the semantic features air bronchogram, necrosis and pleural eﬀusion. A
combination of lung radiomic features detected the semantic features pleural thickening,
satellite nodules and pleural eﬀusion. Comparing the univariate results with the
multivariate results showed that airbronchogram, necrosis and pleural eﬀusion can be
detected using one, as well as, using a combination of radiomic features of the tumor,
and pleural eﬀusion can be detected, using one, or a combination of radiomic features of
the lung. Although, the radiomic features in the top ten highest rank in the multivariate
analysis are not signiﬁcant in the univariate analysis. The diﬀerence between the results
of the multivariate analysis and the univariate analysis may be explained by the fact that
in the multivariate analysis also interactions between radiomic features are included.
Next to that, the results in the univariate analysis most likely overﬁtted, due to a high
number of radiomic features and a small number of patients, which is corrected for in the
multivariate analysis by performing bootstrapping techniques [40].
In conclusion, correlations between semantic features and radiomic features may play
a role to better understand biologic and pathological processes or allow for an early and
objective classiﬁcation of these processes, which in the future can lead to radiomic
features that represent genetic alterations or pathological processes, an example is shown
in Figure 10.1. Large datasets with genetic proﬁling not only in tumors but as well in
lymph nodes metastases and distant metastases are needed for image biomarker studies
in developing prognostic models. Next to that, correlations between radiomic features
and biology need to be investigated, in the next step then genetic proﬁling may be
correlated or complemented with radiomic features to evolve into a non-invasive
characterization of the lesion investigated.
Radiomic image features
Radiomics is a quantitative method to determine the phenotype of a tumor. Although, a
variety of applications of radiomics is currently investigated, there are many methodological
issues that need to be solved, before the larger potential of radiomics is fully utilized. Every
step in the radiomics process, as shown in Figure 10.2, has its own challenges.
Many studies have already shown the potential value of using radiomic features in
prognostic models [43, 44, 45]. One of the ﬁrst studies showing the potential of radiomics
in lung cancer is the study of Aerts et al. [46] from 2014. First, they selected stable
features from 440 radiomic features using a test-retest and a multiple delineation dataset.
The 100 most stable features contained features from the statistics group, the shape group,
the texture group and from the ﬁltered texture group. The single best performing radiomic
feature from each group, were combined in a prognostic model. This model was externally
validated in a cohort of 225 stage I-III NSCLC patients. Next to that, was shown that
the model was also prognostic in two independent cohorts of more than 200 head and
neck cancer patients. The radiomic model performed better than TNM-staging in the
lung validation dataset. And by combining the radiomic model with TNM-staging model
performance increased in all datasets. In this thesis, the applicability of the signature was
tested in a cohort of 195 stage IV NSCLC patients. The signature showed prognostic
value in the stage IV NSCLC cohort, although the c-index was less prominent (c-index
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Figure 10.1: The left image shows the current situation, in which patients have to undergo
invasive biopsies to determine the phenotype of tissue/tumors; the right image shows the future
situation using radiomics. With radiomics the tumor phenotype potentially can be determined in
a non-invasive way, with information from multiple lesions at multiple time points. Adjusted from
Sanduleanu et al. [41].
0.58, p=0.002) vs. 0.65 for the stage I-III group originally. Although, our cohort of
patients was well characterized and in daily practice patients are viewed to have the same
prognosis (stage IV, EGFR and ALK wildtype, non-squamous histology, WHO PS <3,
chemotherapy eligible), by applying the signature and using a routine baseline CT scan we
were able to select a group of patients with poor outcome [HR 1.45 (1.07-1.92), p=0.02].
In our univariate analysis next to the prognostic index of the radiomic signature [HR 1.46
(1.02-2.10), p=0.04], the known clinical prognostic factor WHO performance status [HR
1.52 (1.10-2.11)], N-stage [HR 1.84 (1.15-2.93)] and M-stage [HR 1.53 (1.07-2.19)] were
also prognostic for overall survival. The 195 stage IV NSCLC patients were derived from
two datasets. A reason for the lower c-index in the stage IV patients cohort, can be
that the data from one of the cohorts (n=137) was part of a multicenter study with
no dedicated CT image protocol speciﬁed. There was quite some variation in the CT
image acquisition and reconstruction parameters. Recent publications have shown that
resampling of the voxel size leads to more reproducible CT features [47, 48]. This is a
necessary step as Shaﬁq-Ul-Hassan et al. [47] showed that some radiomic features are voxel
size dependent. To minimize the possible eﬀect of the variation in image parameters, all
scans were resampled, as recommended in Larue et al. [49], to a voxel size of 1 × 1 × 3
mm3, which is comparable to the voxel size of the signature dataset. For radiomic studies
it is important to use large datasets with standardized image acquisition and reconstruction
protocols, to reduce noise. And to use resampling in validation studies when voxel sizes
are not similar.
As the radiomic signature is based on analysis of the primary tumor, tumor volume
might have impact on the outcome. In the stage I-III NSCLC signature cohort of Aerts
et al. [46] the median tumor volume was 251 cm3 (2-489), while in our stage IV NSCLC
cohort the median tumor volume was only 36 cm3, (0-769). In 33 % of our cohort the
tumors were staged as T4, which is comparable to the signature cohort, were 28 % of
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Figure 10.2: Process of radiomics, adjusted from Lambin et al. [42].
the tumors were staged as T4. A T4 staged tumor can be a large tumor, but it can as
well mean that there are multiple nodules in the lung. In case of multiple nodules, the
largest lesion was used for the radiomic analysis, which can also explain the diﬀerence in
tumor volumes between the signature cohort and our cohort. Our cohort has an equal
distribution of cT-stage compared to Aerts et al. [46], which conﬁrms that cT-stage is
not an indicator of tumor volume. In stage IV NSCLC, mainly the cM-stage determines
the prognosis of a patient. With radiomics image characteristics of the primary tumor,
but also of the nodes and metastases, image information can be easily used for prognostic
models [50, 51, 52]. Although the radiomic signature developed in stage I-III NSCLC had
as well prognostic value in stage IV NSCLC, the model is not reliable enough to use in
clinical routine. While N-stage and especially M-stage are important prognostic factors in
stage IV NSCLC, a radiomic signature including radiomic features extracted from lymph
node metastases and distant metastases would potentially have a better prognostic value
for overall survival.
Most radiomic studies use OS as endpoint, however it would also be interesting to have
prognostic factors and models that predict distant metastases [53] or allow to predict the
loss in quality of life . One of those prognostic factors that negatively aﬀect survival in
NSCLC is cachexia. Cachexia is a phenomenon of skeletal muscle and/or adipose tissue
depletion in cancer patients, which is related to increased chemotherapy-induced toxicity,
lower quality of life and lower survival rates in NSCLC patients [54, 55, 56]. Some studies
have shown that the decrease in cross sectional area of the skeletal muscle is prognostic
for overall survival [54, 55, 56, 57]. Another study showed that a decreased volumetric
muscle CT attenuation was associated with increased distant cancer recurrence [34]. In this
thesis we showed that longitudinal diﬀerences in radiomic texture and intensity features are
correlated to a decrease in cross sectional muscle volume, which could be a representation
of myosteatosis. Next to developing models with survival as endpoint, prognostic models
with for example cachexia as outcome could as well help to improve survival and quality
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of life in stage IV NSCLC patients.
Methodological issues
PET imaging
As mentioned before, to investigate, develop and validate the use of image biomarkers
large datasets are needed. However, when using data from diﬀerent hospitals or diﬀerent
PET/CT scanners a large variability in acquisition and reconstruction parameters can exist,
which can inﬂuence the SUV. The European Association of Nuclear Medicine (EANM)
provided in 2010 guidelines for a minimum standard for the acquisition and interpretation
of 18F-FDG PET/CT scans [58]. Earlier national image standardization guidelines, like
the Netherlands protocol for standardization of quantitative whole-body FDG-PET/CT
(NEDPAS) [59] and the German Guidelines for FDG-PET/CT in Oncology [60] have been
integrated in the EANM guideline. Next to recommendations about patient preparation,
image acquisition, image reconstruction and analysis also recommendations for quality
control are given.
Inﬂuence of PET acquisition time
The NVALT12 trial, started in January 2011, study protocol prescribed that image
acquisition had to be done according to the NEDPAS protocol, while image
reconstruction could be done according to institutional standards. The NEDPAS protocol
stated that emission scanning should start 55 to 65 minutes after the administration of
FDG [59]. We showed that in the NVALT12 study, this was only the case in 34 % of the
scans. It is well known that lesion SUV for FDG continues to rise for at least 45 minutes
after FDG injection, reaching a plateau between 60 and 90 minutes [61, 62, 63]. In the
updated guidelines of the EANM version 2.0 from 2015 the acceptable uptake time
window was changed to 55-75 minutes [64], which was the case for 59 % of the scans in
our study. Protocol deviations are quite common in clinical practice, a written survey
among all Austrian PET/CT centers, showed that the average uptake time there was 55
minutes, with a range of 45 to 75 minutes, which is lower than in the EANM guidelines
[65]. The optimal uptake time is as well tumor site speciﬁc, for liver imaging using
18F-FDG PET the optimal uptake time was shown to be 90 minutes after FDG injection
[66]. A possible reason for deviations in our study is that the radiopharmaceutical start
time, extracted from the Digital Imaging and Communications in Medicine (DICOM)
header, was not the time of FDG administration, as we assumed. Because it is currently
not possible to separately store information on injection time and calibration time in the
DICOM header, some ambiguity about what time is in the DICOM header under the
name radiopharmaceutical start time exists. Therefore, we recommend to take the
acquisition time, near the midplane slice of the tumor, and note in the case report form
(CRF) or DICOM header next to the injection time, the start time as well the calibration
time. For response assessment it is important to have a minimum of variation in the
uptake times of the repeated scans. In the uniform protocols for imaging in clinical trials
(UPICT) guidelines it is stated that the acceptable variance in time interval is ± 15
minutes, with a target of ± 10 minutes [67]. In a consensus report for response
assessment using PET is stated that uptake periods with less than 10 minutes diﬀerences
do not lead to SUV variabilities [68]. In the NVALT 12 study only 19 % of the scans
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fulﬁlled the UPICT criteria, which means that a variation in SUV was expected based on
the diﬀerences in uptake times of the repeated scans.
For response assessment studies, when uptake times are both longer than 55 minutes
and the diﬀerence between both uptake times is smaller than 10 minutes no diﬀerences in
SUV values due to uptake time is expected. For shorter uptake times or larger diﬀerences
it is recommended to consult a nuclear medicine expert before analyzing and interpreting
the scans.
Inﬂuence of PET reconstruction algorithms
Reconstruction algorithms and voxel size are diﬀerent for the various available PET systems
and vendor dependent. Therefore, it is a challenge to ensure that images of PET scanners
from diﬀerent vendors are quantitatively comparable [69]. Point-spread-function (PSF)
reconstructed images showed signiﬁcantly higher SUVmax and SUVmean values, as well
as higher heterogeneity and a wider range of heterogeneity compared to ordered subset
expectation maximization (OSEM) reconstructed images. Using PSF reconstruction with
adjusting the Gaussian ﬁltering to meet harmonizing standards resulted in similar SUV
values [70]. SUVref, applies a reconstruction-protocol speciﬁc ﬁlter to clinical PET scans
to reduce reconstruction depended variation in SUV measurements, enabling increased
conﬁdence in quantitative comparisons between institutes [71]. Multiple studies have
shown that liver metabolism can be used as reference organ due to its stable uptake over
time and therefore, suitable for assessment of scan parameters [72]. In this thesis, a
quality score was developed, in which for every parameter that was guideline compliant
a point was given. The total number of points was divided by the number of known
parameters. Parameters that were scored, are the uptake time, the reconstruction method,
the convolution kernel used, the matrix size and the applied corrections (attenuation,
scatter and randoms). The average quality score over all hospitals was 69 %. However,
we could not show a relation between the quality score and SUVmean of the liver. Kuhnert
et al. [73] showed that for parameters other than reconstruction method and settings
(e.g. injected activity and uptake time), the SUVmean of the liver could be used for
quality assessment, in compliance with the EANM guideline, meaning the large variability
in SUVmean of the liver is most probably caused by the diﬀerences in uptake time and net
injected activity. Our results are in agreement with Hristova et al. [72], the variability in
SUVmean of the liver is slightly smaller for the scans with a guideline compliant uptake time
than for the scans with non-compliant uptake times. Therefore, for future multicenter trials
using PET scans for response assessment it is recommended to do a prospective central
quality-review during patient inclusion to improve compliance with image standardization.
Although many factors inﬂuence the SUV, a study investigating the stability of FDG-
PET radiomics features showed that 71 % of the features were test-retest stable and 91 %
were inter-observer stable [74]. Another study showed that for PET radiomics the ﬁxed-
bin-number discretization method resulted in more stable SUV values than the ﬁxed-bin-
size discretization method [75]. For radiomics the segmentation process can have a large
inﬂuence. It is shown that some texture features are highly correlated with the metabolic
tumor volume. Only 17 of 31 investigated texture features were robust with respect to
tumor segmentation method [76]. Other radiomic features, like skewness, cluster shade
and zone percentage, are sensitive for diﬀerences in reconstruction settings [77].
When using 18F-FDG PET scans from diﬀerent institutes, performed on diﬀerent
PET scanners it is important to check if all institutes implemented the EANM guidelines.
This can be checked by performing a prospective quality review of one scan per institute
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before patient inclusion. When diﬀerent reconstruction algorithms are used, SUVref can
be used to minimize variation in SUV values. Before radiomics using 18F-FDG PET can
show it’s potential, PET acquisition and reconstruction need to be standardized. For the
radiomics process the PET scans need to be discretized using a ﬁxed-bin-number method
and segmentation need to be done using a standardized threshold.
CE-CT imaging
For stage III NSCLC patients, who are eligble for treatment with curative intent, current
guidelines advise a post-contrast MRI or CE-CT of the brain to exclude brain metastases
[78]. In (CE)-CT imaging guidelines [79, 80], no recommendations are made on the
minimal technical requirements. However, while medical images are an integral part of
oncological patient records and therefore reviewed by many diﬀerent specialists, it is
relevant that besides imaging experts, other clinicians are also aware that the diagnostic
value of a scan is inﬂuenced by the applied imaging protocol. It is strongly recommended
that the radiologist is informed about the indication for the requested scan and therefore,
clinicians must provide all clinical information that is necessary to determine the optimal
imaging protocol to apply. On the other side, for non-imaging clinicians it is important to
evaluate whether the applied imaging protocol is indeed adequate for the requested
purpose. The quality recommendations we developed potentially lead to a uniform
clinical interpretation and could be helpful during multidisciplinary meetings. Although,
the clinical impact should be tested in a prospective study.
In CE-CT guidelines for brain imaging, the importance of the patient position is not
reported. The FOV of the head, should be adjusted to the size of the head, and the arms
should be at thorax level to reduce artifacts (e.g. beam hardening). Furthermore, the sole
fact that a scan was made with iodine contrast enhancement does not make the CT scan
of the brain of proper diagnostic quality: timing of the scan relative to contrast injection
and the amount of contrast material injected are important. In this thesis, the quality
issues of CE-CT scans in a multicenter study were discussed.
Inﬂuence acquisition parameters on CT radiomics
We investigated the inﬂuence of diﬀerent CT-scanners, slice thicknesses, exposures and
gray-level discretization on radiomic feature values and their stability, with a dedicated
phantom study containing several inserts. CT-scanner, slice thickness and bin width
aﬀected radiomic feature values, whereas no eﬀect of exposure was observed. One of the
scanners had a much wider range of Hounsﬁeld units (HU) for the insert that had CT
properties most similar to tumors, while the same radiation dose output and acquisition
protocol was used as the other CT scanners, this might be caused by an incorrect
calibration of the scanner. When using heterogeneous datasets, images from diﬀerent
scanners and/or diﬀerent hospitals, for radiomics, it is therefore important to perform a
robustness analysis (e.g. test-retest analysis or multiple delineation test) [81], to
eliminate features that are not robust across diﬀerent scanners or scan protocols, or
apply corrections or post-processing steps.
We also showed that a large proportion of CT radiomic features is inﬂuenced by the
slice thickness used for reconstruction, but the variability in feature values could be
decreased by resampling. This is in line with Shaﬁq-ul Hassan et al. [47] who showed
that resampling reduced the feature stability from %COV > 70 % to %COV > 30 %.
Therefore, we recommend to perform resampling prior to any radiomic analysis. Despite
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the fact that resampling can greatly improve the robustness of radiomic features [47], we
advise to keep the voxel size as consistent as possible during image acquisition, because
the variability in feature values is even lower when the voxel size is equal for all images
included in a study. This should also be taken into account when comparing training and
validation datasets that might be reconstructed into diﬀerent voxel sizes. The
distribution of radiomic feature values will be inﬂuenced by the diﬀerent voxel sizes, even
if resampling was applied. Therefore, care should be taken by using interpolation
methods to change the resolution. Our results demonstrate that linear interpolation
resulted in the narrowest feature value range for 48 % of the features and cubic
interpolation for 30 % of the features, whereas nearest neighbor interpolation had the
widest range for 61 % of the features. Therefore, cubic or linear interpolation are
preferred over nearest neighbor interpolation, when resampling to 1 x 1 x 3 mm3 voxels.
For resampling it is important to look at the distribution of slice thicknesses, resampling
to smaller slice thicknesses, lead to extrapolation of the data and therefore to less reliable
results.
For none of the features, we could see a clear relationship between feature value and the
exposure. A study investigating the inﬂuence of tube current on radiomic features showed
that tube current had more eﬀect on features extracted from homogeneous materials than
from materials that are more similar to tissues. Their results indicate that variable x-ray
tube current, in dose (mA) modulated CT scans, are unlikely to have a large eﬀect on
radiomic features [82].
For CT radiomic studies it is important to use a standardized image acquisition and
reconstruction protocol. Diﬀerences in slice thickness can be reduced by resampling the CT
scans to a speciﬁc voxel size using a linear interpolation method. Although no diﬀerence
in radiomic features was seen for diﬀerent exposures, the inﬂuence of contrast agents
on radiomic feature stability need to be investigated. And also the eﬀect of diﬀerent
reconstruction kernels need to be looked into.
Inﬂuence of pre-processing steps
Almost all feature values change when choosing another bin width for gray-level
discretization. For a subset of features, a very small or very large bin width resulted in
very diﬀerent feature values across scans, whereas feature values are more similar with a
bin size in the order of 25 HU. Although the feature values change for diﬀerent bin
widths, we were not able to show that the stability of radiomic features is greatly
inﬂuenced by the choice of bin width. Our ﬁnding is the contrary of what
Shaﬁq-ul-Hassan et al. [47] described. They found that only seven out of 51 features
were reproducible, independent of the gray-level discretization. Next to that, they found
that seventeen out of 44 features showed a trend with varying number of gray levels,
which could be a linear, quadratic or cubic type relation. Normalization of feature values
by the number of gray levels reduced the variation in feature values. However, these
results imply that the choice of bin width could alter the prognostic values of a certain
radiomic signature. In contrast to PET, for CT, the stability of radiomic features is
similar when discretizing using a ﬁxed-bin-size or a ﬁxed number of bins. It is strongly
recommended to be consistent and always clearly report which pre-processing steps have
been used, to improve the reproducibility and (external) validation of radiomic studies
[42]. Next to that, it is important to visualize the distribution of HUs before setting the
discretization bin size. This is especially important when new regions of interest are used,
which could have a smaller HU range than tumors have.
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MR imaging
While CT and PET imaging are quantitative imaging modalities, MR is more qualitative
(T1-weighted, T2-weighted). PET images uptake of radiotraces in tissues and is measured
in SUV, in CT the absorption of x-rays in tissues is measured and quantiﬁed in HUs which
are related to electron densities. Qualitative MR relies on the interpretation of tissue
contrast that results from experimental pulse sequences. Quantitative MR measures tissue
speciﬁc parameters independent of experimental design. An example of quantitative MR
is diﬀusion weighted (DWI) MR [83]. In DWI MRI the random Brownian motion of
water molecules within a voxel of tissue is measured and is quantiﬁed using the apparent
diﬀusion coeﬃcient (ADC). For MR imaging it is important to use the right combination
of sequences for a complete overview. Next to anatomical information also information
about diﬀusion and perfusion can be obtained which helps to distinguish benign lesions
from malignant lesions. For a proper resolution, the slice thickness should be between
3-5 mm and a ﬁeld strength of at least 1.5 T (for adequate signal-to-noise ratio and
resolution) should be minimal used. In a multicenter study, described in this thesis, in
which we evaluated the added value of MRI with respect to CE-CT, in asymptomatic
brain metastases, we could show that quality issues already exist in the study preparation
phase. One hospital could not participate because their MRI scanner could not meet the
required technical standards and two other hospitals had to adjust their MR protocol.
In a phantom study performed by Yang et al. [84], the dependence of image texture
features on MR acquisition and reconstruction parameters was evaluated. They found that
feature variance due to reconstruction algorithm and acceleration factor were generally
smaller than feature diﬀerences between high- and low-grade tumors on T1- and T2-
weighted brain images [84]. Another study including MR scans from three institutes showed
that a prognostic model trained on one institute could be validated in the data from the
other institutes, which showed that a vendor independent model can be developed [85].
However, in prognostic or predictive model development large datasets are needed to train
models and to validate models [86]. A study of Collins et al. [39] showed that to reliable
validate a prognostic model a minimum of 100 events and ideally, 200 or more events
are required. Using such large datasets mostly means that data have to be derived from
diﬀerent hospitals. A standardized quality assurance for DWI can harmonize DWI values
in diﬀerent institutes, which will potentially lead to more robust models [87]. To perform
radiomics on MR data more research need to be done to compare MR images of diﬀerent
institutes. A phantom study help to identify which MR acquisition and reconstruction
parameters inﬂuence stability of radiomic features.
Future perspectives
In 2017 the radiomics quality score (RQS) was published [42]. The RQS allows to aid in the
quality assessment of past and future radiomic studies. It can help clinicians and researchers
to easily ascertain, whether a radiomic study is compliant with best practice procedures or
alternatively, whether the study investigators have suﬃciently justiﬁed any non-compliance
with guidelines. The RQS scores the used image protocol, the performed segmentation, the
feature selection process, the model development, the biological correlation, the statistics,
the comparison to the gold standard and the transparency of the analysis. The use of
this quality score may in the future lead to higher quality radiomic studies, while more
and more points from the RQS are incorporated. In our review about tracking tumor
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biology with radiomics, the RQS was used to score all included articles [41]. While the
RQS score mentions the use of a biological correlate, it does not quantify the link between
tumor biology and radiomics. We found that only a minor discrepancy between lower RQS
studies and the claims about clinical signiﬁcance existed. We also showed that there are
some inter-rater interpretation diﬀerences of the diﬀerent RQS score components. The
RQS score should be made more robust and easily interpretable in the future and will then
potentially lead to more standardized radiomic workﬂows.
To create robust prognostic models representing the complete population, larger
datasets are needed than currently used in almost all analyses. Even when image
acquisition and reconstruction are standardized, it is diﬃcult to analyze all data in a
central location, due to ethical and legal boundaries prohibiting data sharing. Using
distributed learning, it is possible to share data, without identiﬁable patient data leaving
the hospitals. This can be done by instead of storing the data in a central hospital, send
the model to all participating hospitals. A proof-of-concept study of Deist et al. [88],
learned exemplary support vector machine models, to predict dyspnea. They found that
the training AUC over all centers was 0.63 and varied from 0.60 to 0.64 in a
leave-one-out cross validation. With this proof-of-concept study, it is shown that
multi-centric rapid learning healthcare is feasible and that in the future, models can be
developed using distributed databases, across national borders, accompanying technical,
legal and ethical issues.
Figure 10.3: The diﬀerence between machine learning and deep learning is the feature extraction
and segmentation of the region of interest, reproduced from xenonstack.com.
When using distributed learning, large datasets will be available and to analyze them
automated methods need to be used. In radiomics, the segmentation of the region of
interest is the most time consuming step. In a study of Velazquez et al. [89], a
semi-automatic CT-based segmentation method was compared to manual delineations of
ﬁve physicians. They found that automatic segmented volumes, demonstrated a high
inter-observer agreement, lower volume variability, smaller uncertainty areas and a strong
correlation to surgically deﬁned tumor volumes. Machine learning, a method in which
statistics are used to give computers the ability to learn from data, can be used in
medicine as well. Machine learning can be divided in machine learning with pre-processed
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feature input values and machine learning without preprocessing on the raw (image)
input, the latter also called deep learning [90]. Deep learning does not require feature
calculation or lesion segmentation, and it can be classiﬁed as end-to-end machine
learning, that does the entire process from input images to ﬁnal classiﬁcation, see Figure
10.3. With the use of deep learning large datasets can be analyzed automatically and
prognostic models will be more robust and population based. Nevertheless, to make
reliable models with deep learning, large datasets are needed. Challenges in big data
include data storage, information privacy and computer power.
To conclude, using distributed learning infrastructure with standardized data acquisition
and reconstruction, deep learning in combination with radiomics and all other available
prognostic information will lead to robust prognostic and predictive features in lung cancer.
Prognostic and predictive models might be helpful in treatment decisions and may lead to
decrease complications and increase quality of life.
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Background and aim of the thesis
In the Netherlands, each year more than 100,000 people are diagnosed with cancer, and although
many of them are cured, still about 40,000 patients yearly die. Of those 40,000 yearly cancer
deaths, 24 % is due to lung cancer. The overall survival rate in lung cancer depends on the stage
of the disease. Patients with distant metastases are classiﬁed as stage IV, independent of the
size of the tumor and the number of involved lymph nodes. The 5-years survival rate in stage IV
non-small cell lung cancer (NSCLC) is < 10 %. Systemic therapy is advised in all stage IV patients
with a good performance status. Patients with driver mutations, as an epidermal growth factor
receptor (EGFR) mutated tumor or an anaplastic lymphoma kinase (ALK) rearranged tumor, can
be treated with targeted therapy as tyrosine kinase inhibitors.
Prognostic as well as predictive models can be used to tailor treatment decisions by individually
optimizing the balance between side eﬀects, prognosis and quality of life of patients. Clinical
variables used in prognostic models in lung cancer are for example age, gender, smoking history,
performance status, histological grading and mutation status. Prognostic models can also contain
biological markers that for example are measured in the blood, so called biomarkers. Image
characteristics, like standardized uptake value (SUV) metrics, but also computed tomography
(CT) intensity values can potentially improve prognostic and predictive models. Image biomarkers
can be qualitative, so called semantic features, or quantitative, for example radiomic features.
Using radiomics thousands of quantitative features can be extracted from standard-of-care medical
images, like CT, PET and MRI. Radiomic features, typically divided into intensity features, shape
features, texture feature and ﬁltered features oﬀer information about cancer phenotype.
In this thesis, the use of image features of positron emission tomography (PET) and CT
imaging of stage IV NSCLC patients was investigated for prognosis assessment. Simple PET
metrics were used for response assessment, CT radiomic features were used in prognostic models
for overall survival and cachexia and associations between semantic features and radiomic
features for prediction of the mutation status were explored. Next to that, the quality of PET
imaging, the use of contrast-enhanced CT imaging and magnetic resonance (MR) imaging and
the inﬂuence of image acquisition and reconstruction on radiomic features was studied. Because
image biomarkers can only improve prognostic models when the imaging is acquired and
reconstructed on a standardized way.
Methodological challenges in image feature studies
The ﬁrst part of this thesis reviewed the image quality of contrast-enhanced (CE)-CT, magnetic
resonance (MR) and PET imaging in multicenter trials. When using data from multiple centers
a large variability in image acquisition and reconstruction parameters exist. For image biomarker
studies, it is important to use standardized imaging or to correct for variation in image parameters.
The inﬂuence of image acquisition and reconstruction on radiomic feature values and stability is
investigated and methods to correct this variability are proposed. The slice thickness had the
largest inﬂuence on the radiomic features, but this could be reduced by resampling the images
before extracting the features.
In chapter 3, image acquisition and reconstruction parameters from 18F-FDG PET scans of
223 stage IV NSCLC patients included in a phase II multicenter trial were compared to
recommended image parameters of the European Association of Nuclear Medicine (EANM).
Only 19 % of the scans had an uptake time that fulﬁlled the recommendations, and those scans
had a smaller deviation in the mean standardized uptake value of the liver than scans with
non-compliant uptake times. SUVmean of the liver can be used a reference organ due to its
stable uptake over time and is therefore suitable for assessment of scan parameters. We showed
that despite the agreement on a standardization protocol there was a large variability in image
parameters. For future multicenter studies including PET imaging, a prospective central quality
256
527447-L-sub01-bw-deJong
Processed on: 3-1-2019 PDF page: 257
S
Summary
review during patient inclusion is needed to improve guideline compliance.
A multicenter trial, in which the added value of gadolinium MRI to dedicated CE-CT for
detecting asymptomatic brain metastases was investigated in stage III NSCLC patients, showed
that not only in the image acquisition and reconstruction phase diﬀerences develop but also
in the starting phase of a trial (chapter 4). One hospital did not have a MRI scanner that
met the required technical standard and two other hospital had to update their protocols to
be able to participate in the trial. In 26 % of the patients, the CE-CT of the brain did not
meet the criteria for a dedicated brain scan, which was remarkably not reported. Next to all
technical guidelines, we recommend that radiologists need be informed about the indication for
the requested scan to determine the optimal imaging protocol and that non-imaging clinicians have
the knowledge to evaluate whether the applied protocol is adequate for the requested purpose.
These recommendations are expected to lead to a more uniform clinical interpretation.
Although there is a large variability in image acquisition and reconstruction parameters
between diﬀerent centers no eﬀect of exposure on radiomic features was shown in chapter 5.
Slice thickness did inﬂuence radiomic feature values but this could be reduced by resampling the
CT-images before feature extraction. Optimization of gray level discretization to potentially
improve prognostic value can be performed without compromising feature stability.
Image features for prognosis
In the second part of this thesis the use of image features from CT and PET imaging for response
assessment, prognosis, mutation status and cachexia is investigated.
In chapter 6 tumor response deﬁned as a 30 % decrease in CT and PET parameters after
three weeks was compared to the response criteria in solid tumors (RECIST) response at week
6. A 30 % decrease in the peak SUV value identiﬁed more patients as responders compared to a
30 % decrease in CT diameter, however this was not correlated to overall survival. Although the
phase II trial in which patients were randomized between paclitaxel-carboplatin-bevacizumab with
or without nitroglycerin showed no added value of nitroglycerin on progression free survival, there
was a signiﬁcant larger decrease in CT diameter in the control group compared to the intervention
group, which even shows, although not signiﬁcant, negative eﬀect of nitroglycerin. No signiﬁcant
diﬀerence was seen in the PET parameters between the two treatment arms. This might be due
the decreased perfusion caused by bevacizumab in combination with the timing of the PET scan.
In 2014, our group published a prognostic radiomic signature for predicting overall survival.
This signature was trained and validated in a cohort of stage I-III NSCLC patients. In chapter 7
we aimed to validate this prognostic radiomic signature in stage IV NSCLC patients undergoing
chemotherapy. We showed that patients having a prognostic index lower than the signature
median had a signiﬁcantly better overall survival than patients with a prognostic index higher
than that median (Hazard Ratio 1.445, 95 % conﬁdence interval 1.07-1.95, p=0.02). Although
the radiomic signature derived from daily practice CT scans, has prognostic value for stage IV,
the signature performs less than for stage I-III.
Qualitative image characteristics, such as cavitation or air bronchogram are prognostic for
treatment outcome in NSCLC. In chapter 8 we showed that in radiomic features of the primary
tumor could predict the semantic features air bronchogram, necrosis and pleural eﬀusion (area
under the curve 0.71, 0.68, 0.65, respectively) and that radiomic features of the ipsilateral lung
are associated to pleural thickening, satellite nodules and pleural eﬀusion (AUC 0.62, 0.64 and
0.87, respectively).
Skeletal muscle loss is associated with low quality of life, diminished treatment eﬃcacy and
poor survival rates in cancer patients. Early prediction of patients that will suﬀer from cachexia
may lead to timely treatment and prevention. In chapter 9 we assessed if baseline skeletal muscle
radiomic features predicts future muscle loss. Although baseline radiomic features of the skeletal
muscle were not predictive for muscle loss (AUC 0.49), diﬀerences in intensity and texture radiomic
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features over time were seen between patients with and without muscle loss (AUC 0.68, 95 % CI
0.51-0.84).
Future perspectives
In chapter 10 we discussed the results presented in this thesis and the future perspectives of image
features. We hypothesize that standardization of image acquisition, reconstruction and analysis
will lead to less variation in image parameters and therefore more reliable models. In combination
with initiatives as distributed learning in which data does not leave the hospital anymore, deep
learning and machine learning prognostic models will in the future include image characteristics
as well as other clinical variables that will improve patient care by prolonged survival and a better
quality of life.
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Achtergrond en doel van het proefschrift
In Nederland krijgen jaarlijks 100.000 mensen de diagnose kanker, hoewel velen van hen zullen
genezen, overlijden er nog steeds 40.000 patiënten. Van deze 40.000 doden door kanker is
24 % te wijten aan longkanker. Het overlevingspercentage bij longkanker is afhankelijk van
het stadium van de ziekte. Patiënten met uitzaaiingen op afstand worden onafhankelijk van de
grootte van de tumor en het aantal aangedane lymfeklieren geclassiﬁceerd als stadium IV. Het
5-jaarsoverlevingspercentage in stadium IV niet-kleincellig longcarcinoom patiënten is minder dan
10 %. Systeemtherapie wordt geadviseerd voor patiënten met stadium IV ziekte met een goede
conditie. Patiënten met een zogenaamde “driver mutatie” zoals epidermale groei factor receptor
gemuteerde tumor of een tumor met een translocatie in het anaplastic lymphoma kinase gen
kunnen worden behandeld met gerichte therapie bestaande uit tyrosine kinase remmers.
Prognostische en predictieve modellen kunnen worden gebruikt om behandelkeuzes te sturen
waardoor de balans tussen bijwerkingen, prognose en kwaliteit van leven geïndividualiseerd en
geoptimaliseerd wordt. Klinische variabelen die gebruikt worden in prognostische modellen in
longkanker zijn bijvoorbeeld leeftijd, geslacht, rookgeschiedenis, conditie, histologie en
mutatiestatus. Prognostische modellen kunnen ook biologische merkers bevatten die
bijvoorbeeld in het bloed gemeten kunnen worden, de zogenoemde bloed-biomerkers.
Beeldeigenschappen, zoals de activiteit (SUV) van een positronemissietomograﬁe (PET) scan en
de intensiteit (HU) van een computertomograﬁe (CT), kunnen potentieel prognostische en
predictieve modellen verbeteren. Beeldmerkers kunnen zowel kwalitatief, zogenoemde
semantische beeldeigenschappen, als kwantitatief, zogenoemde radiomics beeldeigenschappen,
zijn. Door het gebruik van radiomics kunnen duizenden beeldeigenschappen berekend worden uit
standaard medische beelden, zoals CT, PET en magnetische resonantie (MR) beelden.
Radiomics beeldeigenschappen, te verdelen in intensiteitsbeeldeigenschappen,
vormbeeldeigenschappen, textuurbeeldeigenschappen en geﬁlterde beeldeigenschappen, bevatten
informatie over het kanker fenotype.
In dit proefschrift is het gebruik van beeldeigenschappen van PET- en CT-beelden van
stadium IV niet-kleincellig longcarcinoom patiënten onderzocht met als doel het bepalen van de
prognose van patiënten. Simpele maten voor PET activiteit zijn gebruikt voor responsbepaling
op chemotherapie en CT radiomics beeldeigenschappen zijn gebruikt in prognostische modellen
voor het voorspellen van overleving en cachexie, ongewild gewichtsverlies. Daarnaast zijn relaties
tussen semantische beeldeigenschappen en radiomics beeldeigenschappen voor het voorspellen
van de mutatiestatus onderzocht. Van belang voor deze vraagstelling is de kwaliteit van
contrast-versterkte CT, MR, en PET. Dit is onderzocht in een multicentrische studie waar
gekeken is naar de invloed van beeldacquisitie- en reconstructieparameters op radiomics
beeldeigenschappen. Beeldeigenschappen kunnen prognostische modellen namelijk alleen
verbeteren als er gebruik wordt gemaakt van gestandaardiseerde beeldacquisitie en reconstructie.
Methodologische uitdagingen in beeldeigenschappen
studies
In het eerste deel van dit proefschrift is er gekeken naar de beeldkwaliteit van contrast-versterkte
CT-, MR- en PET-beelden in multicentrische trials. Wanneer er data gebruikt wordt uit
verschillende centra zal er een variatie in beeldacquisitie- en reconstructieparameters zijn. Voor
beeldmarker studies is het belangrijk dat gestandaardiseerde beelden gebruikt worden dan wel
dat er gecorrigeerd wordt voor de variatie in beeldparameters. De invloed van beeldacquisitie- en
reconstructieparameters op radiomics beeldeigenschappen en hun stabiliteit is onderzocht en er
is een voorstel gedaan voor correctiemethoden voor deze variatie. De plakdikte bleek de grootste
invloed te hebben op de radiomics beeldeigenschappen, maar dit eﬀect kan verminderd worden
door de beelden te herschalen.
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In hoofdstuk 3 zijn beeldacquisitie- en reconstructieparameters van PET scans van 223
stadium IV niet-kleincellig longcarcinoom patiënten, die geïncludeerd waren in een fase II
multicentrische studie, vergeleken met de door de Europese associatie van nucleaire geneeskunde
(EANM) aanbevolen beeldparameters. Slechts 19 % van de beelden had een opname tijd die
voldeed aan de aanbevelingen, en deze scans hadden een kleinere variatie in de gemiddelde
activiteit (SUVmean) in de lever dan de scans met een opname tijd die niet-conform de
aanbevelingen was. De gemiddelde activiteit in de lever kan worden gebruikt als referentie
doordat de activiteit stabiel is over de tijd en daardoor gebruikt kan worden om de
beeldparameters te controleren. We hebben laten zien dat ondanks dat men het eens was over
het beeldacquisitie- en reconstructieprotocol er in dagelijkse praktijk een grote variatie in
beeldparameters is. Voor toekomstige multicentrische studies, die gebruik maken van
PET-beelden, is het belangrijk dat vooraf en tijdens patiëntinclusie, een centrale kwaliteitscheck
gedaan wordt om de variatie in beeldacquisitie en reconstructie te minimaliseren.
In een multicentrische studie, waar de toegevoegde waarde van gadolinium MR ten opzichte
van contrast-versterkte CT in de detectie van asymptomatische hersenmetastasen werd onderzocht
in stadium III niet-kleincellig longcarcinoom patiënten, is gebleken dat er niet alleen verschillen
ontstaan in de beeldacquisitie- en reconstructie-fase, maar ook tijdens de opstartfase van een studie
(hoofdstuk 4). Een van de ziekenhuizen had geen MR-scanner die voldeed aan de benodigde
technische speciﬁcaties en twee andere ziekenhuizen moesten hun protocollen herzien voor ze
konden deelnemen aan de studie. Bij 26 % van de patiënten voldeed de contrast-versterkte
CT niet aan de criteria voor een speciale hersenscan, wat opmerkelijk genoeg ook niet vermeld
werd in het verslag. Naast alle technische richtlijnen raden we aan dat radiologen geïnformeerd
worden over de indicatie waar de scan voor gemaakt moet worden, zodat zij kunnen meedenken
over het meest optimale scan protocol. Daarnaast moeten andere specialisten inzicht hebben
in de verschillende protocollen zodat ze mede kunnen evalueren of het toegepaste scan protocol
adequaat is voor het aangevraagde doel. Deze aanbevelingen zouden moeten leiden tot een meer
uniformer klinische interpretatie.
Hoewel er een grote variatie in beeldacquisitie- en reconstructieparameters tussen
verschillende centra is, is er in hoofdstuk 5 geen eﬀect gezien van de exposie op radiomics
beeldeigenschapwaarden. De plakdikte beïnvloedde de radiomics beeldeigenschapwaarden wel,
maar dit kan verminderd worden door de CT-beelden eerst te herschalen voordat de
beeldeigenschappen uitgerekend worden. Optimalisatie van grijswaardendiscretisatie, om
potentieel de prognostische waarde van radiomics beeldeigenschappen te verbeteren, kan gedaan
worden zonder de stabiliteit te veranderen.
Beeldeigenschappen voor prognose
In het tweede deel van dit proefschrift wordt het gebruik van beeldeigenschappen van CT- en
PET-beelden voor response beoordeling, prognose, mutatiestatus en cachexie beschreven.
In hoofdstuk 6 is tumor respons, gedeﬁnieerd als een afname van 30 % in de CT- en PET-
parameters na drie weken, vergeleken met de respons criteria in solide tumoren (RECIST) na
zes weken. Een afname van 30 % in de piek activiteit (SUVpeak) identiﬁceerde meer patiënten
als responders dan een 30 % afname in de CT-diameter, alhoewel dit niet gecorreleerd is aan
overleving. Hoewel de fase II studie, waar patiënten gerandomiseerd waren tussen paclitaxel-
carboplatin-bevacizumab met of zonder nitroglycerine, geen toegevoegde waarde liet zien van
nitroglycerine op de progressie vrije overleving, was er een signiﬁcant grotere afname in CT-
diameter in de controlegroep. Er was geen signiﬁcant verschil in PET-parameters tussen beide
groepen. Dit zou kunnen komen door de verstoorde perfusie, veroorzaakt door bevacizumab, in
combinatie met de timing van de scan.
In 2014 heeft onze groep een prognostisch radiomics proﬁel voor overleving gepubliceerd.
Dit proﬁel is getraind en gevalideerd in een cohort van stadium I-III niet-kleincellig
longcarcinoom patiënten. In hoofdstuk 7 hebben we geprobeerd dit prognostisch radiomics
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proﬁel te valideren in stadium IV niet-kleincellig longcarcinoom patiënten die behandeld werden
met chemotherapie. We hebben laten zien dat patiënten met een prognostische index lager dan
de gemiddelde prognostische index een signiﬁcant betere overleving hadden dan patiënten met
een hoge prognostische index (Hazard Ratio 1.445, 95 % betrouwbaarheidsinterval 1.07-1.95,
p=0.02). Hoewel het radiomics proﬁel afgeleid van standaard CT-beelden ook prognostische
waarde heeft in stadium IV, voorspelt het proﬁel beter in stadium I-III.
Kwalitatieve beeldeigenschappen, zoals cavitatie of luchtbronchogram, zijn prognostisch voor
behandeluitkomsten bij het niet-kleincellig longcarcinoom. In hoofdstuk 8 hebben we laten zien
dat radiomics beeldeigenschappen van de primaire tumor de semantische beeldeigenschappen
luchtbronchogram, necrose en pleurale eﬀusie kunnen voorspellen (AUC 0.71, 0.68, 0.65,
respectievelijk) en dat radiomics beeldeigenschappen van de ipsilaterale long gerelateerd zijn aan
pleurale verdikking, satelliet laesies en pleurale eﬀusie (AUC 0.62, 0.64 en 0.87, respectievelijk).
Skeletspierverlies is gerelateerd met een lagere kwaliteit van leven, een slechtere
behandeluitkomst en een slechtere prognose in kankerpatiënten. Een vroege voorspelling van
cachexie kan leiden tot preventie en eerdere behandeling. In hoofdstuk 9 hebben we
geïnventariseerd of radiomics beeldeigenschappen van de skeletspier op de CT, gemaakt voor de
start van behandeling, toekomstig spierverlies kan voorspellen. Hoewel deze radiomics
beeldeigenschappen niet voorspellend waren voor spierverlies (AUC 0.49), waren er verschillen in
radiomics intensiteitseigenschappen en textuureigenschappen over de tijd te zien tussen
patiënten met en zonder spierverlies (AUC 0.68, 95 % betrouwbaarheidsinterval 0.51-0.84).
Toekomstperspectieven
In hoofdstuk 10 hebben we resultaten en toekomstperspectieven van de studies over
beeldeigenschappen in dit proefschrift besproken. We denken dat gestandaardiseerde
beeldacquisitie, reconstructie, analyse en initiatieven als “distributed learning” , waarbij data het
ziekenhuis niet meer hoeft te verlaten, in combinatie met “deep learning” en “machine learning”
in de toekomst zal leiden tot prognostische modellen die naast klinische variabelen ook
beeldeigenschappen bevatten de patiëntzorg zal verbeteren door langere overleving en een betere
kwaliteit van leven.
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Prognostic models
Although there have been innovations in treatment options for stage IV non-small cell lung cancer,
the overall survival rate for these patients is still low. Innovations in treatment consist for example
of speciﬁc drugs that are optimized for various cancer types, e.g. EGFR mutated tumors treated
using tyrosine kinase inhibitors. However, this treatment is not eﬀective in, for example, patients
with a KRAS mutation. And if patients do not respond on a certain treatment, quality of life
of these patients can be improved by stopping the treatment. In the ﬁrst part of this thesis,
prognostic models including image biomarkers are developed and validated.
Prognostic models help in selecting patients that beneﬁt from certain therapies by which side
eﬀects are reduced and quality of life is improved. If a tumor is not responding on a speciﬁc
chemotherapy, another treatment may be used which is potentially more eﬀective. Prognostic
models already are able to predict the chance that a patient will respond on the treatment
before the start of treatment. We showed that PET-based response assessment showed response
already after three weeks of treatment, which is earlier than CT-based response assessment usually
performed after 6 weeks of treatment. Early response assessment and prognostic models will lead
to economically beneﬁts through less side eﬀects, less expensive treatments and better prognosis.
Additionally cost eﬀectiveness analyses should be performed in which the relative value of a speciﬁc
treatment is measured as the additional cost to achieve an incremental health beneﬁt. Information
from prognostic and/or predictive models can be used as input for cost eﬀectiveness analyses to
predict survival or side eﬀects, by which life expectancy adjusted for morbidity or quality of life
for diﬀerent treatments can be compared.
Next to that, prognostic models can be integrated in decision support systems. Decision
support systems help patients together with their physician to choose between diﬀerent treatments,
based on results of previous studies and personal preferences. For some patients, quality of life
is more important while others prefer a prolonged survival. On www.predictcancer.org prognostic
models for overall survival, local recurrence, cost eﬀectiveness and side eﬀects like dysphagia
can be found for brain metastases, endometrium cancer, head and neck cancer, lung cancer,
esophageal cancer, prostate cancer and rectum cancer. With initiatives like predictcancer.org
decision support systems may easily be implemented in the clinic.
Image features
Imaging is an important part of routine care in diagnosis, treatment and follow up in oncology.
Image biomarkers improve prognostic models in a non-invasive way. Image biomarkers can be
qualitative, so called semantic features, but also quantitative, so called radiomic features. While
scoring semantic features is time consuming and inter observer dependent, radiomic features
are automatically extracted on repeated imaging. Imaging is non-invasive and widely available
because it is used in standard clinical care. In chapter 8 we showed that there are associations
between semantic features and radiomic features that are correlated to mutation status of the
tumor. When imaging is used to determine the mutation status of tumors, invasive biopsies that
are only samples of mostly heterogeneous tumors can be reduced or in the future are not needed
anymore.
Many publications already showed the potential of radiomics. Radiomic signatures can often
be used in diﬀerent tumor sites. Software developments are ongoing and more and more open
source radiomic packages become available. By making radiomic software open source, usage
by more research departments makes external validation of radiomic signatures much easier.
Next to that, initiatives are ongoing in which radiomics is implemented in clinical software. An
example of this is the collaboration between OncoRadiomics and AQUILAB in the ARTIVIEW
software package. Such software could be used in either clinical studies, to develop new predictive
signatures or in clinical decision support systems based on deﬁned signatures. These commercial
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software packages consist of a database system in which multimodality images could be saved,
fused or registered, segmented and used for dose calculations. By implementing radiomics in
already clinical used software packages, radiomics can easily be used in diagnosis, segmentation
and response assessment. External validation studies validated existing radiomic signatures in
diﬀerent tumor sites as well as using diﬀerent image settings. Radiomic signatures that are
externally validated in large datasets will lead to useful clinical products.
Radiomics may also be very useful in diagnosis. In chapter 9 we showed that diﬀerences in delta
texture radiomic features over time might reﬂect myosteatosis. This shows that using radiomics
biological processes behind some diseases, for example cachexia can be unraveled. This can in the
future possibly lead to new treatment options. An increasing number of studies is looking into
radiomics for diﬀerentiating benign lesions and malignant lesions in for example breast, prostate
and lung. Using this information leads to earlier diagnosis and therefore a prolonged survival and
better quality of life.
The most time consuming step in the radiomics process is still segmentation of the region
of interest. Machine learning, which is a subset of artiﬁcial intelligence to automatically detect
patterns in data, by which segmentation is automated, combined with radiomics, will in the future
automatically analyze large datasets used for prognostic or diagnostic models.
Image quality
Although for automatic extracted features it is important that the images used are acquired on a
standardized way. In the second part of the thesis image quality in multicenter trials is reviewed
and from that recommendations are formed to improve image quality in future multicenter trails.
When using images from multiple centers there is a large variation in image acquisition and
reconstruction settings, which inﬂuence radiomic feature values and feature stability and therefore
results from prognostic models including radiomic features. In chapter 5 we showed that slice
thickness inﬂuences radiomic features, however this can be reduced by resampling the images
prior to feature extraction. Studies investigating the inﬂuence of scan parameters on radiomic
features will lead to a more standardized method for imaging in radiomic studies and therefore in
less variation in radiomic features and more reliable radiomic signatures.
Although guidelines for PET imaging in multicenter trials exist, in chapter 3 we showed that
there is still a large variability in image acquisition and reconstruction parameters between Dutch
institutes, which is probably even larger between European centers and centers worldwide. The
largest diﬀerence was seen in the time between FDG injection and the start of the PET scan.
Longer uptake times will lead to higher SUV values, which for response assessment can lead to a
false response assessment. When using PET scans from multiple centers in response assessment
studies we recommend to use a prospective central quality review to reduce the variability between
institutes and to better comply with the existing guidelines, which leads to a better overall image
quality, higher reproducibility and less inter-center variation.
For contrast-enhanced (CE-)CT in diagnosing asymptomatic brain metastases in non-small
cell lung cancer no clear guidelines exist. CE-CT scans with the arms of the patients next to the
head are often reported to be diagnostic, while the arms of the patients induce beam hardening
which inﬂuences the image quality. In chapter 4 we showed that it is important that clinicians
inform imaging experts about the indication of a speciﬁc scan to help radiologists choose the
optimal scan protocol and to check the image quality for the requested purpose. This will lead to
a more uniform interpretation, less variation in multicenter trials and uniform treatment decisions;
all improving treatment quality.
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Na ruim vier jaar is dan het eindelijk tijd het laatste hoofdstuk van mijn proefschrift te
schrijven. Het laatste hoofdstuk is wat mij betreft niet het makkelijkste hoofdstuk, maar wel leuk
om te schrijven omdat ik nu pas besef hoeveel mensen bijgedragen hebben aan de leuke jaren van
onderzoek doen.
Allereerst wil ik graag mijn promotoren prof. dr. Philippe Lambin en prof. dr. Anne-Marie
Dingemans bedanken voor het faciliteren van mijn onderzoek. Philippe, bedankt dat ik deel
uit mocht maken van een wisselende internationale multidisciplinaire onderzoeksgroep die voor
mij begonnen is bij MAASTRO Clinic en welke ik verlaten heb als the D-Lab onderdeel van
Universiteit Maastricht. Ik bewonder uw kwaliteit om op de hoogte te zijn van de grote lijnen van
alle onderzoeken van uw PhD-studenten en het inschattingsvermogen in hoe het onderzoek het
beste gepubliceerd kan worden. Anne-Marie, doordat onze achtergronden veel verschilden, heb ik
heel veel geleerd over de klinische aspecten van longkanker. Bedankt voor het zeer kritisch lezen
en becommentariëren van mijn manuscripten, ze zijn er echt beter van geworden. Daarnaast wil
ik graag mijn copromotor dr. ir. Wouter van Elmpt bedanken. Wouter, wat was het ontzettend
ﬁjn dat ik altijd bij je binnen kon lopen en dat je altijd snel reageert op mail, of het nu inhoudelijk
of meer praktisch was, je hebt altijd een antwoord klaar. Het was ook erg ﬁjn iemand met een
technische achtergrond te hebben in een team wat verder vooral uit clinici bestond. Bedankt voor
je tijd en steun, ook in de projecten die je zelf misschien minder interessant vond en heel veel
succes met de nieuwe uitdagingen in het Physics Innovation Team. Ook wil ik graag prof. dr.
Esther Troost bedanken voor de begeleiding en het controleren van vele intekeningen in het begin
van mijn promotietraject.
Graag wil ik de leden van de beoordelingscommissie bedanken (prof. dr. F.M. Mottaghy, prof.
dr. J.G.J.V. Aerts, prof. dr. W.H. Backes, prof. dr. M. van den Heuvel en dr. A. Hoeben) voor
het kritisch lezen en beoordelen van mijn proefschrift.
De data gebruikt in dit proefschrift maakt deel uit van klinische studies. Dergelijke studies
zijn enkel mogelijk door de bereidheid en het vertrouwen van patiënten om hier aan deel te nemen.
Bedankt voor het participeren in de studies en voor het geven van toestemming om de data te
gebruiken voor wetenschappelijk onderzoek. Ook wil ik hier graag Vincent van der Noort bedanken
voor het datamanagement van de NVALT12 studie. En de medewerkers van de ICT/servicedesk
van MAASTRO Clinic voor het oplossen van alle computerproblemen en het verzamelen van data
uit andere ziekenhuizen. Daarnaast wil ik ook graag Floor bedanken voor het zorg dragen van
de data transfer agreements en algemene onderzoekssupport. En Rianne voor het inplannen van
afspraken met Philippe, maar ook voor alle organisatie rondom mijn promotie.
Tijdens het begin van mijn promotietraject hebben we in het kader van de NVALT12 studie
vele teleconferenties gehad met experts uit verschillende deelnemende ziekenhuizen (prof. dr.
O.S. Hoekstra, prof. dr. E.F. Smit, prof. dr. H.J.M. Groen en prof. dr. R. Boellaard), bedankt
voor de nuttige discussies en voor het kritisch meelezen van de manuscripten. Next to the Dutch
collaborators, I would also like to thank dr. Stefania Rizzo and colleagues from Milan for the
fruitful collaboration in the EGFR/KRAS/ALK mutation projects.
Tijdens mijn HBO studie Technische Natuurkunde heb ik stage gelopen bij de radiotherapie
afdeling RISO in Deventer. Daar is mijn interesse in de klinische fysica bij de radiotherapie
begonnen, wat ook een aanleiding is geweest voor mijn promotieonderzoek, bedankt Rik, Andre
en Guido. Deze interesse is verder aangewakkerd op de kliﬁo kamer (Ellen, Leah, Hanneke, Petra
en Rob) in Utrecht waar ik mijn afstudeerproject gedaan heb onder begeleiding van Bas en Jochem,
bedankt allemaal. Tijdens het 100-uren project bij MAASTRO heb ik veel geleerd over dose-guided
radiotherapie wat tijdens mijn kliﬁoperiode vast nog van pas komt, bedankt Bas, Lucas en Esther.
Ook wil ik graag mijn nieuwe collega’s uit het CZE (Paul, Coen, Danny, Hanneke, Jacco en Wim)
bedanken voor de kans om mijn promotie af te maken tijdens het opleidingstraject tot klinisch
fysicus. En ook mijn medekliﬁo’s uit het CZE (Esther en Kathrin), maar ook uit Maastricht
(Esther en Celine) voor het delen van ervaringen en aanhoren van promotiefrustaties.
Bedankt voor de leerzame longkanker research meetings (Janna, Jules, Juliette, Karin en
Lizza). Lizza ook heel erg bedankt voor het controleren van vele intekeningen, de ﬁjne
samenwerking bij het paper over imaging voor medici en de uitwisseling van medische informatie
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vanuit jouw kant en meer technische informatie vanuit mijn kant. Karin bedankt voor de
gezelligheid tijdens onze koﬃedates, de samenwerking bij de cachexieprojecten en de heerlijke
etentjes. Heel veel succes met het afronden van je eigen promotie en daarna natuurlijk met de
opleiding tot longarts. Ook wil ik graag prof. dr. A.M.W.J. Schols bedanken voor de
samenwerking bij het cachexie paper. Bart bedankt voor het controleren van alle intekeningen,
ik heb er veel van geleerd.
Although I didn’t had a direct collaboration with anyone of MAASTRO-Lab I would like to
thank you all for the nice meetings, wintersport and ESTRO (Ludwig, Ala, Nicolle, Tessa, Marijke,
Carolien, Raymond, Kranthi, Venus en Damiënne).
In the research group of Philippe, in the beginning at MAASTRO Clinic, later at the UM as the
D-Lab, I shared many happy moments during coﬀee-breaks, “vlaai” moments, drinks, lunchwalks,
diners, carnaval and sports, thank you all (Abdalla, Abir, Adriana, Alberto, Ana, Anshu, Bregtje,
Brent, Cary, Celine, Claire, Daan, Daniela, Davide, Emmanuel, Ester, Esther, Frank, Gabriel,
Georgi, Giacomo, Guangyao, Isabel, Inge (ook bedankt voor alle klinische ervaring), Iva, Jane,
Jean, Joana, Johan (ook bedankt voor de ICT support), Jose, Leon, Leonard, Lotte, Lucas,
Manon, Mark, Marta, Mathieu, Matilde, Mariana, Murillo, Patrick, Qing, Pedro, Raghu, Samir,
Scott, Sebastian, Sergey, Simon, Stefan, Turkey, Yvonka, Zhen, Zhenwei). Ook wil ik graag de
studenten bedanken die ik tijdens mijn promotie heb mogen begeleiden, Stefan bedankt voor de
ﬁjne samenwerking, Esma ook bedankt voor de ﬁjne samenwerking en heel veel succes verder met
je stage en het afronden je studie. Shane I would also like to thank you for supervising me during
my internship, you’re a good teacher, it is also because of you that I started my PhD. We still miss
your interesting conversations during lunch and coﬀee breaks. Sara thank you for all the help with
radiomics, you’re a great person to work with and a nice person to have around. Skadi, naast
dat we een interesse delen en daardoor nu allebei klinisch fysicus in opleiding zijn, hebben we
ook een aantal karaktertrekken gemeen, bedankt dat ik jouw rol als detective mocht overnemen.
Karen, de moeder van de groep, het was ﬁjn dat er altijd iemand was om je verhaal mee te delen,
bedankt. Ralph bedankt voor alle hulp met radiomics, elke keer als de software werkte wist ik
toch weer een patiënt te vinden waar het niet bij lukte. En natuurlijk ook bedankt voor alle lunch
wandelingen, je was toch wel de meest stabiele factor in het wandelteam. Arthur, gedurende mijn
hele promotietraject kon ik bij jou terecht voor alle vragen met betrekking tot statistiek, heel erg
bedankt hiervoor en ook bedankt voor de begeleiding bij de laatste papers. Henry, although we
didn’t collaborate on any projects, your door was always open and even more important thank you
for all the nice climbing hours where we discussed more than climbing techniques. Sean, my work
spouse, although I think I probably helped you more than you me, it was nice to have a native
English senior researcher next to me for a couple of years. I wish you, Celine and Luana the best
in life. Timo, the German that speaks better Dutch than most Dutch students, thank you for the
collaboration in the semantic feature paper and the cachexia paper. It is very nice working with
someone that is structured, realistic and funny, good luck ﬁnishing your own PhD. Aniek, bedankt
voor je hulp met Matlab, maar vooral voor de gezelligheid als buurvrouw, maar ook tijdens het
sporten, de borrels, carnaval, de ladiesnights en de etentjes. Jurgen, wat hebben we veel Belgische
woorden en grappen geleerd van jou. Bedankt hiervoor en ook bedankt voor de gezelligheid en
voor je kennis met betrekking tot MRI. Cecile, Relinde en Janita, met z’n drieën/vieren zijn wij
Maastrio/Maasquatro en hebben we regelmatig gezellig met elkaar gegeten, vooral aan het einde
van mijn promotie. Door de stage van Janita in Odense hebben we nu het jaarlijks weekendje
weg geïntroduceerd. Ik wens jullie allen veel succes met het afronden van jullie promoties en hoop
dat we de gezellige etentjes en weekendjes er gewoon inhouden. Relinde ook bedankt voor het
carpoolen van Eindhoven naar Maastricht, was erg ﬁjn dat er af en toe iemand anders terugrijdt
en bedankt voor de ﬁjne gesprekken.
Mijn paranimfen Janita en Ruben, ik ben ontzettend blij dat jullie op deze belangrijke dag
achter mij staan en met mij meedenken. Ruben, bijna tegelijk begonnen en nu bijna tegelijk
gepromoveerd. Het was erg ﬁjn iemand te hebben die hetzelfde proces doorloopt. Bedankt voor
de introductie van carnaval, wat natuurlijk al begint op de 11de van de 11de, de sportieve uurtjes
bij clubpower en squash en de gezellige autoritjes. Na de moleculaire beeldvormingscursus in
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Madrid, waar we samen naar toe geweest zijn, zijn we naast (bijna)buren ook vrienden geworden.
Ook heel erg bedankt voor het op ons huis, huisdieren en planten passen tijdens onze vakanties. Ik
hoop dat we ondanks de afstand en de nieuwe drukke banen vrienden zullen blijven. Janita, vanaf
jouw eerste werkdag had ik mijn werkmaatje gevonden, dit is inmiddels veranderd naar een hele
goede vriendin. Voor alle werk gerelateerde vragen waren we mekaars vraagbaak, daarnaast kon
je me altijd helpen de code (Matlab, R) aan de praat te krijgen. Samen zijn we naar de ASTRO
geweest en hebben we daarnaast twee hele leuke weken vakantie gevierd in Amerika, ik zal die
walvissen nooit vergeten. Ook hebben we samen veel gesport, clubpoweren met Ruben, Aniek,
Jurgen, Cecile en Shane, squash cursus, klimmen samen met Henry en Ciska, of de tenniscursussen
in de winter waar het elke week spannend was of het doorging. Sinds mijn verhuizing hebben
we er ook allebei een logeeradresje bij. Ik wens je heel veel succes met het afronden van jouw
promotie en daarna heel veel succes en plezier in Australië, maar wel terugkomen hoor.
Tijdens een promotietraject is ontspanning ook erg belangrijk. Dr. ir. Dennis Bakhuis (en
Kim), Jeroen (en Emilie en Arthur), Philip, Thomas A., Thomas W. (en Michelle) en Vincent
bedankt voor de gezellige borrels, etentjes, housewarmings en feestjes. Verschillende
vooropleidingen kwam samen in een schakelprogramma voor Biomedische Technologie, na
verschillende masters zijn er vier promotietrajecten uitgerold bij vier verschillende universiteiten.
Ik heb het heel waardevol gevonden te zien welke verschillen er zijn tussen de verschillende
universiteiten. Bedankt voor de gezellige etentjes, bruiloft, en promotiefeestjes (Helen, Karlijn,
Nikita, Simone en Willem) en succes met afronden Helen en Willem. Miriam en Franciska de
meiden van natuurkunde, bedankt voor de gezellige etentjes. Jolanda, we hebben mekaar leren
kennen bij MAASTRO, jij studeerde daar af en ik liep daar stage. Doordat we allebei in regio
Eindhoven woonden hebben we vaak samen bij elkaar in de trein gezeten en veel goede
gesprekken gevoerd. Vervolgens kwamen we elkaar weer tegen in Utrecht, jij als promovendus,
ik als afstudeerder. Nu zijn we allebei gepromoveerd en komen we elkaar mogelijk weer tegen als
klinisch fysicus. Bedankt voor de lekkere etentjes en veel succes met het vinden van jouw
droombaan. Harriët en Marieke, mijn vriendinnen in het Noorden, ondanks dat jullie wellicht het
spoor bijster zijn wat ik eigenlijk doe, kan ik wel altijd mijn verhaal kwijt bij jullie. Bedankt voor
het begrip dat ik de laatste tijd niet zoveel tijd had om langs te komen en bedankt voor de
gezelligheid.
Pappa Erik en Mamma Joostien ik wil jullie graag bedanken voor de steun, er werd nooit
gevraagd wanneer het af was, maar ik kon wel altijd mijn verhaal doen waar jullie altijd
geïnteresseerd naar geluisterd hebben. Floris en Beata; Rosalinde, Herman, Quinten en Pepijn;
Laurens, Marion, Myrthe en Mats; Liselore, Andre en Sven; Charlotte en Jane en Vincent,
bedankt voor de aﬂeiding van mijn onderzoek tijdens de afgelopen vier jaar tijdens verjaardagen.
Ook wil ik graag tante Annie bedanken voor de steun en interesse.
Heit en Mem, wa hie dat ea tocht in doktor yn de famylje. Ik wol jim graach betankje foar
de stipe, mei it begryp en de ynteresse. Jullie hebben me altijd gesteund en de kans gegeven te
studeren, bedankt hiervoor. Ik hoop dat jullie net zo van deze dag genieten als ik, echt iets om
trots op te zijn.
En last but not least Mathijs. Inmiddels zijn we al 11 jaar samen, en jij kent me dan ook als
geen ander. Zonder jou was ik nooit zover gekomen. We hebben elkaar leren kennen tijdens het
begin van mijn lange journey tot klinisch fysicus. Het is ooit begonnen als bijles bij wiskunde,
maar je bent in heel veel zaken mijn betere helft. Samen doorstuderen aan de universiteit, we
hebben elkaar er doorheen gesleept en tijdens mijn promotie stond je altijd achter me. Altijd
stond het eten op tafel als ik laat thuiskwam na het werken, maar ook na het sporten of borrelen
met collega’s. Tijdens het afronden van mijn promotie, tevens de start van mijn nieuwe baan als
klinisch fysicus in opleiding kochten wij ons eerste huis. Jij gaf mij de ruimte mijn promotie af te
ronden en aan mijn nieuwe baan te wennen en probeerde tevens het in huis zo makkelijk mogelijk
te maken voor mij. En natuurlijk ook bedankt voor het helpen met de layout van mijn boekje, nu
is het toch echt ons boekje geworden. Mijn excuses voor alle stress en het gezeur te laatste tijd,
daar is vanaf nu geen reden meer toe. Bedankt dat je er altijd voor me bent, ik hou van je.
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Evelyn de Jong was born on the 24th of July 1987
in Drachten, the Netherlands. After ﬁnishing her
secondary education at the Drachtster Lyceum in
Drachten in 2004, she started with the Bachelor Medisch
Beeldvormende en Radiotherapeutische Technieken at
the Hanzehogeschool in Groningen. She performed her
ﬁrst internship at the Radiotherapy department of the
Medisch Spectrum Twente in Enschede, where she was
a radiation therapist in training. After her internship
she decided to switch to the Bachelor Applied Physics
at Saxion Hogeschool in Enschede. During this bachelor
she did an internship at the Radiotherapeutic Institute
RISO in Deventer, where she investigated absolute ﬁlm
dosimetry for delivery quality assurance for tomotherapy.
The other internship was done at the KVI-Center for
Advanced Radiation Technology in Groningen, where
she studied the dose response of radiochromic ﬁlm to Carbon ions. For her graduation project,
which Evelyn performed in the NIM-biomagnetism group of the University of Twente, she
analyzed, balanced, tested and improved a new 4K SQUID magnetometer, which was designed to
determine the magnetic relaxation behavior of nanoparticles (e.g. iron ﬁlled carbon nanotubes) in
suspension, at low frequencies. After her graduation in 2011, she decided to continue studying and
enrolled in the premaster of Biomedical Engineering at the Eindhoven University of Technology in
Eindhoven. During the master Medical Engineering, she spent three months at the radiotherapy
institute MAASTRO Clinic in Maastricht, where she worked on the eﬀect of diﬀerent tissue
modelling schemes on the dose distribution in low energy breast brachytherapy and the inﬂuence
of adjustment of the treatment plan based on the cone-beam CT for lung cancer patients. For
her Master thesis, she did a nine months project at the radiotherapy department of the University
Medical Center in Utrecht, where she studied small ﬁeld dosimetry in a magnetic ﬁeld. In 2014
she obtained her Master’s degree. In August of the same year, she joined the research team of
Maastricht University. As a PhD candidate she investigated the prognostic value of a variety of
image features of CT and PET images of stage IV non-small cell lung cancer patients. During
her work, she found out that there are many methodological challenges in image feature studies,
which she studied further by which she was able to provide recommendations for future multicenter
trials with respect to imaging. In April 2018, she started as a Medical Physicist in training at the
Catharina hospital in Eindhoven.
Grants
• BIGART travel grant, Biology-Guided Adaptive Radiotherapy, 2017, Aarhus, Denmark.
• NRS young investigator travel grant, Annual Meeting of the American Society for Radiation
Oncology, 2016, Boston, US.
• NRS young investigator travel grant, ESTRO/EANM course on Molecular Imaging and
Radiation Oncology, 2015, Madrid, Spain.
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Scientiﬁc publications
• Lambin P., Zindler J., Vanneste B.G.L., Van De Voorde L., Jacobs M., Eekers D., Peerlings
J., Reymen B., Larue R.T.H.M., Deist T.M., de Jong E.E.C., Even A.J.G., Berlanga A.J.,
Roelofs E., Cheng Q., Carvalho S., Leijenaar R.T.H., Zegers C.M.L., van Limbergen E.J.,
Berbee M., van Elmpt W., Oberije C., Houben R., Dekker A., Boersma L.J., Verhaegen
F., Bosmans G., Hoebers F., Smits K.M. & Walsh S. Modern clinical research: How rapid
learning health care and cohort multiple randomised clinical trials complement traditional
evidence based medicine. Acta Oncol. 2015; 54(9):1289-300.
• White S.A., Reniers B., de Jong E.E.C., Rusch T. & Verhaegen F. A comparison of the
relative biological eﬀectiveness of low energy electronic brachytherapy sources in breast
tissue: a Monte Carlo study. Phys Med Biol. 2016; 61 (1):383-99.
• Scrivener M.∗, de Jong E.E.C.∗, van Timmeren J.E.∗, Pieters T., Ghaye B. & Geets X.
Radiomics applied to lung cancer: a review. Transl Cancer Res. 2016; 5(4):389-409.
• Lambin P., Zindler J., Vanneste B.G.L., Van De Voorde L., Eekers D., Compter I., Panth
K.M., Peerlings J., Larue R.T.H.M., Deist T.M., Jochems A., Lustberg T., van Soest J., de
Jong E.E.C., Even A.J.G., Reymen B., Rekers N., van Gisbergen M., Roelofs E., Carvalho
S., Leijenaar R.T.H., Zegers C.M.L., Jacobs M., van Timmeren J.E., Brouwers P., Lal
J.A., Dubois L., Yaromina A., van Limbergen E.J., Berbee M., van Elmpt W., Oberije
C., Ramaekers B., Dekker A., Boersma L.J., Hoebers F., Smits K.M., Berlanga A.J. &
Walsh S. Decision support systems for personalized and participative radiation oncology.
Adv Drug Deliv Rev. 2017; 109:131-153.
• de Jong E.E.C., van Elmpt W., Leijenaar R.T.H., Hoekstra O.S., Groen H.J.M., Smit E.F.,
Boellaard R., van der Noort V., Troost E.G.C., Lambin P. & Dingemans A.-M.C. [18F]FDG
PET/CT-based response assessment of stage IV non-small cell lung cancer treated with
paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. Eur J Nucl Med
Mol Imaging 2017; 44(1):8-16.
• Leijenaar R.T.H., de Jong E.E.C., Larue R.T.H.M., van Timmeren J.E. & Lambin P.
Radiomics: de toekomst in medische beeldvorming. Ned Tijdsch Oncol. 2017; 14:82-9.
• de Jong E.E.C., van Elmpt W., Hoekstra O.S., Groen H.J.M., Smit E.F., Boellaard R.,
Lambin P. & Dingemans A.-M.C. Quality assessment of positron emission tomography
scans: recommendations for future multicenter trials. Acta Oncol. 2017; 56(11):1459-
1464.
• Larue R.T.H.M.∗, van Timmeren J.E.∗, de Jong E.E.C.∗, Feliciani G., Leijenaar R.T.H.,
Schreurs W.M.J., Sosef M.N., Raat F.H.J.P., van der Zande F.H.R., Das M., van Elmpt W.
& Lambin P. Inﬂuence of gray level discretization on radiomic feature stability for diﬀerent
CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta
Oncol. 2017; 56(11):1544-1553.
• Lambin P., Leijenaar R.T.H., Deist T.M., Peerlings J., de Jong E.E.C., van Timmeren J.E.,
Sanduleanu S., Larue R.T.H.M., Even A.J.G., Jochems A., van Wijk Y., Woodruﬀ H., van
Soest J., Lustberg T., Roelofs E., van Elmpt W., Dekker A., Mottaghy F.M., Wildberger
J.E. & Walsh S. Radiomics: the bridge between medical imaging and personalized medicine.
Nat Rev Clin Oncol. 2017; 14(12):749-762.
• Sanduleanu S.∗, Woodruﬀ H.C.∗, de Jong E.E.C., van Timmeren J.E., Jochems A., Dubois
L. & Lambin P. Tracking tumor biology with radiomics: A systematic review utilizing a
radiomics quality score. Radiother Oncol. 2018; 127(3):349-360.
• de Jong E.E.C.∗, Hendriks L.E.L.∗, van Elmpt W., Gietema H.A., Hofman P.A.M., De
Ruysscher D.K.M. & Dingemans A.-M.C. What you see is (not) what you get: tools for a
non-radiologist to evaluate image quality in lung cancer. Lung Cancer 2018; 123:112-115.
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• de Jong E.E.C., van Elmpt W., Rizzo S., Colarieti A., Spitaleri G., Leijenaar R.T.H.,
Jochems A., Hendriks L.E.L., Troost E.G.C., Reymen B., Dingemans A.-M.C. & Lambin
P. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III
non-small cell lung cancer in stage IV non-small cell lung cancer. Lung Cancer 2018;
124:6-11.
• Rizzo S., Raimondi S., de Jong E.E.C., van Elmpt W., De Piano F., Bagnardi V., Jochems
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during chemotherapy is predictive for poor survival in metastatic non-small cell lung cancer.
Submitted work.
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Jochems A., Barakat M.S., Leijenaar R.T.H. & Lambin P. Decision Support Systems in
Oncology. Submitted work.
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& Lambin P. Can quantitative radiomic features describe qualitative semantic features in
non-small cell lung cancer patients? In preparation.
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